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Abstract  
 
Human response to ionising radiation (IR) shows a wide variation. This is most clearly seen in 
the radiation-response of cells as measured by frequencies of chromosomal aberrations. 
Different frequencies of IR-induced aberrations can be conveniently observed in 
phytohaemagglutin-stimulated peripheral blood T-lymphocytes from both normal individuals 
and sporadic cancer cases, in either metaphase chromosomes or as micronuclei in the 
following cell cycle. Metaphase cells show frequent chromatid breaks, defined as chromatid 
discontinuities or terminal deletions, if irradiated in the G2-phase of the cell cycle. It has been 
shown that the frequency of chromatid breaks in cells from approximately 40% of sporadic 
breast cancer patients, are significantly higher than in groups of normal individuals. This 
suggests that elevated radiation-induced chromatid break frequency may be linked with 
susceptibility to breast cancer.  
 
It is known that chromatid breaks are initiated by a double strand break (DSB), but it appears 
that the two are linked only indirectly as repair kinetics for DSBs and chromatid breaks do not 
match. Therefore, the underlying causes of the wide variation in frequencies of chromatid 
breaks in irradiated T-lymphocytes from different normal individuals and from sporadic breast 
cancer cases are still unclear but it is unlikely to be linked directly to DSB rejoining.  
 
My research has focused on the mechanism through which chromatid breaks are formed 
from initial DSBs. The lack of a direct association suggested that a signalling process might 
be involved, connecting the initial DSB and resulting chromatid break. The signal model, 
suggested that the initial DSB is located within a chromatin loop that leads to an intra- or 
interchromatid rearrangement resulting in incomplete mis-joining of chromatin ends during the 
decatenation of chromatids during G2. It was therefore proposed that topoisomerase II alpha 
(topo IIα) might be involved, mainly because of its ability to incise DNA and its role in sister 
chromatid decatenation.  
 
During my PhD research I have used a strategy of altering topo II activity or expression and 
studying whether this alters IR-induced chromatid break frequency. The first approach 
involved cell lines that varied in topo IIα expression. The frequency of IR-induced chromatid 
breaks was found to correlate positively with topo IIα expression level, as measured in three 
different cell lines by immunoblotting, i.e. two cell lines with lower topo IIα expression 
exhibited lower chromatid break frequency. Topo II activity in these three cell lines was also 
estimated indirectly by the ability of a topo IIα poison to activate the G2/M checkpoint, and this 
related well with topo IIα expression. A second approach involved ‘knocking down’ topo IIα 
protein expression by silencing RNA (siRNA). Lowered topo IIα expression was confirmed by 
immunoblotting and polymerase chain reaction. SiRNA-lowered topo IIα expression 
correlated with a decreased IR-induced chromatid break frequency. In a third series of 
 vi
experiments cells were treated with ICRF-193, a topo IIα catalytic inhibitor. It was shown that 
inhibition of topo IIα also significantly reduced IR-induced chromatid breaks. I also showed 
that lowered chromatid break frequency was not due to cells with high chromatid break 
frequencies being blocked in G2 as the mitotic index was not altered significantly in cells with 
lowered topo IIα expression or activity. These experiments show that topo IIα is involved in 
IR-induced chromatid break formation.  
 
The final experiments reported here attempted to show how topo II might be recruited in the 
process of forming IR-induced chromatid breaks. Hydrogen peroxide was used as a source of 
reactive oxygen species (reported to poison topo IIα) and it was shown that topo IIα under 
these conditions is involved in the entanglement of metaphase chromosomes and formation 
of chromatin ‘dots’ as well as chromatid breaks. Experiments using atomic force microscopy 
attempted to confirm these dots as excised chromatin loops. 
 
The possible role of topo IIα in both radiation- and hydrogen peroxide-induced primary DNA 
damage was also tested. It was shown that topo IIα does not affect radiation-induced DSBs, 
even though it does affect chromatid break frequency. Also, topo IIα does not affect hydrogen 
peroxide-induced DNA damage at low doses. The results support the idea that topo IIα is 
involved in the conversion of DSBs to chromatid breaks after both irradiation and treatment 
with hydrogen peroxide at a low concentrations. 
 
I have demonstrated that topo IIα is involved in forming IR-induced chromatid breaks, most 
likely by converting the initial DSBs into chromosomal aberrations as suggested by the signal 
model.  
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CHAPTER 1 
 
INTRODUCTION 
Introduction 
 
2
1.1 Aim 
The aim of my thesis was to further investigate chromosomal aberrations induced by gamma-
radiation and how they arise from deoxyribonucleic acid (DNA) damage. More specifically to 
investigate how chromatid breaks form from double strand breaks (DSBs). The process 
behind chromatid break formation is unclear. Here the role of topoisomerase IIα in chromatid 
break induction was investigated and as it is known that DNA DSBs are the initiating lesions, 
the importance of induction and rejoining of DSBs in chromatid break formation was also 
tested.  
 
1.2 Ionising radiation-induced DNA damage 
The purpose of a cell is to replicate its DNA as accurately as possible and pass it on to 
daughter cells, avoiding DNA and chromosome damage. DNA and chromosome damage can 
come in many different forms, including single strand breaks (SSBs) and DSBs as well as 
chromosomal exchanges and breaks. The focus of this thesis is on chromosome damage 
caused by low linear energy transfer (LET) ionising radiation (IR), namely γ-rays, and more 
specifically on induction of chromatid breaks.  
 
Firstly it is important to define low LET IR. IR is so-named as it can carry enough energy per 
quantum to ionise atoms or molecules. IR can be categorised in to either high or low LET with 
high LET referring, for example, to alpha particles that are more densely ionising but do not 
penetrate very far in biological material as their positive charge interacts with the DNA. Thus 
they deposit most of their energy within the volume of one cell. However, low LET IR 
encompasses X-rays, beta particles and gamma rays; the latter being the type of radiation 
used in all experiments described in this thesis. Gamma rays are emitted by radioactive 
isotopes (here 137Caesium or 137Cs) resulting from excess energy released as the unstable 
nucleus decays 1.  
Ionising radiation is a well-known carcinogen as determined from many human studies 1. It, 
more specifically X-rays, was also the first environmental agent shown to be mutagenic in 
Drosophila melanogaster 2.  We are all exposed to ionising radiation as either background 
irradiation from for example cosmic rays, or medical uses such as radiography. Damage to 
the DNA by ionising radiation can occur either directly or indirectly (Figure 1.1). Direct 
damage refers to IR ionising components of the DNA, whereas indirect damage occurs when 
IR interacts with water molecules in the vicinity of DNA producing free radicals that in turn 
diffuse short distances to reach the DNA molecule and lead to DNA damage. It is thought that 
low LET radiation, such as γ-rays, mainly acts on DNA indirectly through the production of 
radicals 3. Ionised water (H2O+) reacts with other water molecules (H2O) surrounding it which 
results in the formation of the hydroxyl radical 
.
OH (as well as H3O+). Free radicals attack 
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hydrogen bonds in the DNA double helix, causing DNA damage 4 and hydroxyl radicals are 
thought to play a major role in IR-induced DNA damage 1,3.  
 
 
 
 
Figure 1.1: Mechanisms of radiation-induced DNA damage: the direct and indirect actions of 
ionising radiation. Ionising radiation can affect DNA both indirectly, where photons ionise water 
to form hydroxyl radicals .OH, and directly. Adapted from Hall (1994) 1.  
 
 
A source of DNA and chromosomal damage other than γ-radiation used in this thesis is 
hydrogen peroxide (H2O2). H2O2 also forms 
.
OH radicals in the presence of ferrous ions and 
its action is known to be radiomimetic 5. H2O2 is produced endogenously and is a key cellular 
signalling molecule 6.  
 
Ionising radiation results in a wide range of DNA lesions including SSBs, DSBs, base damage, 
DNA-DNA crosslinks, protein-DNA crosslinks and sugar damage 7. A SSB refers to breakage 
of one phosphodiester backbone. Double strand breaks, the lesion most relevant to the 
experiments here, can be described as the breakage of both phosphodiester strands at sites 
less than four nucleotides apart. This DSB is regarded as the most important initial lesion and, 
unlike SSBs, has been associated with cell death 8,9. DSBs can be classified as either blunt- 
(with no or few bases overlapping) or sticky-ended (with cohesive free ends of many bases) 
and the type of DSB determines the ability for it to cause chromosomal aberration 10. It is 
known that per cell approximately 36 - 40 DSBs arise per Gy of low LET IR 11,12. 
 
IR can also induce partial destruction or alteration of bases which can include up to 20 
different modifications of molecular structure for each of the 4 bases 7,13. As well as base 
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damage IR also causes sugar damage leading to base loss (abasic site), SSBs and 
crosslinking of DNA with itself (interstrand cross-links) or with proteins 1. So far all IR-induced 
lesions have been explained as individual IR effects. However, due to its indirect effect, 
ionising radiation can also induce complex lesions where SSBs, DSBs and damaged bases 
are localised within one helical turn (1-10 base pairs). These complexes were termed locally 
multiply damaged sites in 1985 by Ward 14 and are referred to as complex DSBs within this 
thesis. 
 
It is important to understand that simply the presence of single or double strand breaks, or 
other types of DNA lesions does not automatically lead to aberrant cell growth or disease 
progression as under normal circumstances these breaks would be repaired.  
 
1.3 DNA repair 
The “molecule of the year” goes to … DNA repair systems! 15 
 
DNA repair is an essential process to ensure integrity of genetic material before it is replicated 
and passed on to daughter cells. Single strand breaks caused by IR can be repaired through 
many proteins also involved in base excision repair 16. This requires the base as well as the 
deoxyribose phosphate in the backbone to be excised, the DNA to be re-synthesised and 
finally sealed with a DNA ligase.  
 
1.3.1 Double strand break repair  
Double strand breaks are repaired through two major pathways, namely homologous 
recombination (HRR) and non-homologous end-joining (NHEJ) repair (Figure 1.2) 17,18. 
Double strand breaks can also be repaired by single strand annealing (Figure 1.2), which is 
activated when a DSB is located between two repeat sequences. It repairs the DSB through 
pairing up sequences of direct repeats with the intervening repeats and other DNA being lost, 
followed by DNA synthesis by DNA polymerase and DNA ligation 19. This repair process does 
not conserve the DNA sequence and involves the activity of RAD50 and some proteins, such 
as hMRE11, that are also involved in homologous recombination repair 19 of double strand 
breaks (see next section). SSA is therefore often thought of as a special form of HRR. 
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SSA         HRR   NHEJ 
 
Figure 1.2 DSB repair systems simplified. Single strand annealing (SSA, left) and homologous 
recombination (HRR, middle) require homologous sequences. The red sequences shown as 
part of SSA refer to direct repeat sequences. The grey sequences shown as part of HRR are 
homologous sequences. Non-homologous end-joining (NHEJ, right) is able to repair DSBs by 
resection of the DNA ends and then ligation of the two blunt DSBs without maintaining genomic 
integrity. For full description see text. Protein XLF is also associated with NHEJ as it interacts 
directly with the XRCC4/Ligase IV complex 20. 
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Firstly, as the name suggests, homologous recombination repair (HRR) requires the presence 
of homologous sequences in order to repair the DSB; it needs around 200 bp overlap 21. In 
HRR of IR-induced DSBs in mammalian cells, the DSB is first processed by the eukaryotic 
MRN complex (hMRE11, hRad50 and NBS1 (Nijmegen Breakage Syndrome protein 1, also 
known as Nibrin or NBN) 22, which ‘cuts back’ or removes damaged DNA sequences next to 
the DSB (Step 1, Figure 1.2). The MRN complex then recruits ATM (Ataxia Telangiectasia 
Mutated), which in turn phosphorylates histone H2AX at serine 139 23. The phosphorylated 
form of H2AX is termed γ-H2AX and it forms foci at and around (up to several megabases) the 
DSB 24. The protein mediator of DNA damage checkpoint protein 1 (MDC1) is recruited to the 
site and increases γH2AX foci formation either by decreasing phosphatase or increasing 
kinase activity 25. γH2AX ubiquitination results in the recruitment of BRCA1 (BReast CAncer 1) 
and p53 binding protein 1 (53BP1) to the damaged DNA site 25,26. BRCA1 is a crucial DNA 
repair protein due to its function as an E3-ubiquitin ligase 27 that attaches subsequent repair 
proteins to the damaged site 28. Proteins with the C-terminal domain of breast cancer proteins 
(BRCT regions) are known to be involved in cell cycle regulation and DNA repair. BRCA1 and 
2, two such BRCT proteins, are no exception and are able to regulate hRad51 as well as the 
G2 checkpoint 29,30. It is known that mutations in these two BRCA proteins are associated with 
an increased risk of breast cancer 31. 53BP1 on the other hand activates p53 and cell cycle 
checkpoints ultimately resulting in cell cycle arrest 32. Therefore shortly after IR γ-H2AX, MRN, 
MDC1, 53BP1, ATM and BRCA1 can all be visualised at the DSB site by 
immunocytochemistry 22,33,34. Also, γH2AX foci recruit chromatin remodelling complexes that 
allow access to the DSB by other repair proteins 35. Another important consequence of IR-
induced DNA damage is the recruitment of the cohesin complex via the phosphorylation of 
SMC1 (structural maintenance of chromosome protein 1, part of the cohesin complex) by 
ATM 35,36. This tethers the sister chromatid in place to allow for HRR.   
 
After the DSB has been processed, the proteins ‘search’ for a homologous sequence (Step 2, 
Figure 1.2), which then allows base pairing and strand exchange by the eukaryotic proteins 
hRAD51/52/54 and replication protein A (RPA) 37-40. Interestingly, in murine cells where 
Rad54 is absent, cells will repair by single strand annealing rather than HRR 41, which as 
mentioned earlier is not conservative as large sequences can be deleted.  
 
The two ends of homologous sequences in HRR invade each other and serve as primers for 
DNA synthesis by a DNA polymerase (Step 3, Figure 1.2). These Holliday junctions are then 
resolved by X-ray repair cross-complementing protein XRCC3/Rad51 38 as well as SLX1, 
SLX4, ERCC1, MUS81 and EME1 proteins 42-44. Finally the gaps are filled by an as yet 
unknown ligase (Step 4, Figure 1.2).  
 
In addition to HRR, DSB rejoining can also be accomplished by NHEJ which is non-
conservative and can occur in the absence of homologous sequences. In eukaryotes, NHEJ 
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requires the recruitment of the ku70/80 heterodimer, which recognise the damaged site, DNA-
dependent protein kinase catalytic subunit (DNA-PKcs) and XRCC4/DNA ligase IV 18,45. 
Together ku70/80 and DNA-PKcs are referred to as DNA-PK. The ATM kinase used as part of 
HRR also has a role in regulating the activity of the NHEJ protein Artemis, which is bound to 
DNA-PK. Hyperphosphorylation of Artemis by ATM activates the Artemis/DNA-PK complex, 
which results in nuclease (trimming) activity on the DSB 46 followed by the ligation of the DNA 
by the XRCC4/DNA ligase IV complex 47. Several NHEJ proteins are also involved in V(D)J 
recombination in maturing B and T lymphocytes 48. 
 
It is now not only known that HRR mainly repairs IR-induced double strand breaks in the G2 
phase of the cell cycle 49,50, as it requires the availability of homologous sequences, but also 
that NHEJ can occur in all phases of the cell cycle including G2 50. The HRR pathway appears 
to be regulated mainly through ATM signalling 51. The phosphorylation of CtIP and recruitment 
of BRCA1 during S and G2 phases of the cell cycle can also influence the type of DSB repair 
mechanism 52. Also, the type of DSB can lead to ‘selection’ of the repair pathway as more 
complex DSBs created by ionising radiation are rejoined by HRR, whereas simple DSBs (e.g. 
bleomycin-induced) are repaired via NHEJ as determined by the lack of recruitment of the 
HRR protein RAD51 53. 
 
1.3.2 Cell cycle checkpoints 
Another effect of DNA damage is the activation of cell cycle checkpoints. Most DNA repair 
proteins mentioned in the previous section affect and ‘slow down’ or arrest the cell cycle to 
allow time for DNA damage to be repaired and to ensure that DNA damage does not get 
passed on to daughter cells. The cell cycle (Figure 1.3) consists of a gap (G1) phase where 
cells prepare for DNA replication or synthesis in S phase. Gap phase 2 (G2) prepares the cells 
for the equal segregation of DNA in each daughter cell. The G2/M cell cycle checkpoint is 
located between G2 and mitosis (M), after DNA replication. This G2/M checkpoint is crucial in 
halting cells in G2 when DNA has been damaged or is not yet decatenated to ensure correct 
sister chromatid separation at anaphase 54,55. G1/S and anaphase checkpoints are also in 
place, however as these are irrelevant to this thesis, they will not be covered.  
 
In G2, both cyclin A and B expression levels are altered, although only cyclin B is involved in 
the G2/M checkpoint. Cyclin B binds to the kinase p34, also known as cyclin-dependent kinase 
2 (cdc2) and cyclin-dependent kinase 1 (CDK1). Together cyclin B and p34 are termed the 
mitosis promoting factor (MPF). At G2 MPF, although present, is inactive until the 
phosphatase cdc25 is activated by checkpoint protein 1 (Chk1). Cdc25 now activates MPF 
which in turn targets lamins that are part of the inner nuclear envelope (lamina). MPF also 
activates condensins that allows chromosome condensation and proteins that promote 
spindle formation.  Decreased nuclear expression of cyclin B due to ubiquitination or 
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localisation to the cytoplasm defines the onset of anaphase. This signalling pathway has been 
reviewed by many groups 56-58. 
 
 
 
 
Figure 1.3: Cell cycle and G2/M checkpoint control. Cells cycle from S phase, where DNA is 
replicated, to G2, where cells prepare for mitosis, and finally mitosis where the genetic material 
is split evenly in to daughter cells. If the environment is unfavourable, such as lack of nutrients, 
cells will go into quiescence (G0) and can start cycling again when the milieu has recovered.  
The G1/S checkpoint stops cells from going into S phase if DNA is damaged. The grey box 
shows a more detailed time-line of the G2/M checkpoint. For a full description of the G2/M 
checkpoint see text. 
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As mentioned, both DNA damage and lack of DNA decatenation activate the G2/M checkpoint 
and halt cells in G2. The mechanism behind this involves a complex signalling cascade 
involving many repair proteins as well as the ultimate checkpoint protein p53 58-60, which is 
activated by ATM 61. This ultimately inhibits cdc25 and keeps the MPF in an inactive state 
until DNA repair has taken place. 
 
1.4 Chromosomal damage 
1.4.1 Types of chromosomal damage 
Chromosomal damage can be categorised into either chromosome or chromatid aberrations. 
As mentioned earlier, the aim of this thesis was to find out more about the mechanism behind 
chromatid damage (breaks). The difference between chromosome and chromatid breaks is 
illustrated in Figure 1.4.  
 
 
 
 
Figure 1.4 Difference between chromosome (A) and chromatid (B) breaks. DNA damage 
acquired through ionising radiation (IR) in the G0 or G1 phase of the cell cycle will result in 
chromosome breaks when viewed in mitosis (M) after replication of the DNA in S phase. 
Chromatid breaks arise from DNA damage acquired by IR in the G2 phase of the cell cycle. (C): 
chromatid break with displacement of broken segment. 
 
 
Chromosome aberrations (Figure 1.4A) refer to damage accumulated in the G0/G1 phase of 
the cell cycle. If left unrepaired, the initial DNA damage is replicated in S phase and manifests 
itself as breaks (or gaps) in both chromatid arms. These chromosome breaks can be seen in 
metaphase, a phase of mitosis where chromosomes are condensed but have not yet 
separated into daughter cells.  In most cases however, the initial damage would have been 
A 
B 
C 
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repaired by NHEJ or HRR (section 1.3.1). It should be noted that chromosome aberrations 
other than breaks also include telomeric deletions (end of chromosomes deleted), interstitial 
deletions (deletions not at terminus), translocations and dicentrics (exchanges between 
different chromosomes), rings (exchanges within a single chromosome), chromosome 
insertions, inversions and duplications.   
 
Chromatid aberrations (Figure 1.4B) include chromatid gaps, breaks and exchanges. Unlike 
chromosome aberrations, chromatid breaks are classified as breaks in only one of the two 
chromatid arms and result from IR-induced DNA damage acquired during the G2 phase of the 
cell cycle. Classically, chromatid ‘breaks’ were considered to be discontinuities larger than the 
width of the chromatid, whereas ‘gaps’ were those smaller than the chromatid width. However, 
Sandford et al. counted chromatid breaks as chromatid discontinuities with displacement of 
the broken segment (Figure 1.4C) and gaps as aligned breaks 62. It was therefore unclear 
whether or not ‘gaps’, defined as discontinuities smaller than the width of the chromatid, 
should be included when calculating chromatid break frequency. A study in which the size of 
chromatid discontinuity was compared to their frequency displayed a continuous pattern of 
sizes 63. If gaps and breaks do arise from different mechanisms, two peaks in the distribution 
would be expected, referring to either type of chromatid discontinuity 63. However, as no two 
clear peaks were detected, it can be assumed that gaps and breaks are not two qualitatively 
different types of discontinuity 63. Also, in another study the kinetics of the disappearance of 
both the gaps and breaks after IR were comparable 64, again suggesting that breaks and gaps 
can be regarded as a similar type of chromatid discontinuity.  
 
In this thesis, following the example of Bryant et al. 65, chromatid breaks are defined as any 
type of chromatid discontinuity, including chromatid ‘gaps’, where aligned discontinuities are 
smaller than the width of the chromatid, and ‘breaks’ where discontinuities are larger than the 
width of the chromatid. It is thought that the displacement of the broken segment occurs in a 
random fashion during sample preparation and these were therefore also included during 
analysis. 
 
Terminal fragments (Figure 1.4) are kept close to the chromatid break due to cohesion of the 
two sister chromatids mediated by the cohesin complex 66. Cohesins are proteins that 
maintain ‘sister chromatid’ adhesion after replication and it is generally accepted that they do 
this by encircling the DNA 66,67. This cohesin complex includes Smc1 and 3, which belong to 
the structural maintenance of chromosomes (SMC) protein family, as well as Scc1 66,67. 
Before metaphase most cohesin complexes are removed from chromosome arms, resulting in 
the well known X-shaped chromosome. If sister chromatids were not still slightly cohesed at 
metaphase, chromatid breaks would not be visible as the structures shown in Figure 1.4B. 
Instead these breaks would cause the end of the chromatid to separate completely from the 
chromosome and be lost as a telomeric deletion in the preparation of the sample. How then 
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do these chromatid breaks still allow all homologous sections of the chromosome to remain 
‘attached’ to each other in metaphase? Although chromosome arms in metaphase are often 
visibly separated, i.e. appear in optical microscopy to be only connected via the centromere, 
some arm cohesion nevertheless persists throughout metaphase and is sufficient to maintain 
sister chromatid cohesion 68. How arm cohesion is maintained until metaphase is still 
unknown although small amounts of cohesin can be detected in the interchromatid region of 
metaphase chromosome arms.  
 
1.4.2 Chromosomal radiosensitivity 
Radiosensitivity is formally defined as 1/D0 of a cell survival curve with D0 representing the 
dose required to reduce the surviving fractions by 63% along the exponential portion of the 
curve. Here however, the term ‘high radiosensitivity’ is used to refer to cells responding 
sensitively to ionising radiation and resulting in an elevated frequency of chromatid breaks or 
other types of chromosomal damage.  
 
Wide intra-individual differences have been found in the radiosensitivity of 
phytohaemagglutinin (PHA)-stimulated peripheral blood samples from normal donors and 
inter-individual G2 values ranged from 86 to 154 chromatid gaps and breaks per 100 
metaphases 69.  This wide range in normal donors was also seen in studies by other groups, 
where the G2 score, or number of chromatid breaks per 100 cells, varied from 15 to 115 70 
and from 80 to 120 71, in all cases showing a Gaussian distribution. Some of the differences in 
values found between different studies could probably be attributed to what is defined as a 
chromatid break. Nonetheless, it is clear that significant inter-individual differences between 
peripheral blood samples of normal donors exist. The mechanism underlying the inter- and 
intra-individual variations is as yet unclear.  
 
High cellular and chromosomal radiosensitivity is seen in cells from ataxia telangiectasia (AT) 
patients. AT is an autosomal, homozygous recessive condition with ataxia (inability to 
coordinate voluntary muscle movements) and ocular and cutaneous telangiectasia (small 
dilated blood vessels). Other symptoms include progressive neural degeneration, severe 
immunodeficiency, spontaneous chromosomal instability, predisposition to cancer and high 
cellular and chromosomal radiosensitivities after IR. Studies with skin fibroblasts 62,72 and 
PHA-stimulated lymphocytes 71,73 from AT heterozygotes showed a higher chromatid break 
frequency than in normal individuals after irradiation. These studies also found that AT 
homozygotes showed a further increased radiosensitivity 62,72,73.  
 
As mentioned, the protein mutated in AT (ATM) is required for normal repair of DSBs and 
thus it logically follows that AT cells might be radiosensitive due to deficient repair. However, 
in AT lymphoblastoid cell lines, γ-irradiated cells do not show a higher number of radiation-
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induced DSBs 74. However, a two-fold increase in chromosomal damage was seen in AT cells 
in G1 or G2 suggesting that AT cells have a higher rate of conversion of DSBs into 
chromosomal aberrations 74. One group incorrectly assumed a DNA repair defect from data 
that showed higher chromatid break frequency in cells of AT patients four hours after 
irradiation 75, as this was not substantiated by specific DSB experiments. As in AT 
lymphoblast cells 74, no difference in DSB induction after γ-irradiation of fibroblast AT cells 
was seen 76,77. In these studies it was also reported that radiation-induced DSB repair was 
normal 76 or more rapid then normal 77.  
 
Cell cycle irregularities in AT have also been suggested to cause radiosensitivity. Interestingly, 
X-irradiation of AT cells caused a linear decrease in % DNA synthesis, whereas normal 
diploid cells showed first a steep followed by a shallow decline seen in AT cells 78. It was 
postulated that AT cells lack a response to strand replication initiation. Another group showed 
that γ-irradiation of lymphoblastoid AT cells did not affect the mitotic index, unlike in normal 
cells 55. It therefore appeared that the G2 block response (Section 1.3.2) is inactive in AT cells 
55,79. Also AT cells, when treated with calyculin A, which condenses cells in G2, showed the 
same IR-induced chromatid break frequency as AT cells treated with colcemid and allowed to 
enter mitosis. Control cells however showed a decrease in chromatid break frequency in cells 
treated with colcemid rather than calyculin A, suggesting that the G2 block found in control 
cells is inactive in AT cells 55.  
 
In this thesis colcemid, also known as demecolcine, is also used to block cells in mitosis. It 
was derived from colchicine, originally extracted from the Colchicum autumnale plant. It 
maintains cells in prometaphase by depolymerising microtubules and inhibiting new 
microtubule formation. Cells are thus kept in prometaphase as a lack of spindle fibres inhibits 
correct seperation of sister chromatids 80.  
 
Treatment of cells with caffeine, which abrogates checkpoint activity, does not affect 
chromatid break frequency in AT cells, though it does increase chromatid break frequency in 
control cells 55. The data thus shows that the G2/M checkpoint is not fully functional in 
homozygous AT cells. High radiosensitivity has also been attributed to altered G2/M cell cycle 
checkpoint in non-AT cells as chromosomal damage in G2 was no different in radiosensitive 
compared to radioresistant cells however, radiosensitive cells did show higher chromosomal 
damage in mitosis 81.  Data implying that altered radiosensitivity is not linked with altered G2/M 
checkpoint activity 82,83 however suggest that abnormal G2/M checkpoint control does not 
necessarily result in increased chromatid breakage.   
 
As previously discussed AT chromatid radiosensitivity is not necessarily due to lowered DNA 
repair 76,77,84 and therefore might be due to increased DNA damage or altered conversion of 
DSBs to chromatid breaks. For example, it has been shown that the kinetics of DSB and 
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chromatid break disappearance in Chinese hamster ovary cells do not correspond since 
treatment of cells with the nucleoside analogue 9-β-D-arabinosyladenine (ara A or adenine 
arabinoside) inhibits chromatid break rejoining while DSB repair remains unaltered 85 
suggesting a conversion stage between DSBs and chromatid breaks. 
 
Several studies by Scott’s group 71,86-88 showed that irradiated PHA-stimulated peripheral 
blood lymphocytes (PBLs) of breast cancer patients also showed elevated frequencies of 
chromatid breaks in comparison to controls. More specifically, it was determined that 40% of 
breast cancer patients showed increased radiosensitivity compared to 10% in healthy controls 
71. High radiosensitivity of breast cancer PBLs has been confirmed by several other groups 
after either X- or γ-irradiation 70,81,89-92. However, the largest and most recent of this type of 
study, encompassing 211 breast cancer patients and 170 control cases, did not show any 
significant difference in radiosensitivity between breast cancer cases and normal controls 93. 
This study did however suggest increased radiosensitivity in women (both with and without 
breast cancer) with a strong family history of breast cancer, suggesting a link between 
radiosensitivity and risk of breast cancer in heritable cases 93. 
 
It has been hypothesised that this increase in radiosensitivity in breast cancer patients is due 
to aberrant or lack of DNA repair 94,95.  It is known that certain genes mutated in breast cancer, 
namely BRCA1 and 2, are involved in DNA repair 29-31. These proteins are associated with 
many DNA repair proteins mentioned in section 1.3 and are also known to activate the G2/M 
checkpoint (see reviews Bucher and Britten 56, Lobrich and Jeggo 57 and Stark and Taylor 58). 
In these studies 94,95 however, DNA repair was extrapolated indirectly from measurements of 
the number of chromosomal breaks and gaps left unrepaired at a certain time point. Also 
BRCA1 and BRCA2 gene mutations are found in only a low percentage of inherited breast 
cancer cases and breast cancer patients or cell lines derived from patients with BRCA1 and 
BRCA2 mutations did not show significant radiosensitivity as measured by the G2 assay 96.  
 
As BRCA1 and 2 mutations account only for a small proportion of the overall familial risk of 
breast cancer 97 and the mutations are not necessarily associated with increased 
radiosensitivity 96, the radiosensitivity seen in breast cancer patients must be due to other 
factors. One study 88 showed that high radiosensitivity was heritable and, alongside data 
suggesting that increased radiosensitivity is also found in young cancer patients (<20 years 
old) 98, substantiated the idea that inter-generational transmission of cancer predisposing 
genes of low penetrance allows this familial inheritance. Also in one study 62% of first-degree 
relatives of radiosensitive breast cancer patients were themselves radiosensitive, compared 
to 7% of first-degree relatives of breast cancer patients with normal G2 scores 88. A more 
recent study has also shown the heritability of radiosensitivity in peripheral blood samples of 
childhood and adolescent cancer survivors (52%) and their offspring (53%) 99. All these 
results led to speculation on the presence of genes of low penetrance. It seems that breast 
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cancer susceptibility is largely polygenic, where a large number of low-penetrance genes 
confer small risks individually that then act in combination to cause a wide variation in risk in 
the population 100. The penetrance of a disease-causing mutation is the proportion of 
individuals with the mutation who exhibit clinical symptoms. Thus a low penetrance gene will 
only sometimes result in clinical symptoms. Interestingly, ATM has been associated with 
intermediate risk (two-fold increase) of breast cancer and can be classified as one of these 
low-penetrance genes 101.  
 
The associated risk of (breast) cancer found in individuals with high radiosensitivity, has also 
tentatively been connected with risk of other types of cancer, such as colorectal cancer 87, 
head and neck cancer 102,103, and cancer of the larynx 104.  
 
1.5 Models of chromatid aberrations  
1.5.1 Breakage-and-reunion model  
An early study of the formation of X-ray-induced chromatid breaks was made by Sax in 1938 
using pollen from Tradescantia, where chromosomes are few in number and large in size. 
Sax’ model regards chromosome breaks as both the initial and final lesion as a consequence 
of single (‘one-hit’) interactions of ionising tracks with chromosomes 105. A modified form of 
Sax’ ‘breakage-and-reunion’ model 106, proposed that polynucleotide breaks or abasic lesions 
modified into strand breaks were the initiating lesions 107. These breaks would then be 
rejoined, left unrepaired or mis-joined such that genetic material between different 
chromosomes is exchanged (Figure 1.5).  
 
 
Figure 1.5 Breakage-and-reunion model of chromatid break formation. The initial strand break, 
now known to be a double strand break (DSB), results in a chromatid break in mitosis after 
chromosome condensation. This DSB is repaired, mis-repaired or left unrepaired. The diagram 
is based on Bryant 1998 108. 
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Studies using restriction endonuclease-induced DSBs showed that the initiating lesion in the 
formation of chromatid breaks was a DSB 10,109,110. Previously, studies combining Neurospora 
endonuclease and X-rays had shown that conversion of single strand damage to a DSB 
increased chromatid aberration frequency, although the initial damage would have been a mix 
of single and double strand breaks 111. Therefore the strand breaks proposed to be involved in 
chromatid breakage by Bender are actually now known to be DSBs. 
 
Chromatid breaks can be up to 40 Mbp in size (based on human haploid genome size of 
around 3000 Mbp 112,113). Bender’s model 107 would implicate two strand breaks that interact 
with each other, deleting the region in between the two and thus predicts a quadratic rather 
than linear relationship between radiation dose and chromatid breaks. The probability of two 
strand breaks occurring near each other on the same chromatid is unlikely, especially at the 
low doses used in many chromatid break studies, namely 0.25 – 1 Gy as it can be inferred 
that 0.25 Gy will induce about ten DSBs per diploid cell (based on 40 DSBs per Gy 11,12). 
Even more unlikely is finding two DSBs on one chromosome in control (unirradiated) cells, 
where a low number of chromatid breaks can also be found. This might instead result from 
massive exonuclease activity surrounding the initiating strand break or due to extensive 
condensation of the chromatin at the end of the break, although both are rather unlikely. This 
breakage-and-reunion model therefore does not explain how the strand break, with no genetic 
material lacking, increases in size to become a chromatid break. 
 
It was shown by Sax that chromatid breaks yielded a linear relationship with radiation dose 
105,106. This linear dose response was also found in other cell types 108,112. Experiments with 
carbon K-shell ultrasoft X-rays, the range of which is very short so they affect only one double 
helix, show that chromatid breaks still occur when only one DSB is formed 114. These results 
suggest that one DSB is enough to cause a chromatid break, which does not correspond with 
the two DSBs required to induce a chromatid break as proposed with the breakage-and-
reunion model. If two DSBs were involved, a quadratic, and not a linear, relationship between 
radiation dose and chromatid break induction would occur and therefore an interaction of two 
DSBs to form a chromatid break seems even more unlikely. 
 
1.5.2 Exchange model  
Another theory of chromatid break formation is the ‘exchange model’ proposed by Revell 115 
(Figure 1.6). It suggests that chromatid breaks are formed or seen only as a result of the 
partial failure of exchanges within and between sister chromatids. Thus, if the process of 
exchanging genetic material were halted or interrupted after irradiation, chromatid breaks 
could be seen. The exchange was proposed to occur at the base of looped chromatin regions 
where IR could have caused ‘initiating lesions’. Revell classified the types of chromatid breaks 
as colour-switch and non-colour-switch (Figure 1.6), where exchange between or within 
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chromatids had occurred respectively. Colour-switches can be observed through Harlequin 
staining which involves treatment of cells with bromodeoxyuridine 116 or tritiated thymidine 
117,118. Cells are then allowed to proceed through two cell cycles, halted at metaphase with 
colchicine and finally stained with Giemsa 117 or Giemsa plus Hoechst 116. The darker 
chromatid will have been through more cycles than the lighter sister chromatid. 
 
The colour switches seen by Harlequin staining correspond to the exchange of genetic 
material between chromatids. Revell’s model predicted that 40% of chromatid breaks involve 
colour-switches assuming exchanges were equally probable as (D+E)/(A+B+C+D+E) = 40% 
(Figure 1.6). A value close to this, 38%, was in fact found in rat kangaroo cells 118. However, 
later studies on X-irradiated or endonuclease-treated Chinese hamster cells showed a lower 
percentage of chromatid-exchange breaks, namely 15-18% 112,117,119. Thus it appears the ratio 
of colour-switch to non-colour-switch breaks is species-dependent.  
 
The looped domains mentioned in Revell’s model are thought to be associated with 
transcription ‘factories’ 120 and might be surrounded by RNA (ribonucleic acid) polymerases, 
other transcription factors or DNA processing enzymes such as helicases and 
topoisomerases (topos). Evidence for transcription ‘factories’, formed from large loop domains 
that interact within the nucleus, came from studies where the incorporation of biotin-labelled 
CTP or UTP as well as the localisation of ribonucleoprotein and RNA polymerase II was 
detected by either light or electron microscopy and shown to appear in overlapping clusters 
120. It is also known that topo II is located at the base of chromatin loops 121.  
 
As with the ‘breakage-and-reunion’ model, the ‘exchange’ model assumes two lesions are 
formed close to each other which is not only unlikely at the low radiation doses used in 
experiments, but also does not conform to the linear dose-effect relationship 106,108,112. 
However, Harlequin staining has shown that exchange between two chromatids occurs.  
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Figure 1.6: Revell’s exchange model of chromatid break formation. The diagram is based on  a 
figure from Heddle et al. 1969 118. Only the types that include chromatid breaks have been 
included. Chromosomes have been stained through Harlequin staining (tritiated thymidine). 
According to this model the proportion of chromatid breaks showing colour-switches is equal to 
(D+E)/(A+B+C+D+E) = 40% assuming the exchanges are equally probable.  
 
 
A second exchange model was proposed by Radford 122. His transcription-based model 
proposed that one DSB is brought into contact with a topoisomerase I molecule via 
transcription and results in a cleavage complex that interacts with another topoisomerase I 
molecule within the same chromosome (intra-strand) or a transcription ‘factory’ located 
nearby on a different chromosome (inter-strand). He proposed this would result in strand 
exchanges, cleavage and formation of an exchange aberration, more specifically non-colour-
switch and colour-switch chromatid breaks depending on intra- or inter-strand exchange 
respectively 122.  
 
The transcription-based model 122 fits with data suggesting a linear relationship between 
chromatid break induction and IR dose, as only one IR-induced DSB is proposed to initiate 
exchange aberrations. According to this model, the initial radiation-induced DSB would be 
located in a transcription factory close to the area of mis-exchange and chromatid breakage. 
However, no direct evidence exists that supports this model.  
 
The ‘exchange’ model proposed by Revell implies a quadratic relationship between chromatid 
breaks and radiation dose since the probability of two lesions occurring close together would 
increase with dose. As mentioned previously, it is unlikely at the low radiation doses used in 
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chromatid break experiments that two DSBs would occur close enough to each other  to  
interact and form a chromatid break 112. 
 
1.5.3 Signal model 
Unlike Sax’ and Revell’s models, the signal model does accommodate the linear relationship 
between chromatid break induction and radiation dose 108,112. The signal model proposes that 
a single DSB, as suggested by the carbon K-shell ultrasoft X-rays study 114, initiates a signal 
ultimately leading to the formation of chromatid breaks.  
 
 
 
Figure 1.7: Signal model of chromatid break formation. The diagram is based on a figure from 
Bryant 1998 112. A single DSB is induced by ionising radiation in the chromosomal loop. This 
causes a signalling cascade to the base of chromatin loop, causing a mis-exchange during 
chromatid decatenation resulting in the formation of an omega loop. The initial DSB is repaired 
and the omega loop presents itself as a non-colour-switch chromatid break if not completed. 
 
 
The signal model (Figure 1.7) is based on Revell’s model in that the mis-exchange of genetic 
material is suggested to take place at the base of chromatin loops where they cross over. 
Thus chromatid breaks are, under the signal model, incomplete exchange aberrations 112. 
According to the signal model, a single DSB is hypothesised to be induced somewhere within 
the chromatin loop, rather than the base of the chromatin loops. It was later confirmed that a 
single initiating DSB can create a chromatid break when cells were treated with a 
Meganuclease ‘targeted’ to a single I-SceI restriction enzyme site 119. Interestingly, it also 
suggests that the disappearance of chromatid breaks with time is simply the completion of the 
exchange, rather than the repair of the initial DSB. The signal model would also explain why 
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the number of chromatid breaks found in cells is substantially less than the DSB frequency as 
the signal might only be produced in actively transcribed areas where the DNA is accessible 
112.  Omega loops as suggested by both the exchange (Figure 1.6) and signal model (Figure 
1.7) have also been observed in cells treated with ICRF-193 (Imperial Cancer Research 
Fund-193) for several hours 123. Cells escaping the G2 block induced by this agent showed 
omega figures as well as multiple chromatid breaks. Mis-joining of chromatin strands at the 
base of loops following γ-radiation could reflect a similar mechanism. 
 
1.5.4 Topoisomerase II and the signal model 
The signal model proposes that the DSB formed by irradiation is repaired, but a ‘signal’ 
triggers the formation of a transient chromatid break that can be seen in metaphase when the 
exchange of chromatin ends is abruptly halted by cell fixation. The nature of the signal is 
unknown. However, it might for example result from a distortion of the chromatin loop domain 
due to the presence of an initial DSB  112. Possible candidates playing a role in this signalling 
pathway include DNA-PK, ATM or ku80 108,112.  
 
Another candidate for producing a chromatid break is topo IIα. Topoisomerase II is an 
enzyme that can cut both DNA strands as part of chromatid decatenation 124 and as such is a 
perfect candidate to play a role in the formation of chromatid breaks after irradiation. Other 
reasons include its location at the base of chromatin loops 121,125, its ability to excise these 
loops 126, its role in exchanges 127, cell cycle expression patterns 128 and it is the target of 
many endogenous and exogenous compounds that lead to a change in activity resulting in an 
excess of DSBs. Experiments in a hamster-human hybrid cell line also showed that topo II is 
capable of excising loops as amsacrine-induced deletions in the MICI locus on the human 
chromosome 11 resulted in the loss of 1.5 – 2 megabases 129. Topo II-targeting drugs in 
histone-depleted nuclei and native chromatin resulted in similar DNA cleavage patterns 
suggesting that these drugs mainly target matrix-associated topo II and that DNA close to 
these regions is preferentially damaged by topo II 130.  Also, after precise ultraviolet-A (UV-A) -
treatment, topo IIα and β localise to that specific irradiated area 131, which suggests that topo 
II is either involved in DNA damage repair or, is signalled to mis-join DNA ends. The normal 
role of topo IIα and its characteristics will be discussed in more detail in the following section.  
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1.6 Topoisomerase II 
1.6.1 Introduction 
 
“DNA topoisomerases are the magicians of the DNA world” 132 
 
Topoisomerases are so named for their role in changing the topology of DNA into different 
isomers. Their role in the cell is extremely important and in some cases even essential for cell 
survival. Through their action, topoisomerases control many processes including replication, 
transcription and most importantly mitosis in which daughter chromosomes are decatenated. 
For reviews see Wang 1985 133, 1996 134 and 2002 132, Gellert 1981 135, Watt and Hickson 
1994 136 and Deweese and Osheroff 2009 137. There is much interest in topoisomerases on 
account of the drugs that are used clinically that target them and the role of topoisomerases in 
DNA topology. Topoisomerases are classified as either type I or II according to their ability to 
cause either single 138,139 or double 140,141 strand breaks and changing the linking number by 1 
or 2 respectively (Figure 1.8). The linking number represents the number of times two strands 
are intertwined. Type I topoisomerase cuts a single DNA strand, allowing the DNA to unwind 
by one linking number, and then rejoins the break 138. This activity is employed ahead of the 
replication fork where DNA is overwound, also known as positively supercoiled (Figure 1.8). 
Topo I is required alongside helicases at the replication fork as helicases alone would only 
separate, and not unwind, DNA strands. In the absence of topo I this would then lead to 
overwound strands which would inhibit replication fork progression. Topo I is therefore 
required to unwind these strands so replication can continue. A similar requirement for topo I 
is found during transcription and even chromosome condensation 132.  
 
 
 
Figure 1.8: Negative (-) and positive (+) supercoiling. Numbers represent the linking number. 
 
Although topo I has important roles in cellular processes, it is not essential as yeast mutation 
studies have shown. If topo I is absent, topo II, a type II topoisomerase, can replace its 
cellular function 142,143. 
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1.6.2 Topoisomerase II isoforms 
There are two different isoforms of topo II present in mammalian cells, topo IIα and β. These 
are present in all higher eukaryotes, excluding Drosophila which only encodes one isoform 
most reminiscent of topo IIα 144. The topo IIα gene, located on chromosome 17q21-22 as 
determined through cloning its complement DNA (cDNA) from human cells (HeLa and Raji-
HN2 Burkitt’s lymphoma) 145,146, codes for a 172 kDa protein that is immunologically distinct 
from the 180 kDa protein 147-149 encoded by the topo IIβ gene on chromosome 3p24 146,150. 
Topo IIα and β also vary in the number of exons coding the proteins; topo IIα has 35 and topo 
IIβ 36 exons 151,152. The two isoforms show 72% identity and contain highly conserved regions 
apart from the N-terminus and a large proportion of the C-terminus 150. It is thought that as 
their intron-exon arrangement is very similar, the two isoforms have arisen by gene 
duplication 151,152. Topo IIβ has two differentially spliced forms of mRNA (messenger RNA), 
one leading to a protein that has TFLDQ inserted following valine at position 23 153. The role 
of this insertion is unclear, but it might alter subcellular localisation or post-translational 
modification. As well as two topo IIβ mRNA forms, cells also express a novel 160 kDa protein 
form of topo IIα that was discovered in mitoxantrone-resistant cells 154-156. 
 
More interest has been placed on topo IIα for several reasons. Not only was it the first of the 
two to be purified in mammalian cells in 1981 140 , six years before topo IIβ 148, but it was also 
the first to be cloned 145. Also its expression patterns suggest a more functional role. Whereas 
topo IIβ is expressed at a constant level throughout the cell cycle, increased only during cell 
quiescence, topo IIα expression peaks at the G2/M phase before decreasing during G0/G1 and 
increasing again at S phase 128. In human PBLs it was also shown that topo IIα was required 
less in resting cells 157. Expression of both isoforms increased to comparable levels after PHA 
stimulation, although topo IIβ, not topo IIα, expression was lowered by 50% after longer PHA 
stimulation 157. This increased topo IIβ expression in cycling cells contradicts previous findings 
128 and is thought to be due to different methodology and antibodies. Topo IIα is also thought 
to be the dominant isoform as Chinese hamster lung cells, in which topo IIβ has been 
inactivated to confer resistance to 9-OH-ellipticine, are still viable 158. Cells can only 
temporarily survive a knockdown of topo IIα expression which can be circumvented by using 
temperature-sensitive topo IIα mutants 124,142. Topo IIα expression is also increased in 
transformed cells, suggesting it could be a marker for cell proliferation 159. Interestingly, topo 
IIα expression is increased in breast tumours where erbB (Her2), the target for the drug 
Herceptin, is amplified in tandem arrangement 160.  
 
One main question that as yet lies unanswered is: ‘Why does the cell encode two isoforms 
that are structurally and mechanistically very similar?’  
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1.6.3 Functions 
Topo II has many cellular functions including replication and transcription. As negative and 
positive supercoils (Figure 1.8) form behind and ahead of both the replication and 
transcription complex respectively, topo II is required to relax these supercoils or else the 
complexes cannot proceed or be removed 161-164. As replication is topology dependent 165, 
topo IV, an Eschericia coli homologue of human topo II, is necessary to ensure together with 
DNA gyrase ahead of the complex that enough, but not too much, negative supercoiling is 
present to initiate replication, as well as transcription 166. In human cells, topo I and II both 
function ahead of the complex and only topo II is found to act behind it 161,166,167 as it is able to 
relax duplex DNA by transporting one strand through the other 140,141, whereas topo I can only 
act within, rather than between, duplex DNA 139.  
 
After newly replicated strands are untangled by topo II, they are still kept slightly catenated 
until closer to mitosis. However, nearer to mitosis, these catenations must be removed by 
topo II to allow for chromosome condensation in prophase 124, although it appears topo II 
stabilises rather than initiates condensation 168,169. 
 
Cells might survive without topo IIα if it were not for its role in sister chromatid decatenation at 
mitosis 168-172. If topo II is inhibited, G2 checkpoint activation (section 1.3.2) prevents cells from 
entering mitosis, or if already in mitosis, a different checkpoint prevents cells from entering 
anaphase. Cell cycle progression is resumed only when cells are capable of decatenating 
sister chromatids as if this is not ensured DNA damage can occur after the chromatids are 
pulled to either side of the cell in anaphase. Topo II has also been associated with apoptosis 
173. 
 
All functions mentioned above have been attributed mostly to topo IIα. Topo IIβ cannot adopt 
the mitotic function in human cells 174, even though both isoforms can substitute yeast type II 
topoisomerase in mitosis 175. Although it has been suggested that topo IIβ can act at the 
transcription complex too 176, the only functions this isoform has been convincingly associated 
with are ageing 177, differentiation 178,179 and neuronal development 180. In some cases topo II 
activity is thought to be decreased in differentiated cells 181, however this is most likely 
influenced by a decrease in topo IIα not β activity. 
 
Whereas topo IIα preferentially binds AT rich domains 147 such as those found at the nuclear 
scaffold 182; topo IIβ preferentially binds GC rich areas such as in nucleolar DNA suggesting a 
role in ribosomal RNA transcription 147 . 
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1.6.4 Localisation  
Although topo IIα and β activity is similar mechanistically, how is it that their cellular functions 
vary? Perhaps tissue, cellular and chromosomal localisation might be a key to this.  
 
Tissues 
Topo IIα expression is high in highly proliferating tissues such as the spleen, testes and 
proliferating endometrium 183,184. Topo IIα mRNA levels are also high in the spleen, testes, 
thymus, bone marrow and intestine 185. Interestingly, although low amounts of topo IIα protein 
are found in the liver, it appears to be inactive as after purification it cannot decatenate 
kinetoplast DNA (kDNA). This might be because the liver proliferates only during acute injury, 
so perhaps topo IIα levels and activity increases only after injury 184. Topo IIβ protein on the 
other hand is generally distributed in differentiated or lowly proliferative tissues such as the 
brain 177. It can therefore be concluded that the tissue distribution does suggest that topo IIα 
is mostly required in proliferative tissues and that only after differentiation does topo IIβ 
become the primary isoform. 
 
Cellular 
Although topo II might be active, if it is not located near DNA, one would not expect it to 
function on a cellular level. Cellular localisation is determined by both nuclear localisation 
sequences and nuclear export sequences (NES), located between the breakage/reunion and 
nuclear localisation domains (in the C-terminus),q of topo IIα and β 186. Topo IIα is rarely in 
the cytoplasm, except in the plateau phase of cell growth 187, again suggesting that it is the 
more dominant and functional isoform. Nuclear localisation sequences (NLS) found in the C-
terminus of topo II bind importin α, which ensures nuclear localisation of the protein 187. It has 
been suggested that topo IIα does not shuttle constantly between the cytoplasm and nucleus 
in proliferating cells, but only becomes cytoplasmic after certain signals allowing for the active 
export of this protein 187. 
 
In interphase, topo IIα and β are expressed in the nucleolus and nucleoplasm 185,188-191. 
However, due to its role in the decatenation of sister chromatids, most of the focus has been 
placed on cellular localisation during mitosis. In most phases of mitosis topo IIα is associated 
with chromosomes 190,192. It is thought that topo IIα has a role in human condensation in 
prophase as it is located on chromosomes 193,194. In late anaphase and telophase, topo IIα 
starts moving to the cytoplasm, with foci appearing in the reforming nucleoli 188.  It is thought 
that Drosophila has three separate mitotic topo II pools, which all leave the nucleus at 
different stages of the cell cycle. In human cells this would mostly relate to the topo IIα 
isoform. The first topo II pool in Drosophila dissociates at prophase, which might infer a role in 
condensation, another leaves at metaphase, after chromosome segregation, and the rest 
remains attached to chromosomes which suggest a structural role 195. Topo IIβ on the other 
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hand is mostly cytoplasmic during mitosis with little to none found on chromosomes; perhaps 
because topo IIβ is pushed out of the nucleolus due to either higher affinity of topo IIα to DNA 
185,192, or through active export 192. It was thought that as topo IIβ was not bound to 
chromosomes during mitosis 178 that it could not be involved in the mitotic function usually 
associated with topo II. 
 
Chromosomal 
The association of topo II with chromosomes is essential for its activity in decatenating sister 
chromatids. The overall paradigm is that topo IIα is chromosome-bound during mitosis 125,191. 
However, where on the chromosome does topo IIα bind? Results are varied due perhaps to 
species type 189, fixation methods or stage of mitosis. What is certain is topo IIα’s location at 
the base of chromatin loops 121,125,182,196.  
 
It was shown that after histone-depletion the DNA is still highly folded suggesting other 
proteins must be holding it together, collectively forming an X-shaped central proteinaceous 
scaffold from which DNA radiates as a halo 197,198. Scanning electron microscopy data 
confirmed this radial loop model 199. Other data suggests that these radial loops coexist with 
helical coils in metaphase 200. It was quickly determined that the main non-histone protein 
present was scaffold protein 1 (SC1) at 1-2% of total mitotic chromosomal protein and this 
was established to be the 170,000 molecular weight protein, topo IIα 121,125,201.  Average loop 
size in HeLa metaphases is 70,000 bases 198 and the matrix/scaffold-associating region 
(MAR/SAR) found at the bases of these loops are preferential binding sites for topo II 
125,182,196,201,202. Topo II is known to excise these chromatin loops suggesting that poisoning 
topo II can result in the loss of these genetic areas 130.  
 
The precise areas of the chromosomes bound by topo IIα varies according to the stage of 
mitosis. In prophase, topo IIα is nucleolar with some bound at kinetochores 188, in 
prometaphase and metaphase it moves to areas along the central axis of the chromosomal 
arms 193 and in anaphase less is expressed at the centromere, with some still present on the 
arms 203. Other groups have also determined that topo IIα is bound in mitosis to chromosome 
arms 192.  It was also concluded that the 13S condensing complex and topo IIα together show 
a barberpole appearance with one being expressed, then the other 194, substantiating a role 
for topo IIα in chromosome condensation.  
 
As well as binding chromosomally during mitosis topo IIα is also bound during interphase, as 
is topo IIβ.  Chromosomal localisation of topo IIβ in mitosis 203 however is quite controversial 
as it does not decatenate sister chromatids 174. It was determined that some topo IIβ localises 
at centromeres only in early mitosis and at chromosome arms until telophase 203. Studies with 
biofluorescent chimera of topo IIβ also determined low levels of topo IIβ bound to 
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chromosomes at metaphase, yet topo IIα is still the main isoform present on chromosomes 
during mitosis 191. It therefore seems that the main isoform involved in mitotic topo II activity is 
topo IIα.  
 
In the same study it was suggested that some chromosome-associated human topo IIα 
remains non-motile after photobleaching suggesting a structural role 191. This structural role 
was also proposed after experiments using pBR322 DNA relaxation studies showed that topo 
II activity was reduced in mitosis yet topo IIα still bound to chromosomes in mitosis 190,192. 
However, in in vitro studies of Xenopus cells topo II was easily extracted and chromosome 
shape did not change, suggesting that topo II is not involved structurally 204. Also the rapid 
exchange between the cytoplasm and chromosome of topo IIα does not support a structural 
role, although the authors do allow the possibility of some topo IIα remaining bound to 
chromosomes 188. Although topo IIβ is present at low levels on chromosomes in mitotis, it is 
more likely that topo IIα is the active isoform in this stage of the cell cycle.  
 
1.6.5 Structure  
Currently, no complete crystal structure of human topo II has been determined. A large 
amount of the information regarding mammalian topo II structure has been determined from 
studies on bacterial DNA gyrase and topo IV, Schizosaccharomyces pombe and 
Saccharomyces cerevisiae topo II, and archeal topo VI as their primary sequences are 
homologous 205. Human topo II mostly forms a homodimer 140 and occasionally a heterodimer 
206, thus when looking into topo II isoform localisation, expression or regulation, it is important 
to note that heterodimers might act differently.  
 
Topoisomerase II has three functional domains. Firstly, the N-terminal domain contains an 
adenosine triphosphate (ATP) binding site and is capable of ATP hydrolysis and dimerisation 
205,207. Secondly, a highly conserved part of the enzyme, the central region, includes the 
catalytic tyrosine residue as well as the breakage and reunion activity. Finally, the C-terminus 
includes another DNA binding site as well as dimerisation, nuclear localisation/export 
sequences and posttranslational modification sites, including serine/threonine 
phosphorylation sites 187,205,208. These three domains correspond with those found in type II 
topoisomerases of Schizosaccharomyces pombe, Saccharomyces cerevisiae 136,166. For 
instance, E. coli DNA gyrase regions Gyr A and B are similar not only to the Par C and Par E 
subunits of E. coli topo IV respectively, but also to the central domain and N-terminus of 
eukaryotic topo II 136,205.  
 
Interestingly the N-terminus is the most conserved domain of type II topoisomerases. The 
central region is still quite highly conserved, but the C-terminus appears to be the area of 
most variability 136.  
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1.6.6 Mechanism 
Much of topo II’s mechanism (Figure 1.9) has been determined from various dimer 
intermediates crystallised with a DNA duplex or nucleotide. There is a high sequence 
homology between human, yeast and Drosophila topo II 145 and as mentioned human topo II  
can replace yeast topo II mechanistically 175. It is therefore logical that in the absence of a full 
human topo II crystal structure, data derived from yeast or Drosophila type II topoisomerases 
such as the following can be applied to human topo II. The first mechanistic step involves the 
dimer binding a duplex DNA, also called the gated segment (G-segment) as it forms a gate 
through which the other duplex DNA is transported (T-segment). The affinity of topo II to the 
G-segment is increased when magnesium ions are bound 209 or when the DNA sequence is a 
specific topo II-targeting sequence although topo II activity is also affected by DNA structure 
and bendability 210,211.  When the G-segment binds topo II, this dimer changes structurally 
resulting in its two catalytic tyrosine residues to become located close to each other 210. This 
change in protein structure also renders these tyrosine residues and the magnesium ions 
close to the DNA duplex. This DNA duplex becomes bent at an angle of 150° when bound to 
topo II.  
 
After the DNA (G-segment) is bound, it is in an equilibrium state between cleavage and 
religation 210,212. Cleavage of DNA involves each monomer of topo II creating a single strand 
break and remaining linked to a 5’ end of DNA by phosphotyrosine on opposite strands, 4 
base pairs apart 212-216. This covalent bond keeps the dimerised topo II bound to the DNA 
ensuring that the genetic material of the G-segment is maintained as accurately as possible 
and is often referred to as the cleavable complex.  
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Figure 1.9: Mechanism of topoisomerase II. The enzyme dimer binds the gate segment DNA 
double helix (G-segment) and is in an equilibrium state between cleavage and religation. When 
ATP is bound, the transported double helix (T-segment) is able to bind and pass through the G-
segment and be released. ATP hydrolysis to ADP and Pi allows for the recycling of the dimer.  
 
 
Once one ATP molecule binds each monomer, the dimer undergoes a conformational change 
resulting in DNA (T-segment) strand passage 212. This strand passage allows for the 
decatenation of daughter duplex DNA 123,170,217. Interestingly, although the use of non-
hydrolysable ATP analogues suggests a role for ATP in protein turnover, no ATP is required 
for the cleavage-religation equilibrium of the G-segment 218,219. After ATP hydrolysis to 
adenosine diphosphate (ADP) and inorganic phosphate Pi, another conformational change 
occurs resulting in the opening of the C-terminal gate through which the T-segment can now 
be released 212. DNA binding alone also results in the opening of the C-terminal gate, 
suggesting that the T-segment does not need to be present 210. 
 
It is now predominantly accepted that, as suggested by the two-gate model, the T-segment 
enters the topo II dimer through the ATP-containing N-terminal domain and leaves through 
the C-terminal domain 220,221.  
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1.6.7 Poisons and inhibitors 
As already pointed out, topo II is involved in many important cellular processes. For this 
reason, many drugs used clinically target topo II and affect its activity, resulting ultimately in 
cell (tumour) death. Similar drugs are being used as antibiotics, such as the quinolones 
nalidixic acid and ciprofloxacin 222,223. Topo II-targeting drugs can be classified into either 
catalytic inhibitors or poisons, with most clinical drugs falling in the latter category. These 
poisons however are mostly referred to as topo II inhibitors in the literature. Here, for the sake 
of clarity, they will be referred to as topo II poisons.  
 
As already explained (section 1.6.6) topo II activity requires the binding of a G-segment, 
which when cleaved, will form the gate through which the T-segment is moved. This T-
segment is released, the G-segment is religated and ultimately the DNA linking number has 
changed by a factor of 2 140,141. A drug is generally considered a ‘topo II poison’ when it 
interferes with topo II activity in such a way that the G-segment is still cleaved and DSBs are 
still formed. This is unlike catalytic inhibitors, which do not cause DSB.  
 
Inhibitors 
Although many type II topoisomerase inhibitors exist, the only inhibitor used in this thesis is 
the bis (2,6-dioxopiperazine) derivative ICRF-193. This inhibitor is known to target type II 
topoisomerases 224. As a true catalytic inhibitor ICRF-193 does not stabilise a cleavable 
complex, instead inhibiting protein activity by trapping the enzyme as a closed protein clamp. 
It maintains this closed clamp formation only in the presence of ATP 224. As topo II activity is 
inhibited, chromosome segregation will no longer occur in anaphase and to prevent further 
damage cells are blocked through the G2/M checkpoint in G2 54.  
 
Most non-intercalating drugs affect one isoform more than the other. ICRF-193 is no 
exception as it preferably targets topo IIα rather than β 225. Although the definition of catalytic 
inhibitors suggests that they do not cause DNA damage, at high drug concentrations ICRF-
193 can 226. However, as the concentrations used here are low, this should not be the case in 
the experiments performed here. 
 
Exogenous poisons 
The most clinically used drug is etoposide, also known as VP-16, which is classified as a topo 
II poison and has been used in the last 20 years for the treatment of leukemias, lymphomas 
and several solid tumours 227. Topo II poisons are used alongside radiotherapy as they 
sensitise cells to the effects of radiation and thus increase cell death and tumour size 
diminishment. They are considered tumour specific as cells, such as breast cancer cells, 
generally have a higher topo II level and therefore are more sensitive to the topo II-targeting 
drugs 160,228,229. Other antitumour topo II-targeting drugs exist although the only one relevant 
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to this thesis is amsacrine hydrochloride; also known as mAMSA or 4’-(9-
acridinylamino)methanesulfon-m-aniside 222,230. It acts on topo II in a similar way to etoposide, 
stabilising the cleavable complex 231 and ultimately inducing cell death.  
 
mAMSA is an intercalator that stabilises the cleavable complex, which defines the DNA 
duplex bound to the topo II dimer 230. Generally, when a drug is bound to the cleavable 
complex, it is referred to as the ternary complex. Stabilising the cleavable complex, in this 
case by inhibiting religation, increases the number of DSBs formed by topo II 230,231. Unlike 
ICRF-193, mAMSA targets both topo IIα and β equally 225.  
 
Other exogenous poisons that are relevant, though which have not been used experimentally 
in this thesis include quinones. Quinones, such as 1,4-benzoquinone found in cigarette 
smoke, bind topo II and trap the G-segment causing DSBs and have been associated with the 
t(8;21) translocation found in acute myeloid leukemias 232 and translocations involving 11q23 
often associated with infant leukemias.  
 
As well as inhibiting topo II catalytic activity, many topo II inhibitors also affect topo II poison 
activity. If added before the addition of topo II poisons, such as etoposide or mAMSA, ICRF-
193 and other inhibitors can prevent the cleavable complex from forming in the first place, 
thus decreasing DNA damage 233-235.  
 
Endogenous poisons 
As part of the signal model it is possible that topo II activity, if involved in chromatid break 
formation, is affected by endogenous topo II poisons. Both topo IIα and β activity can be 
affected by DNA lesions and they can locate one in a background of several 1000 
undamaged base pairs 236. Oxidized and mono-alkylated DNA adducts fall into this category 
236 and show the general ‘positional specificity’ 237 found with all endogenous poisons, where 
they only affect activity if located between the four base pair scissile bonds of topo II. This 
‘positional specificity’ could be regarded as a ‘signalling’ mechanism to topo II. 8-oxoguanine 
is an endogenous topo II poison that is found in normal tissues at 7500 per genome, though 
levels in smokers are 50% higher 236. O6-methylguanine is normally found at 20,000/genome 
in people who smoke or have occupational exposure to alkylating agents. Neither affect DNA 
religation by topo II 236. 
 
DNA lesions such as abasic sites, which are normally found during excision repair, 
recombination or after ionising radiation or reactive oxygen species, can be more potent than 
etoposide. Abasic sites, and more specifically apurinic sites, do not interfere with religation 
and are considered more than 2000 times more potent than etoposide. Although they can be 
quickly removed, if repair is faulty or a few sites are left behind, they can dramatically 
increase the formation of topo II-induced DSBs 237-239.  
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Bioflavonoids such as quercetin and genistein, which are normally recommended as part of a 
healthy diet due to their antioxidant content, are associated with mainly infant leukaemia. In 
these cases, although the infant had not come into contact with topo II-targeting drugs in 
utero, they still developed leukemia as their mother’s dietary intake of bioflavonoids during 
pregnancy had affected topo II activity 240,241. One might question why topo II is allowed to 
cause such levels of DNA damage if the alterations could be mutagenic. Perhaps it acts as a 
“cellular barometer for genomic damage”, causing cell death when the level of damage is too 
high and repair is unfeasible 242. 
 
Another endogenous topo II poison is the hydroxyl radical. This is important to mention as in 
Chapter 6 hydrogen peroxide is used to question the role of topo II in forming DNA and 
chromosomal damage via 
.
OH radicals and it will be discussed later in this thesis.  
 
1.7 Topo II and DNA or chromosomal damage 
1.7.1 Topo II in chromosomal aberrations  
Although normal topo II action involves DSB induction, the DSBs are protein-associated and 
the DSB is usually religated soon after, so no overall damage will have occurred. One can 
assume that if something goes wrong during this process, a DSB might either remain 
unrepaired or topo II might mis-join the ends of the DSB. In S-phase, the replication fork can 
collide with the topo II cleavable complex, where the DSB is still bound to the dimer. This 
results in the enzyme being released from the DSB and this damage can cause sister 
chromatid exchanges (SCEs) and chromosome aberrations (CAs) 243. Here, chromosome 
aberrations refer to breaks or gaps on both sister chromatids as well as dicentrics, rings and 
multi-centric chromosomes. Other groups have also shown that topo II poisons, such as 
amsacrine, etoposide, doxorubicin and ellipticine can produce CAs and SCEs 127,244 as the 
cleavable complex is often stabilised and DSB induction rather than religation is favoured. 
The SCE induction by these drugs is known to be formed through topo II activity because in 
drug-resistant cells, in which topo II activity and expression is reduced, CAs or SCEs were not 
created 127,244.  
 
It has also been shown that the presence or absence of a cleavable complex can determine 
the type of chromosomal damage, whether chromosome or chromatid aberrations. As 
explained earlier, chromatid aberrations refer to damage to only one sister chromatid, 
whereas chromosome aberrations refer to damage to both chromatids. If the drug used 
causes the formation of a cleavable complex, CAs can often be found in drug-sensitive, but 
not drug-resistant, cells 245. Topo II poisons that stabilise cleavable complexes such as 
etoposide, adriamycin and mitoxantrone induce CAs 246. Aclarubicin, a topo II inhibitor, rather 
than poison, does not stabilise the cleavable complex and actually decreases the number of 
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poison-induced CAs 246,247. Although these studies do also mention chromatid aberrations 
after 6 or 24 hours of continuous drug treatment, the focus has always remained on 
chromosome aberrations and the definition of chromatid aberrations is ill-defined. It was also 
suggested that the stage within the cell cycle as well as the presence of a cleavable complex 
determines the type of chromosomal damage. If this complex is formed before replication, 
CAs occur and if after, only chromatid aberrations, such as breaks, exchanges and gaps, can 
be seen; the cleavable complex however is not, unlike for chromosomal aberrations, always 
required in the formation of chromatid aberrations 245.  
 
1.7.2 Topo II in translocations 
Cell death occurs when topo II expression and activity is either too low or high 232. Minimum 
activity is required mainly for the decatenation of sister chromatids in mitosis. A maximum 
topo II activity threshold is also in place as without it, the cell will accumulate far more DNA 
damage than it can repair and tolerate. However, if the topo II level is in between these two 
thresholds it is evident from its involvement in CAs and SCEs that higher than normal activity 
levels may lead to disease states 232.  
 
More specifically, topo II can cause translocations at the chromosomal location 11q23 
resulting in MLL where differentiation of pluripotent hematopoietic stem cells or committed 
myeloid or lymphoid stem cells is affected 232. This is thought to be due to the replication or 
transcription complex colliding with the cleavable complex creating a permanent, non-
reversible DSB to which topo II is no longer covalently bound 232,240. Most MLL 
rearrangements occur within a 8.3 kb region that contains putative topo II cleavage 
recognition sequences and it is thought that topo II causes the initial DSB. Mis-repair of these 
DSBs by either the nonhomologous end-joining or single strand annealing repair pathways 
results in the translocations 240,248.  
 
As mentioned earlier, etoposide is the most commonly prescribed anticancer drug and 2-12% 
of patients treated with etoposide-based regimens result in therapy-related leukemia and 50% 
of these show translocations in the MLL gene breakpoint cluster region 249. 11q23 
translocations have also been associated with infant leukemias even in the absence of these 
drugs. It is now thought that endogenous topo II poisons, such as abasic sites, or maternal 
consumption of bioflavanoids are the cause 232,240. Other topo II poisons consumed maternally 
during pregnancy linked to infant acute myeloid leukemia (AML, t(8:21)) include legumes, soy, 
apples, onions, berries and caffeine 240. 
 
As well as etoposide, teniposide is also used clinically for treatment of lung cancer in adults 
and pediatric acute lymphoblastic leukemia (ALL) 240. Also mitoxantrone and anthracyclines 
are used for breast cancer treatment resulting in acute promyelocytic leukemia (APL). 
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Cigarette and wood smoke include phenols, catechols, hydroquinones and benzene which 
cause chromosomal abnormalities at 11q23 in amniocytes from foetuses of smoking mothers. 
Another topo II poison involved in infant ALL caused by the translocation t(4;11) is p-
benzoquinone that is normally detoxified by nicotinamide adenine dinucleotide phosphate 
(reduced) (NADPH) quinine reductase except when its gene is inactivated by a polymorphism 
240. 
 
It has been suggested that topo II activates the NHEJ pathway and mis-repair causes the 
secondary leukemias 250, though NHEJ does not appear defective in AML patients 251. It is 
likely that topo II can become error prone, resulting in the mis-repair of topo II-induced DSBs, 
which ultimately lead to various types of leukemia. This is substantiated in experiments where 
purified topo II was shown to be able to cleave the translocation hotspot MLL breakpoint 
cluster in vitro 240. Mis-repair or mis-recombination has also been suggested as a mechanism 
of chromatid break induction 252. 
 
1.7.3 Topo II in syndromes showing high radiosensitivity 
As well as looking into the role of topo II in leukemia-related translocations, many groups 
question if topo II levels or activity can be a marker for early cancer diagnosis or even predict 
the outcome of topo II-targeting drug treatment. In ovarian, cervical, colon and non-small-cell 
lung cancer both topo IIα and β are upregulated and overall topo II activity is higher 253,254. In 
precancerous and cancerous lesions of the oral mucosa immunohistochemical detection of 
topo IIα was increased when compared to normal squamous epithelium and is related to 
disease stage progression and prognosis 255. It is also known that topo II autoantibodies are 
produced in systemic lupus erythematosus 223. However, what I am interested in is the role of 
topo II in chromatid breaks and in this next section I will focus on topo II and syndromes of 
high radiosensitivity as these show higher than normal numbers of chromatid breaks after 
ionising irradiation. 
 
As mentioned previously, in many disease states, such as breast cancer, deficient repair is 
thought to be a predisposing factor leading to high radiosensitivity. As the area of interest in 
this thesis is the role of topo IIα in chromatid break formation, this section focuses on topo IIα 
expression in syndromes of high radiosensitivity. In primary breast cancer cases, topo IIα 
gene status is increased as determined by fluorescent or chromogenic in situ hybridisation 
(FISH or CISH) 256. Topo IIα expression was also increased as determined by 
immunohistochemistry, although in these cases gene amplification did not correlate with 
anthracycline response 256. This amplification was also seen in two out of five Her-2/neu-
positive breast cancer cell lines, although interestingly one cell line also showed a deletion of 
the top2a gene. Here, in primary breast cancer carcinomas it was also determined that this 
gene amplification or deletion, determined by FISH, was associated with altered topo II 
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expression as well as doxorubicin (anthracycline) sensitivity and resistance respectively in 
Her-2/neu-positive breast cancer cells 160. It was confirmed elsewhere that topo II gene status 
as determined by FISH might be a marker of anthracycline response in vivo as assessed by 
pathological complete remission, here in non-endocrine response breast cancer cases 
overexpressing Her-2/neu 229. In human breast cancer cell lines, sensitivity to amsacrine and 
etoposide correlated with topo IIα and β expression respectively, as determined by western 
blotting 228. As well as determining drug response, topo II expression can also be related to 
the histological grade and lymph node status in breast ductal invasive carcinomas 257.  It has 
also been suggested that unlike Her-2 or topo II gene status or expression, topo II mRNA 
levels cannot act as a marker for anthracyclines, etoposide, amsacrine or taxane sensitivity of 
breast tumours or in breast cancer cell lines 228. This is unexpected as topo IIα expression is 
linked with Her-2 expression even though both topo IIα and Her-2 are found on chromosome 
17q and this area is often overamplified together in breast cancer 160.  
 
The role of topo II in AT is still unclear. AT is thought to be due to mainly increased topo II 
expression and activity found in AT cell lines 258,259 though others suggest that a defect in 
repair might be behind the high radiosensitivity of AT cells 75,260. The mechanism behind 
radiosensitivity and the role of normal cell cycle and DNA repair function is unclear but 
perhaps topo II is involved. This role however is uncertain as in some cases topo II activity is 
lowered rather than increased, suggesting that the AT phenotype is not topo II-dependent 261. 
 
Fanconi’s anaemia (FA) cells are hypersensitive to crosslinking agents and show increased 
spontaneous chromosome aberrations and Bloom’s syndrome (BS) cells show an increased 
number of SCEs. This was thought to be due to decreased topo II activity which originally 
might have provided access to repair proteins to the damaged site. However, topo II activity 
was not altered in FA or BS cells as topo II-targeting drugs did not contribute to this 
hypersensitivity 262,263. 
 
As already mentioned, many topo II-targetting drugs are used clinically, as the amount of 
DNA damage they cause often leads to apoptosis of tumour cells. However, it is possible that 
topo II can cause DNA damage that ultimately does not lead to cell death and if maintained 
might even contribute to disease initiation or progression as stated above. If this is the case, it 
is possible that topo II can be poisoned and its activity become aberrant in such a way that 
chromatid breaks, initiated by DSBs, are formed.  
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1.7.4 Repair of topo II-induced breaks 
A puzzling mechanism is the repair of topo II-induced DSBs. Cells incubated with a topo II 
poison cause cleavable complexes and thus topo II–induced DSBs. These can be repaired by 
NHEJ 264,265. In fact, two separate NHEJ pathways have been suggested for the repair of topo 
II-induced DSBs, namely with and without DNA-PKcs 266. However how do NHEJ repair 
proteins gain access to topo II-induced DSBs as the topo II poison etoposide for example 
stabilises the cleavable complex with topo II still linked to the DSB 267? This would leave the 
DSB inaccessible to repair proteins and the site of damage could therefore not be accessed 
by DNA-PK, which is dependent on the binding of the Ku70 and 80 proteins to single strand 
DNA ends for recruitment 268. It appears that the protein-bound DSB complicates matters 
when trying to determine how they are repaired. 
 
One way in which topo II-linked DSBs might become ‘visible’ to repair proteins is through 
collision of the protein with a replication fork 269. Stalled replication forks allow RPA to bind 
single strand DNA, thus recruiting ATR (ATM-related protein) and all the Rad proteins 
eventually phosphorylating Chk1 and halting DNA replication allowing for DNA repair 270. 
Although replication forks are not present in the G2 phase, where the initial damage of 
chromatid breaks are formed, one can imagine that transcription complexes might act in a 
similar fashion.  
 
It has also been shown that cleavable complexes caused by topo II poisons can be 
proteolytically degraded by proteasomes 271,272. It therefore appears most likely that cleavable 
complexes are degraded leaving DSBs accessible to NHEJ proteins for repair. 
      
1.7.5 Role of topo II in DNA repair  
Due to the mechanistic action in which DSBs are created and repaired, topo II has already 
been implicated in SCEs 127 and illegitimate recombination 273 and a role in DNA repair has 
been suggested. For example, it has been proposed that topo II creates a DSB, thus altering 
chromatin structure and allowing access for repair proteins to DNA damage 274. Although 
Downes et al. 275 found no or little involvement of topo II in excision repair of UV-induced DNA 
damage, DSB repair-deficient X-ray sensitive (xrs) 5 hamster cells have shown a 
corresponding change in total cellular topo II activity 276. These studies have referred only to 
general topo II activity and not either topo II isoform specifically. 
 
Woessner et al. 128 suggested that as DNA repair was more efficient in the G0 phase, in which 
topo IIβ is highly expressed, that it was more likely that this isoform is involved in repairing 
DNA damage. This topo II isoform was also implicated in repair when it was determined that 
topo IIβ knock-out mice, at the late stages of embryogenesis, showed similar neural and 
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neuromuscular abnormalities as seen in cells lacking the repair proteins XRCC4 and ligase IV 
180. Mandraju et al. 277 determined that topo IIβ and not α was involved in repair, as in human 
cells treated with hydrogen peroxide topo IIβ expression, as determined by western blotting, 
increased and followed the trend of already determined repair proteins such as Ku70 and 
WRN (protein affected in Werner’s syndrome). Also, Mielke et al. found that UV-irradiation 
caused an increase in topo IIβ expression at that site 131.  
 
One way in which topo IIβ might be involved in repair is through its role in transcription 176, in 
a similar way to BRCA1, which is involved in transcription-coupled repair where BRCA1 
induces transcription of p21 29. Topo IIβ-related DNA repair could also be indirect through the 
binding of the C-terminus of topo IIβ to topoisomerase II-binding protein 1 (TopBP1) 278. 
TopBP1 has 8 conserved BRCT regions that bind DNA breaks 278 and its involvement in 
replication-related repair has been well-documented through its activation of ATR 279 after 
phosphorylation by ATM 280. Also, in breast cancer TopBP1 changes its cellular localisation 
from the nucleus to the cytoplasm 281. 
 
The literature reviewed above, though not completely convincing as yet, does suggest a role 
for topo IIβ and not α in DNA repair. 
 
1.8 Experimental outline 
As briefly mentioned at the start of this introduction, the aim of this thesis is to determine how 
low dose ionising radiation-induced chromatid breaks are formed and whether data support 
the signal model. The signal model suggests that the initial radiation-induced DSB is 
eventually repaired, yet still results in a chromatid break through the recruitment of as yet 
unknown proteins. In this thesis I have tested the involvement of topoisomerase IIα in the 
formation of chromatid breaks. There are several ways in which this was done. Firstly in 
chapter 3, I used cell lines that expressed topoisomerase IIα intrinsically at varying levels 
compared to each other. In chapter 4 I employed the short interfering RNA technology to 
‘knock down’ or lower topoisomerase IIα expression and in chapter 5, I lowered 
topoisomerase IIα activity with the catalytic inhibitor ICRF-193. In all these cases, altered topo 
II expression or activity was linked with the frequency of γ-irradiation-induced chromatid 
breaks. In chapter 6, I looked into a way topo II might become involved in chromatid break 
formation, namely via the formation of 
.
OH radicals. Hydrogen peroxide was used as a source 
for 
.
OH radicals and the possible effect on DSB and chromatid break induction was 
determined.  
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2.1 Propagation of mammalian cells  
2.1.1  HL60 and variant cell lines (MX1 and MX2) 
Human promyelocytic leukaemic parental HL60 and mitoxantrone-resistant variants MX1 and 
MX2 cell lines (ATCC: American type culture collection, Manassas, USA) were grown in 
suspension in RPMI-1640 medium (Royal Park Memorial Institute medium; Gibco, Paisley, 
UK) containing 10% foetal calf serum (FCS) (Globefarm Ltd, Cranleigh, UK), 2 mM L-
glutamine (Invitrogen Life Technologies, Paisley, UK), 50 μg/ml streptomycin (Invitrogen) and 
50 units/ml penicillin (Invitrogen) at 37°C, 5% CO2. Passaged cells were kept in 75 cm2 tissue 
culture flasks (T75) (Thermo Fischer Scientific, Roskilde, Denmark) and experimental cells in 
25 cm2 flasks (T25). Cells were passaged before they reached maximum concentration to 
prevent differentiation into neutrophils. The cells were counted (see 2.1.3) and seeded at 
200,000 cells / T75 or T25 to continue culture or start an experiment.  
 
2.1.2  hTERT-RPE1 cell line 
Human telomerase reverse transcriptase-transformed retinal pigment epithelial (hTERT-RPE1) 
cells were obtained from the ATCC and were maintained in exponential growth in DMEM-F12 
medium (a 1:1 mixture of Dulbecco’s Modified Eagle’s medium and Ham’s F12 medium; 
Gibco) containing 10% FCS, 2 mM L-glutamine, 50 μg/ml streptomycin and 50 units/ml 
penicillin at 37°C, 5% CO2. hTERT-RPE1 cells are adherent and therefore were passaged by 
removal of medium and two washes of 4 ml trypsin/ethylenediaminetetraacetic acid (EDTA) 
(Sigma, 0.5 mg/500 ml). The flasks were incubated for 5 minutes at 37°C in 1 ml of the last 
trypsin wash and were then tapped gently. 10 ml of medium was added to neutralise the 
trypsin, cells were counted and cells seeded at 200,000 cells per T75 or T25 to continue 
culture or start an experiment. Cells were passaged up until passage number 13, when they 
were replaced by fresh stocks from liquid nitrogen (section 2.1.5). 
 
2.1.3  Cell counting 
Cell counts were made using the electronic Beckman Coulter Particle Counter Z1 (Coulter 
Particle Characterization, Hialeah, USA). 100 μl medium-suspended cells was added to 9.9 
ml isoton and the number of cells was automatically determined, above or equal to a size of 
275 fl.  
 
2.1.4 Cryopreservation of cell lines 
To keep stocks of cells at low passage numbers, a number of vials were cryopreserved. Cells 
were pelleted by centrifugation at 2000 rpm (600 x g) for 5 minutes at room temperature and 
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the supernatant was discarded (Heraeus Labofuge 400R, Heraeus Instruments, Hanau, 
Germany). 2 x 106 cells were resuspended in 1 ml medium (containing 10% FCS) and a final 
concentration of 10% dimethyl sulfoxide (DMSO). Cell suspensions were then stored in 1.5 ml 
cryo vials (Corning Incorporated, New York, USA). These vials were placed in a plastic holder 
(Nalgene Cryo 1°C Freezing Container, Roskilde, Denmark) containing a propane-1,2,-diol 
bath and then transferred to a -80°C freezer overnight and then to liquid nitrogen for long-term 
storage.  
 
2.1.5  Defrosting cell lines 
Cells were taken out of the liquid nitrogen, thawed by hand and added to a T75 culture flask. 
9 ml medium was added to the cells in a drop-wise fashion and flasks were incubated for 24 
hours before the medium was refreshed.  
 
2.2 Cell lysate preparation 
Lysates were prepared for immunoblotting against topoisomerase IIα or β-actin. Exponentially 
growing cells were washed twice in phosphate buffered saline (PBS) (Gibco) by centrifugation 
and resuspended in 14 μl/106 cells sample reducing buffer (2% sodium dodecyl sulphate 
(SDS) (BDH Biochemical, Poole, UK), 100 mM dithiothreitol (DTT) (Sigma-Aldrich, Poole, UK), 
10% glycerol (BDH) and 60 mM Tris pH 6.8 (BDH). Protein was then denatured for 5 minutes 
at 100°C and stored at -20°C. 
 
2.3 Protein quantification 
The amount of protein in cell lysates was quantified to ensure equal loading in western blot 
gels. Here the Bio-Rad Laboratories (Hemel Hempstead, UK) Protein Assay was used in 
which known bovine serum albumin (BSA, Promega Corporation, Southampton, UK) 
concentrations, namely 0-8 μg/ml, were used as reference values. The method is based on 
the Bradford assay 282. Briefly, the 5x dye reagent concentrate was diluted 1 in 5 with 
deionised water. The standard samples were prepared as a 1:10 dilution of 10 mg/ml stock 
solutions of BSA. The stock solutions were diluted in 1x protein assay solution in sterile water 
as follows: 
 
Materials and methods 
 
 
39
 
BSA (1 mg/ml) 8 μl 6 μl 4 μl 2 μl 0 μl 
Protein Assay 
Solution 1x 1 ml 1 ml 1 ml 1 ml 1 ml 
Final BSA 
Concentration 8 μg/ml 6 μg/ml 4 μg/ml 2 μg/ml 0 μg/ml 
 
Table 2.1 Bradford dilution solutions for standard curve. 
 
 
Samples were prepared by adding 1 μl of lysate sample to 1 ml of 1x protein assay solution. 
Both samples and BSA controls were mixed by inversion and left at room temperature for 5 
minutes. Prepared standard BSA concentration samples were read at absorbance 595 nm 
and a standard curve was drawn. Protein concentrations in unknown samples were 
extrapolated from the linear part of this curve. 100 mM DTT, found in the sample reducing 
buffer, does not affect the Bio-Rad Protein Assay. 
 
2.4 Western blot 
All gels were prepared freshly and for a western blot, two separate gels, namely resolving and 
stacking gel, needed to be prepared. This is known as the Laemmli method 283. The same 
vertical electrophoresis apparatus (Thistle Scientific Ltd, Glasgow, UK) was used for 
electrophoresis and protein blotting.  
 
2.4.1 Laemmli method 
Firstly, glass plates (8.5 cm) were wiped with 70% ethanol, which was allowed to evaporate 
off, and then assembled onto a setting rig. No rubber spacers were added as they were 
already fixed to the glass plates. Sterile water was then applied to check that the set-up was 
tightly sealed. A 7% resolving gel was made first as follows: 
 
• 5 ml sterile water 
• 2.5 ml Tris (1.5 M pH 8.8) (BDH) 
• 100 μl SDS (10%) (BDH) 
• 2.33 ml acrylamide:bisacrylamide (37:1, 30%) (Sigma) 
• 100 μl ammonium persulphate (APS) (10%) (Sigma) 
• 10 μl N,N,N’,N’-tetramethylethylenediamine (TEMED) (Sigma). 
 
The tube containing the above ‘ingredients’ was mixed thoroughly and 7 ml added to the 
setting rig between the glass plates, covered with 1 ml 70% ethanol and left to set for about 
30 minutes. Once set, the alcohol was poured off and the 3.4% stacking gel was prepared as 
follows: 
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• 5 ml sterile water 
• 2.5 ml Tris (0.5 M pH 6.8) 
• 100 μl SDS (10%)  
• 1 ml acrylamide:bisacrylamide (30%) 
• 100 μl APS (10%) 
• 10 μl TEMED. 
 
Again all ingredients were mixed by inversion and then 1-2 ml applied on top of the already 
set resolving gel and a comb put in. Once the gel was set, the comb was taken out and the 
wells cleaned out with sterile water to ensure the removal of all acrylamide. The 10x running 
buffer was prepared as follows for 1 L: 
 
• 250 mM Tris 
• 1.92 M glycine (VWR, East Grinstead, UK) 
• 1% w/v SDS  
• pH 8.56. 
 
1x running buffer was made up to 1 L with 100 ml 10x stock and 900 ml sterile water mixed 
well. The set gels were removed from the setting rig and placed in the running rig. 1x running 
buffer was poured into the rig ensuring the plates were covered. 
 
Meanwhile, 1 L of 10x blotting buffer was prepared as follows: 
 
• 250 mM Tris 
• 1.92 M glycine 
• pH 8.48. 
 
100 ml 10x blotting buffer was mixed with 50 ml methanol (VWR) and made up to 1 L with 
sterile water. 
 
2.4.2 Sample preparation 
Approximately 10 μg of samples were run mixed with 5 μl sample reducing buffer and 0.1% 
bromophenol blue (BPB). The volume of the sample to be added to the gel to get 10 μg of 
protein was determined from the protein concentration (see section 2.3). 
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2.4.3 SDS-polyacrylamide gel electrophoresis (-PAGE) 
6 μl of prestained broad range protein marker (7-175 kDa) ladder (New England Biolabs Inc., 
Ipswich, USA) was added to the first well and samples were added to the other wells. The 
amount of sample or marker added to each well was made up to the same volume by adding 
the appropriate amount of sample reducing buffer plus BPB. The gel was run in 1x running 
buffer at 100 V for the first 30 minutes with a BioRad PowerPac 300 (BioRad Laboratories 
Ltd., Hemel Hemstead, UK) and then at 150 V until the dye had run to the bottom of the gel 
(approximately another hour).  
 
2.4.4 Transfer of protein to nitrocellulose 
Nitrocellulose membrane (Watman, Schleicher & Schuell, Dassel, Germany), sponges and 
filter paper were soaked in 1x blotting buffer. Once the gel had finished running it was 
removed from the running rig and glass plates. The order of layers in the transfer cassette 
were arranged as follows: 
 
• black cassette 
• sponge 
• filter paper 
• gel 
• nitrocellulose membrane 
• filter paper 
• sponge 
• red cassette. 
 
This blot ‘sandwich’ was slotted into the rig with the black cassette facing the back. Blotting 
buffer was poured into the electrophoresis rig (Thistle Scientific Ltd, Glasgow, UK) and 
proteins were transferred at 100 V for 1 hour.  
 
2.4.5 Western blot analysis 
Protein transfer was checked with Ponceau S red stain (0.5% Ponceau S in 1% acetid acid) 
(Sigma). Membranes were blocked with 2% milk powder in PBS/Tween (0.1%) (Sigma) for 15 
minutes at room temperature. Membranes were further incubated for 2 hours (or at 4°C 
overnight) in either rabbit anti-topoisomerase IIα or mouse anti-β-actin (Abcam, Cambridge, 
UK) at 1:20,000 and 1:5,000 respectively in 10 ml PBS/Tween-20. After being washed twice 
in 10 ml PBS/Tween for 15 minutes, the membranes were incubated in either anti-mouse or 
anti-rabbit antibody both of which were horse-radish peroxidase-conjugated (Pierce 
Biotechnology, Rockford, USA) at 1:100,000 in 10 ml PBS/Tween. Membranes were then 
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washed twice as before. Enchanced chemiluminescent (ECL) reagents were used for 1 
minute for visualisation (Millipore, Watford, UK). Under red light, 1 piece of film (Fuji Medical 
X-ray film, Fujifilm USA) was placed on top of the membrane and the cassette was closed. 
The film was exposed to the membrane for 30 seconds. The film was then removed and 
placed in developer (Sigma) for approximately 3 minutes with agitated movement so as to 
acquire an image that was not overexposed, yet still exposed enough to allow all bands to 
show up. The film was then removed with forceps and placed in methanol to fix for 5 minutes 
and then washed in water and hung to dry.  The film images were scanned to obtain a digital 
image and the amount of protein in samples was estimated using image analysis (Image J).  
 
2.5 Mitotic index 
2.5.1 Flow cytometry 
Mitotic indices were determined by the proportion of mitotic cells labelled by an anti-
phosphohistone 3 antibody. Exponentially growing cells were treated under various 
experimental conditions as explained in each individual chapter. Cells (1 x 106) were then 
washed in PBS, pelleted at 600 x g for 5 minutes at 20°C and fixed in 1 ml 70% ethanol for 30 
minutes on ice. After centrifugation, cells were permeabilised with 90% ice-cold methanol and 
incubated for 30 minutes at 37°C in 1 mg/ml ribonuclease A in 0.5% donkey serum in PBS. 
Cells were then centrifuged as before and resuspended in 2 μg/ml propidium iodide in PBS 
for 30 minutes at room temperature in the dark before being washed once in 1 ml PBS. All 
further steps were performed in the dark. Cells were further stained for phosphohistone 3 
according to the manufacturer’s protocol (Cell Signalling Technology, Danvers, MA, USA). 
Briefly, cells were resuspended in 1 ml incubation buffer (0.5 % BSA in PBS) and centrifuged 
as before. 180 μl incubation buffer was then added to the pelleted cells and samples were 
blocked in this buffer for 10 minutes at room temperature. 20 μl of Alexa-conjugated anti-
phosphohistone 3 antibody was added for 30 minutes at room temperature before cells were 
pelleted by centrifugation as before, resuspended in 0.5 ml PBS and acquired by FACScan 
(Becton-Dickinson BioSciences, Oxford, UK) with CellQuest software (San Jose, CA, USA). 
Data was analysed with Summit software (Dakocytomation, Glostrup, Denmark).  
 
2.5.2 Manual counting 
Mitotic indices were also determined manually to verify trends in siRNA-treated hTERT-RPE1 
cells observed from flow cytometric data in a more cost effective way. Exponentially growing 
cells were treated under experimental conditions as explained in chapter 4. Cells were then 
trypsinised (section 2.1.2), pelleted by centrifugation and resuspended in 5 ml hypotonic 
solution (75 mM potassium chloride (KCl), Sigma) for approximately 10 minutes at room 
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temperature. Cells were fixed 3 times in 5 ml 3:1 methanol:acetic acid (BDH) for 10 minutes 
at room temperature. Cells were finally resuspended in 200 μl fixative. Metaphase spreads 
were then prepared by dropping 10 μl of each sample in fix onto a glass slide allowing the fix 
to evaporate in air. When dry, slides were stained with 10% Giemsa (BDH) in Gurr’s buffer 
(BDH) for 10 minutes, washed in Gurr’s buffer followed by water and then left to dry. 
Remaining samples were kept in fixative at -20°C. The number of cells in mitosis was 
determined at x10 magnification (Zeiss Axioplan 2, Welwyn Garden City, Hertfordshire, UK) 
for 1000 cells of each sample. Cells in mitosis were defined as cells with no nuclear 
membrane and DNA clearly condensed into chromosomes. 
 
2.6 Chromatid break analysis 
Cells underwent mostly the same protocol as described under section 2.5.2. Briefly cells were 
irradiated (137Cs γ-rays, IBL437C; CIS UK Bio-International, High Wycombe, UK), pelleted, 
resuspended in hypotonic followed by fixative solution. The final volume fixative cells were 
resuspended in was 200 μl. Chromatid break analysis in HL60, MX1 and MX2 cells involved 
preparing metaphase spreads on ethanol-prewashed glass slides (BDH) using a humidity 
control cabinet (Hanabi, AO Science Technologies, Chiba, Japan). Metaphase spreads of 
hTERT-RPE1 cells were prepared in air. In all cases, 10 - 20 μl of sample was added to the 
slide and allowed to evaporate in air. When dry, slides were stained with 10% Giemsa in 
Gurr’s buffer (pH 6.8) for 10 minutes, washed briefly in Gurr’s buffer followed by water and left 
to dry. Remaining samples were kept in fixative in eppordorf tubes at -20°C. 100 metaphases 
were examined for chromatid breaks using oil-immersion (x100 magnification) optics (Zeiss 
Axioplan 2). Chromatid breaks were defined as any chromatid discontinuity i.e. gaps and 
breaks with either aligned or misaligned terminal fragments 65. 
 
2.7 DNA double strand break measurements 
2.7.1 DSB induction 
DSB induction was measured either by low-voltage gel electrophoresis or γH2AX 
immunocytochemistry. 
 
Low-voltage gel electrophoresis 
DSBs were determined by low voltage electrophoresis. After treatment (see relevant results 
chapters), exponentially growing cells were centrifuged at 600 x g for 5 minutes at 1oC. 
Medium was aspirated and cell pellets resuspended in 160 μl of 0.8% low melting point (LMP) 
agarose (Sigma) in PBS at 37oC. 80 μl was transferred to each of two gel plug moulds (Bio-
Rad Laboratories) and placed on ice for approximately 5 minutes to set. Plugs containing 
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cells were extruded into 1 ml of ice-cold lysis solution (0.4 M EDTA (Sigma), 2% sodium N-
lauryl sarcosine (Sigma), 1 mg/ml proteinase K (Sigma), pH 8.0) in eppendorf tubes for 30 
minutes. Tubes were then incubated overnight (18 hours) at 37oC. A 200 ml 0.8 % agarose 
gel (Life technology Ltd, Paisley, UK) was prepared in 0.5 M tris acetate EDTA (TAE: Sigma) 
buffer containing 1 μg/ml ethidium bromide (Serva, distributor AMS Biotechnology (Europe) 
Ltd, Abingdon Oxon, UK). Plugs were recovered from the lysis solution and placed in comb 
wells of the 200 ml agarose gel in a BioRad Sub-Cell horizontal electrophoresis apparatus. 
Wells were sealed using 0.8% LMP agarose in PBS, and the gel run in 0.5 M TAE buffer at 
0.6 V/cm (6 mA, 8 V; constant current) for 96 hours. The fraction of DNA released from the 
wells during electrophoresis was used to calculate the induced double-strand breakage. DNA 
was quantified by ethidium bromide fluorescence, analysed using Syngene Genetools 
software (Syngene, Cambridge, UK). The mean fraction of DNA released (FDR) from each 
well (two wells per sample) was determined by the following equation: 
 
FDR = DR/(DR + DW)  
 
Where: 
 
DR = DNA released 
DW = DNA remaining in well 
 
γH2AX immunocytochemistry 
hTERT-RPE1 cells were added as a drop of 2 x 105 cells in 200 μl onto a 22 x 22 mm 
coverslip in a 55 mm in diameter dish. Cells were allowed to attach to the coverslip surface for 
3 hours after which 4 ml complete medium was added to the dish and cells were allowed to 
grow for 2 days. Cells were grown for another 2 days in complete medium until 90% confluent 
or incubated overnight in serum-free complete medium. Cells were then treated 
experimentally as described in the relevant results chapters in complete medium. After a 
fixative stage of 10 minutes in 4% formaldehyde in PBS at room temperature, cells were 
washed twice for 5 minutes in PBS before being permeabilised with fresh 0.2% Triton X-100 
in PBS for 10 minutes. All washes, fix, permeabilisation and probe stages of the procedure 
were performed in a total volume of 4 ml, agitated on a rocker and at room temperature. Cells 
were washed as before and were then blocked four times for 15 minutes in PBS containing 
1% BSA and 0.2 M glycine. 50 μl primary anti-γH2AX mouse monoclonal antibody (Millipore) 
was added at a dilution of 1:100 in fresh 0.5% BSA in PBS with the coverslips covered in 
Nescofilm for 1 hour before being washed four times for 15 minutes in 0.5% BSA in PBS. 
Cells were further incubated in 1:250 dilution of anti-mouse-FITC-conjugated secondary goat 
antibody (Sigma) in the dark, with the coverslips bearing cells covered in Nescofilm for 1 hour. 
Control experiments were also carried out where cells were incubated with secondary 
antibody only. Coverslips were washed twice in PBS, applied to slides with cells face-down on 
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a drop of 12 μl 4',6-diamidino-2-phenylindole (DAPI) /Vectashield (Vector Laboratories Inc, 
Burlingame, CA, USA). Coverslips were sealed with nail-varnish and left overnight at 4°C in 
the dark.  
 
2.7.2 DNA double strand break repair 
HL60, MX1 and MX2 cells were irradiated and further processed in the same manner as 
described above in section 2.7.1 by low voltage gel electrophoresis; the only difference being 
that cells were allowed to repair at 37oC for a predetermined amount of time. Once a time-
point was reached, cells were kept on ice until the last time-point in the series had been 
sampled. Cells were then centrifuged and resuspended in LMP agarose as described above. 
These experiments were carried out by Dr P. Bryant. 
 
2.8 Cell cycle synchronisation 
hTERT-RPE1 cells were seeded at 2 x 105 cells per T25 flask containing 5 ml DMEM-F12 
complete medium and left to grow for 24 hours at 37°C, 5% CO2. The next day sterile 2 mM 
thymidine (Sigma) in medium was added to the flasks and cells were incubated for 16 hours 
at 37°C and in 5% CO2. Cells were then washed with fresh medium to remove thymidine and 
placed back at 37°C, 5% CO2 in medium containing no thymidine. At certain time points cell 
samples were harvested by trypsinisation as described in section 2.1.2 and washed in PBS. 
Cell pellets were fixed in 1 ml 70% ethanol for 30 minutes on ice. Samples were stored in 
70% ethanol at -20°C.  
 
2.9 Silencing RNA treatment 
hTERT-RPE1 cells were seeded at 2 x 105 in a T25 flask 24 hours prior to transfection. They 
were then transfected with various concentrations of short siRNA oligos against 
topoisomerase IIα or, as a control, scrambled siRNA (Negative Control siRNAs that have no 
significant sequence similarity to mouse, rat, or human gene sequences) (Ambion, Warrington, 
UK) using Dharmafect transfection reagents (Dharmacon, Chicago, IL, USA). Briefly, both 7.5 
μl Dharmafect and in a separate tube, siRNA, were incubated in a total volume of 0.5 ml 
antibiotic- and FCS-free DMEM-F12 for 5 minutes at room temperature. The contents of the 
two tubes were then mixed together and incubated for 20 minutes at room temperature. 
Meanwhile cells were washed twice in 4 ml 10% FCS-containing DMEM-F12, and finally 1 ml 
siRNA mix was added to 4 ml 10% FCS-containing DMEM-F12 and subsequently added to 
the cells. The final concentrations of siRNAs used ranged from 0.25 – 2 nM. Cells were 
incubated with siRNAs for 12 hours.  
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2.10  Immunocytochemistry 
Exponentially growing hTERT-RPE1 cells were transfected with siRNA as described in 
chapter 4, before trypsinisation (section 1.2.1) and centrifugation for 5 minutes at 600 x g.  
10,000 cells were cytospun per slide at 50 x g, high acceleration for 7 minutes (Cytospin 2, 
Thermo Fischer Scientific Inc, Waltham, MA, USA) and fixed in 100% cold acetone for 15 
minutes at room temperature. Cells were then washed twice for 15 minutes in PBS before 
permeabilisation with fresh 0.2% Triton X-100 in PBS (PBST). Cells were washed twice as 
before and blocked overnight at 4°C in 5% BSA in PBST in a Copland jar.  Cells were then 
probed with primary anti-topoisomerase IIα rabbit polyclonal antibody at a dilution of 1:500 
(Abcam, Cambridge, UK) in fresh 5% BSA/PBST in a moisture chamber for 1 hour at room 
temperature before being washed as before. Cells were further incubated in 1:160 dilution of 
anti-rabbit IgG-Cy3-conjugated secondary goat antibody (Abcam) in a moisture chamber for 1 
hour at room temperature and in the dark. Slides were washed twice in PBS and finally 12 μl 
DAPI/Vectashield was added and slides were mounted, sealed with nail varnish and kept 
overnight in the dark at 4°C until ready the next day for observation at x63 magnification 
under a fluorescent microscope (Zeiss Axioskop, Welwyn Garden City, Hertfordshire, UK). 
 
2.11 Polymerase chain reaction (PCR) 
2.11.1 RNA extraction 
RNA was extracted from exponentially growing hTERT-RPE1 cells according to the protocol 
accompanying the RNeasy mini kit (Qiagen, Crawley, UK). Briefly, 350 μl RLT lysis buffer, 
which contained guanidine salts at a high concentration (molar range) that denature proteins, 
was added to 5 x 105 cells. Cells were then homogenised to reduce lysate viscosity by 
shearing high molecular weight genomic DNA and cellular components with a 21-gauge 
needle (5-10 times) and mixed with 350 μl 70% ethanol. Samples were then transferred to a 
silica column in a 2 ml collecting tube to allow the RNA to bind to the column, and spun for 15 
seconds at 8000 x g using a bench top centrifuge (centrifuge 5414D: Eppendorf, Hamburg, 
Germany). The flow-through was discarded and the column washed with 700 μl RW1 buffer 
that also contained guanidine salts. The column was then washed twice in RPE buffer 
containing 95% ethanol to remove salts and spun dry to ensure no liquid remained. The 
column was finally placed in a new 1.5 ml eppendorf tube with the lid cut off so that the 
eppendorfs could be placed in the bench top centrifuge. It was ensured that the lids were kept 
sterile. 30 μl sterile water was added to the column and after a spin for 1 minute, RNA was 
eluted. Samples were kept on ice to be used immediately to make complement DNA (cDNA) 
and the rest stored at -80°C. 
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2.11.2 cDNA conversion 
cDNA was made following the protocol of Quantitect Reverse Transcription kit (Qiagen). 
Briefly, 2 μl of 7x genomic DNA wipe-out buffer, containing DNase, was added to 12 μl 
template RNA and left to incubate for 2 minutes at 42°C. These were then placed on ice for 
no longer than 10 minutes whilst the remaining solutions were prepared. 1 μl quantiscript 
reverse transcriptase (RT), which contained RT as well as RNase inhibitors, was added to 4 
μl of 5x RT buffer, which contained deoxynucleoside triphosphates (dNTPs), 1 μl RT random 
primer mix and finally the 14 μl of RNA mentioned above. These were left for 15 minutes at 
42°C on a PCR machine (Techgene, Techne, Cambridge, UK), before being heated at 95°C 
for 3 minutes to inactivate DNase and RT, and stored at -20°C. cDNA concentrations were 
quantified by adding 1 μl to the Nanovue spectrophotometer (Nanovue 4282 V1.7.3, GE 
Healthcare, Little Chalfont, UK). 
 
2.11.3 PCR 
Approximately 1 μg of cDNA was added to each polymerase chain reaction (PCR). Other 
components of the reaction were added as recommended by the Readymix Taq PCR kit 
(Sigma): 12.5 μl buffer, containing the thermostable Taq DNA polymerase from Thermus 
aquaticus and dNTPs, 11 μl dH2O, 0.5 μl cDNA and 0.5 μl forward and reverse primers (0.5 μl 
of 10 μM stock per reaction; VH Bio). The primer sequences were as follows: 
 
• Topo IIα forward primer: ‘5-GCGTGTTGAGCCTGAATG-3’ 
• Topo IIα reverse primer: ‘5-GGTCTTAGGTGGACTAGC-3’ 
 
• β-actin forward primer: ‘5-ACCCCGTGCTGCTGACC-3’ 
• β-actin reverse primer: ‘5-AGGAAGGAAGGCTGGAAGAGT-3’ 
 
Primer sequences were taken from the literature 152,284. PCR was performed on a Techgene 
Thermocycler using the following conditions:  
 
• Preheat lid to 110°C 
• Initialise: 95°C for 3 minutes 
• Cycle of 35 repeats 
o Denature: 94°C for 30 seconds 
o Anneal: 52°C for 30 seconds 
o Extend: 72°C for 1 minute 
• Final extension: 72°C for 10 minutes. 
 
PCR products were stored at -20°C. 
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2.11.4 Agarose gel 
4 μl of PCR sample was loaded onto a 2% agarose gel in 175 ml TAE containing 1 μg/ml 
ethidium bromide buffered with TAE. 1 μl 5x DNA loading buffer blue (Bioline, London, UK) 
was added to each sample. 4 μl marker (Quickload 100 base pairs DNA ladder, New England 
Biolabs) plus 1 μl loading buffer was also run on each gel. The gel was run at 110 V (7.3 V/cm) 
for 1 hour and quantified by ethidium bromide fluorescence, analysed using Syngene 
Genetools software. 
 
2.11.5 Sequencing 
PCR products were purified (Wizard SV gel and PCR cleanup system: Promega, 
Southampton, UK) by adding an equal volume of membrane binding solution to the sample 
and adding it to a column. This was then incubated for 1 minute, spun at 16,000 x g for 1 
minute, washed with 700 μl membrane wash solution containing ethanol and washed again 
with 500 μl membrane wash solution. The column was then transferred to a clean 1.5 ml 
eppendorf tube and after 50 μl nuclease-free water was added, columns were spun for 1 
minute as before to elute the product and samples were stored at -20°C.  The amount of DNA 
present in PCR products was quantified by running the samples alongside a DNA marker 
(Hyperladder I, Bioline) of which the quantity of DNA (ng/band) was known.  
 
3-10 ng of PCR products in 15 μl sterile water, alongside corresponding forward and reverse 
primers (each 3.2 μM) was sent to be sequenced at the Sequencing Service, University of 
Dundee, using Applied Biosystems Big-Dye Ver3.1 chemistry on an Applied Systems Model 
3730 automated capillary DNA Sequencer.  
 
2.12 Topoisomerase II activity assay 
Decatenation of kDNA minicircles from the parasite Crithidia fasciculata was performed 
according to the protocol suggested by TopoGEN, Inc. (distributed by Axorra, Nottingham, 
UK). Briefly, fresh 5x complete assay buffer was prepared by mixing buffer A (0.5 M Tris/ 
hydrogen chloride (HCl) pH8, 1.5 M sodium chloride (NaCl), 100 mM magnesium chloride 
(MgCl2) and 5 mM DTT) with an equal volume of buffer B (20 mM ATP in water). This assay 
buffer was then diluted 1:5 with water to make 20 μl 1x assay buffer per sample. 0.2 μg kDNA 
was then added and the solution was incubated at 37°C for 30 minutes. 4 μl stop 
buffer/loading dye (5% Sarkosyl, 0.125% bromophenol blue and 25% glycerol) and 1.8 μg 
proteinase K (Sigma) was added before further incubation for 30 minutes at 37°C.  
 
The total volume of the assay sample was loaded on to a 1% agarose gel in 175 ml TAE 
containing 1 μg/ml ethidium bromide buffered with TAE. 3 μl decatenated and linearised 
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kDNA markers (TopoGEN Inc.) were also loaded alongside the sample. The gel was run at 
110 V (7.3 V/cm) for 1 hour and quantified by ethidium bromide fluorescence, analysed using 
Syngene Genetools software. 
 
2.13 Single cell gel electrophoresis (SCGE, comet) assay 
hTERT-RPE1 cells were seeded at 2 x 105 cells per T25 flask and allowed to grow for 24 
hours. 300 μl 1% agarose in TAE was added to fully frosted microscope slides (Surgipath, 
Richmond, Illinois, USA) and covered with a 22 x 50 mm coverslip (VWR), to ensure equal 
spreading of the agarose across the slide. Once the agarose was set, coverslips were 
removed and cells were trypsinised (section 2.1.2) and spun at 600 x g to pellet cells. 
Meanwhile cells were counted (section 2.1.3) to ensure that 5000 cells were added to each 
slide. Cells were resuspended in 75 μl of 0.75% LMP agarose in PBS, which had been 
retained at 37°C for at least 30 minutes. As soon as the LMP agarose was added, the mixture 
was spread onto the first agarose layer on the slide with another 22 x 50 coverslip. Again, 
once the agarose was set the coverslip was removed. Cells were treated with hydrogen 
peroxide at 0.1 – 10 nM and then immersed in freshly prepared neutral lysing solution (2.5 M 
lithium chloride (LiCl) (Sigma), 10 mM Tris, 0.03 M EDTA, 0.1% lithium dodecyl sulphate 
(LiDS) (Sigma), 0.03 mg/ml proteinase K, pH 8.0 dissolved at 37°C) overnight at 37°C. Slides 
were kept in fresh cold alkaline lysing solution (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% 
triton X-100, pH10) at 4°C for 1 hour. Slides were then removed, dabbed dry and added to a 
horizontal electrophoresis tank side by side. The tank was filled with electrophoresis buffer 
(0.3 M sodium hydroxide (NaOH), 1 mM EDTA, pH>13) to cover the slides and left for 40 
minutes to allow the DNA to unwind. Slides were then electrophoresed for 20 minutes at 26 V, 
with the buffer volume altered to maintain a constant current at 275 - 300 mA. Slides were 
then drained and washed 3 times in neutralisation buffer (0.4 M Tris, pH8.5) for 5 minutes 
each and washed once in PBS for 5 minutes. Slides were then drained and allowed to dry in 
air. 40 μl of 2 μg/ml propidium iodide in PBS was added to the slides and spread with a 22 x 
22 mm coverslip (VWR). Slides were kept in a moisture chamber in the dark for 2 hours 
before analysis.  
 
Pictures of comets were taken at x10 magnification using a fluorescent microscope (Zeiss 
Axioplan2). It was ensured that the head of the comet was to the left of the tail so that the 
analysis program Comet Assay IV (Perceptive Instruments, Suffolk, UK) could recognise the 
comet and the percentage of DNA in the head (cell nucleus) and tail of the comet could be 
analysed by densitometry. An example comet analysed by Comet Assay IV is shown below 
(Figure 2.1). 
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Figure 2.1: An example of a comet analysed by Comet Assay IV. The blue line represents the 
start of the head, the green line is the middle of the head and the purple line is the end of the 
tail. 
 
 
Analysis was done for 50 comets per experiment and the tail moment was used to define 
DNA damage. The tail moment takes into account both the migration of the genetic material 
and the relative amount of the DNA in the tail.  
 
  
 
 
 
 
CHAPTER 3 
 
LOWER TOPO IIα LEVEL AND ACTIVITY AFFECTS 
CHROMATID BREAK FREQUENCY IN HUMAN CELL 
VARIANTS  
 
 
Lower endogenous topo IIα expression 
 
52
3.1 Introduction 
To determine if human topoisomerase IIα has a role in forming chromatid breaks, I first used 
cell lines that intrinsically show lower topo IIα levels. The parental Human promyelocytic 
Leukemia cell line HL60 was originally derived from a 36-year old woman with acute 
promyelocytic leukaemia at the National Cancer Institute 285,286. Myeloid cells are defined as 
leukocytes that are not lymphocytes (B- and T-cells) and the promyelocytic HL60 cells can be 
induced to differentiate into predominantly neutrophils with a small proportion of monocytes 
285. HL60 cells are tumorigenic and express the oncogene c-myc (cell line information 
provided by the ATCC), which activates telomerase 287. C-myc is a well-known oncogene that 
increases cell proliferation through its activity as a transcription factor 288. Telomerase is 
another protein often expressed at a higher level in cancer cells. It increases telomere length 
by adding TTAGGG to the 3’ end of DNA strands through its reverse transcriptase activity on 
a RNA template 289. Usually cells that divide without telomerase lose some telomeric 
sequences and when telomeres get to a critical length DNA replication can no longer occur. 
Due to its ability to increase telomere length and thus extend cellular lifespan 289 telomerase is 
often inserted into cells to produce immortalised cell lines.  
 
HL60 cells were used by Harker et al. (1989) to create cell lines that were resistant to 
mitoxantrone (MX). MX is a known topo II poison and the MX1 and MX2 variant cell lines 
were produced as follows 290. Briefly, HL60 cells were exposed to the drug for 3 days followed 
by a 3-7 day period of growth in the absence of MX. After 21 passages in gradually increasing 
concentrations of MX, a cell population, named HL60/MX1, emerged that could grow 
continuously in the presence of MX at a concentration of 3.9 x 10-8 M. Further exposure to the 
drug at successively higher concentrations led to the emergence of cells capable of growing 
at 1.9 x 10-7 M MX, named HL60/MX2 cells. Resistance to the drug is associated with 
decreased general topo II activity as well as lower topo IIα and β expression levels 154. As 
explained in section 1.5.4 I have focussed on the isoform topo IIα mainly due to its role in 
DNA decatenation. 
 
3.2 Aims 
The aim was to verify whether lower topo IIα expression and total cellular activity levels were 
actually found in the MX1 and MX2 variant cell lines when compared to parental HL60 cells. 
Also, I aimed to determine whether the drug-resistant variants MX1 and MX2 showed lower 
radiation-induced chromatid break frequency and whether the lower frequencies of chromatid 
breaks correlated with topo II expression and/or activity. 
 
Lower endogenous topo IIα expression 
 
53
3.3 Measurement of topo IIα expression in HL60 and variant 
cell lines 
Procedure 
HL60, MX1 and MX2 cells were grown to a high density (1 x 106 cells per ml) in suspension 
culture, cell lysates were prepared (section 2.2) and the protein concentration within these 
lysates quantified as described in section 2.3. Immunoblotting experiments were carried out 
as described in section 2.4. The data was normalised against β-actin and HL60 values were 
equalled to 100%. Experiments were carried out in triplicate.  
 
Results and discussion 
The relative levels of topo IIα expression in exponentially growing HL60, MX1 and MX2 cells 
were determined by quantitative western blotting. Figures 3.1A and B show that MX1 and 
MX2 cells have lowered topo IIα expression compared to HL60 cells. Protein loading was 
similar in comparative samples as shown by β-actin expression in Figure 3.1A. It is clear that 
the antibodies are specific to either topo IIα or β-actin as the corresponding bands align with 
the marker at their known molecular weight, namely 170 kDa and 42 kDa respectively. 
Although the topo IIα band in a western blot is located just above the 175 kDa marker band, it 
is certain that this band represents the 170 kDa protein as when purified topo IIα was added 
to the gel, the band occurred at exactly the same molecular weight (data not shown). Data 
was normalised against β-actin, although β-actin levels were similar in all cell lines, to ensure 
that slight changes in topo IIα expression were not a result of slightly altered protein loading 
within the different lanes. Following quantification by densitometry, topo IIα values obtained 
for HL60 were set at 100% and topo IIα values in MX1 and MX2 cells expressed as a 
percentage of this HL60 value. This extra normalisation step was imposed as triplicate 
experiments were not carried out on the same gel or membrane and values even within the 
HL60 cell line varied slightly after normalisation against β-actin. These different values, as 
visualised in Figure 3.1A as topo IIα bands in HL60 cells of different intensities, are most 
likely due to slight differences in antibody or blocking agent concentrations or exposure time. 
Increased concentrations of blocking agents alone or combined with decreased 
concentrations of antibodies would decrease band intensity. Also, the development of the film 
was done manually and the developer and fix were not always used fresh, which might have 
affected band intensities between experiments too.  
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Figure 3.1: A: Whole cell lysate probed against topo IIα and β-actin showing lower topo IIα 
expression in MX1 and MX2 cells when compared to HL60 cells. β-actin acts to control for 
protein loading. To the left the molecular weights (kDa) of the marker are shown. B:  Analysis 
through densitometry of western blot data probed against topo IIα and normalised against β-
actin levels that represent protein loading. The data was also normalised against HL60 values. 
Bars represent standard errors of the mean from triplicate experiments.  
 
 
Analysis of the immunoblotting data (Figure 3.1B) by densitometry confirmed that topo IIα 
levels are lower in MX1 and MX2 cells when compared to the parental HL60 line, with MX2 
cells showing the lowest expression of topo IIα. More specifically, MX1 and MX2 cells 
expressed on average 25% and 72% less topo IIα than HL60 cells respectively. This verifies 
previous findings by Harker et al. who stated that MX2 cells have lowered topo IIα expression 
levels, which explained the increased mitoxantrone resistance found in these cells when 
compared to the parental HL60 lines 155. Harker et al. (1995) determined through western 
blotting that topo IIα expression was 40% lower in nuclear extracts of MX2 cells when 
A 
B 
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compared to HL60 cells; they did not determine topo IIα expression in MX1 cells 155. This 
decrease in MX2 topo IIα value is less than the decrease of 72% found here. This is most 
likely down to their use of nuclear extracts, whereas data here was produced only for whole 
cell lysates. Other factors might be the use of different antibodies or the different amount of 
protein loaded in each well. Harker et al. added 100 μg of protein per well, whereas my 
experiments incorporated only approximately 10 μg of protein per well.  
 
3.4 Measurement of total topo II activity as measured by 
mAMSA-induced G2 block in HL60 and variant cell lines 
Procedure 
Amsacrine hydrochloride, also known as mAMSA, was used to indirectly estimate topo II 
activity. mAMSA is a topo II poison that induces DSBs, which in turn elicits a G2 block. 
Therefore an increase in mAMSA concentration should increase the number of DSBs and 
consequently decrease the number of cells in mitosis. It is assumed that this effect is 
dependent on cellular topo II activity as topo II is the only known target protein of mAMSA. 
Exponentially growing HL60, MX1 and MX2 cells (1 x 106) were incubated with mAMSA 
(Sigma, stock in 30% ethanol), ranging from 0 to 20 μM for 30 minutes at 37°C. Cells were 
centrifuged and washed in growth medium before being resuspended and incubated in 
growth medium with or without colcemid (Gibco) at 0.15 μg/ml for 2 hours at 37°C and further 
washed in medium by centrifugation. Mitotic indices were calculated by flow cytometry as 
described under section 2.5.1 for 1 x 104 cells. The mitotic index at 0 μM amsacrine was set 
at 100% for each cell line. The total change in mitotic indices of MX1 and MX2 cells were 
normalised against HL60 change in mitotic index. 
 
Results and discussion 
In addition to establishing topo IIα expression levels in HL60, MX1 and MX2 cells, it was also 
important to establish topo II activity. As it is impossible to distinguish between topo IIα and β 
activity within the cell without purifying them separately, the total enzyme activity was 
calculated. The ability of mAMSA to decrease the number of cells in mitosis, presumably 
through causing double strand breaks 230,231,291 and arresting cells in G2, was measured. Topo 
II activity was assumed to be the cause of this mAMSA-induced G2 block as this drug has not 
been shown to affect any other protein. Therefore, any difference in mAMSA-induced mitotic 
index between HL60, MX1 and MX2 cells can be related back to a difference in topo II activity. 
 
Firstly, the combination of an antibody against phosphohistone 3, as a marker for mitotic cells, 
and a dye against DNA was tested. Flow cytometry is a useful, high throughput tool for 
detecting proteins and determining normal cell cycle distribution. Propidium iodide is used 
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here to label DNA. As it can bind both DNA and RNA, cells were treated with ribonuclease A 
prior to data acquisition to rid the cells of RNA and ensure only DNA content was measured 
292. Here I used propidium iodide (PI) alongside an Alexa-conjugated antibody against 
phosphohistone 3 to determine the mitotic index. If cells are labelled with PI alone, then cells 
in G1, S and G2/M could only be distinguished according to their DNA content. G1 cells peak 
with a DNA content of 1x, G2/M cells would peak at 2x the DNA content and S phase cells 
would be located in between the two peaks as DNA synthesis has yet to be completed. 
Because PI binds DNA indescriminately, it cannot distinguish between cells in G2 or mitosis 
as both have the same DNA content. It is therefore essential to use a marker of mitosis, such 
as histone 3, which is phosphorylated at serine 10 during mitosis 293. Figure 3.2 shows that 
this protocol combining PI and an antibody against phosphohistone 3 is a good way of 
determining mitotic index; with the addition of colcemid, the mitotic index increased from 2% 
to 4% 80. As colcemid blocks cells in mitosis, they cannot proceed to G1 and therefore the 
mitotic index would be expected to increase. 
 
 
 
Figure 3.2: Flow cytometric analysis of non-treated (Panels A-C) or colcemid-treated (Panel D) 
HL60 cells. Cells were labelled with propidium iodide (PI) (FL2-H) and an Alexa-conjugated 
antibody against phosphohistone 3 (FL1-H), a marker of mitosis. Panels A and B are controls 
with single labelling with either PI (A) or anti-phosphohistone 3 (B). Panel C shows a mitotic 
index of 2% which increases to 4% if colcemid is added for two hours (D). 
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Topo II activity is usually measured through the kinetoplast DNA assay that assesses the 
ability of topo II to decatenate many DNA minicircles resulting in non-tangled minicircles 
which can be visualised by gel electrophoresis 294. As I was unable to purify topo II from HL60 
and variant cells, other ways of measuring topo II activity were explored. The assay presented 
here is based on the ability of mAMSA to ‘poison’ topo II. As amsacrine targets both topo IIα 
and β equally 225, activity cannot be attributed to one particular isoform. Therefore this assay 
only estimates total topo II activity. Amsacrine prevents the religation of the G-segment by 
topo II which then results in DSBs 291. As the G2 checkpoint is sensitive to DNA damage, 
amsacrine treatment halts cells in G2 without allowing them to proceed to mitosis. Hence the 
higher the topo II activity is in a cell, the more DSBs will form following treatment with 
amsacrine and the higher the proportion of cells are found in G2 and consequently the lower 
the mitotic index.  Figure 3.3A shows that an increase in amsacrine concentration decreases 
the mitotic index until it reaches a plateau. What is important in this graph is the difference 
between initial values at 0 μM mAMSA and the percentage of cells in mitosis at which the 
response plateaus. This plateau suggests that at high amsacrine concentrations, inhibition of 
topo II activity is saturated and therefore the total decrease of mitotic index must be 
representative of total cellular topo II activity; hence the higher cellular topo II activity, the 
larger the difference. Figure 3.3A shows that the mitotic index decreases most in HL60 cells 
(96%), less in MX1 cells (77%) and least in MX2 cells (55%). These values were calculated 
as the difference between the mitotic index at 0 and 20 μM mAMSA. This implies that 
amsacrine causes less DSBs in MX1 and MX2 cells than in HL60 cells, most likely due to less 
topo II activity.  
 
Harker et al. 154 previously determined total cellular topo II activity in HL60 and MX2 cells with 
the kinetoplast DNA decatenation assay and found that topo II purified from nuclear extracts 
was on average four times (75%) less active in MX2 cells when compared to HL60 cells. They 
also found that total cellular topo II activity, i.e. including both nuclear and cytosolic fractions, 
was decreased by 50% in MX2 cells 154,155. These topo II activity values determined by Harker 
et al. differ from the data presented here. My assumption that the difference in mitotic index 
caused by mAMSA in HL60 and MX2 cells was due to altered topo II activity is therefore not 
completely valid as according to this method, topo II activity is only 57% less in MX2 cells 
when compared to HL60 cells (100%) (Figure 3.3). Harker et al. on the other hand had 
determined topo II activity to be decreased by 75% in MX2 cells for nuclear fractions. One 
reason for this discrepancy might be that not every single topo II-induced DSB is recognised 
as DNA damage. A signalling cascade that would normally result in a G2 block might therefore 
not be induced. Perhaps a threshold of DNA damage is required to induce this G2 block and 
therefore any values obtained through this mAMSA-induced G2 block, which is then assumed 
to be equal to topo II activity, would be an underestimation. The reason I compared my values 
only to nuclear, and not total cellular topo II activity values obtained by Harker et al. is 
because of the nature of the kinetoplast DNA assay. This assay involves adding purified topo 
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II to catenated DNA. Therefore any cytoplasmic topo II if active would still decatenate the 
DNA, however this would not reflect the situation in vivo where topo II is not associated with 
DNA in the cytoplasm. I therefore do not believe that I should compare my results to total 
cellular topo II activity values as the data obtained from the mAMSA-induced G2 block assay 
would not incorporate cytosolic topo II activity. Just because topo II is present and active in 
the cytosol, does not mean it would induce DSBs as it would not be located near the DNA.  
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Figure 3.3A: Flow cytometric analysis of HL60, MX1 and MX2 cells treated with varying 
concentrations of mAMSA up to 20 μM. All cells were incubated with colcemid. Each data point 
represents the mean of 1 x 104 cells within one experiment. The mitotic index was measured 
through labelling of cells with propidium iodide and an Alexa-conjugated antibody against 
phosphohistone 3, a marker of mitosis. The mitotic index at 0 μM amsacrine was equalled to 
100% for each cell line. The dashed arrows refer to the difference in mitotic index caused by 
mAMSA. B: Total difference in mitotic index (determined from Figure 3.3A) for HL60, MX1 and 
MX2 cells plotted against relative topo IIα expression (Figure 3.1B) showing a positive 
correlation. The relative mitotic indices were normalised against HL60 total change in mitotic 
index.  
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Although topo II activity was only determined within a single experiment, it does correlate well 
with topo IIα expression as determined by immunoblotting (Figure 3.3B). The mitotic index 
values are based on the values obtained from Figure 3.3A where the 96% decrease in mitotic 
index found in HL60 cells was equalled to 100%. This makes the decrease in mitotic index 
found in MX1 and MX2 cells at 20 μM mAMSA 80% and 57% respectively when compared to 
the decrease in mitotic index found in HL60 cells. The correlation between topo II activity as 
measured by mAMSA-induced G2 block and western blot-determined topo IIα levels suggests 
that topo IIα is a good indicator of total cellular topo II activity and that it is in fact the dominant 
isoform. Also it confirms that MX1 and MX2 cells do show less topo II activity when compared 
to HL60 cells as previously suggested by Harker et al.  
 
3.5 Chromatid break analysis 
Procedure 
Exponentially growing HL60, MX1 and MX2 cells were prepared for chromatid break analysis 
following the protocol found in section 2.6. More specifically, cells were irradiated at 0.4 Gy 
and alongside unirradiated controls incubated for 30 minutes at 37°C, 5% CO2 in air before 
the addition of colcemid at 0.1 μg for 1.5 hours. Metaphase spreads were prepared on slides 
using a humidity control cabinet (Hanabi system) where 20 μl of sample was added to each 
slide. Slides were further stained in 50 ml Copland jars with 10% Giemsa in Gurr’s buffer for 
10 minutes, washed in Gurr’s buffer followed by distilled water and allowed to dry in air. 
Experiments were carried out in duplicate. 
 
Results and discussion 
The ‘G2 assay’ is a useful way to determine chromatid break frequency. It is called the G2 
assay as it is assumed that if the time between irradiation and fixation is short, metaphases 
were originally irradiated cells in the G2 phase of the cell cycle. Chromatid breaks, as seen in 
Figure 3.4 can be seen not only after cells have been irradiated with low doses of ionising 
radiation; they can also occur at very low levels spontaneously. In this thesis chromatid 
breaks were defined as any type of discontinuity, including chromatid ‘gaps’, where 
discontinuities are smaller than the width of the chromatid, and ‘breaks’ where aligned or 
misaligned discontinuities are the width of the chromatid or larger 65.  
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Figure 3.4: Metaphase spreads of control and irradiated (0.4 Gy γ-rays) Giemsa-stained HL60, 
MX1 and MX2 cells at x100 magnified. The red boxes surround chromosomes with chromatid 
breaks. Scale bar represents 10 μm.  
 
 
The number of chromatid breaks formed in both control and irradiated cells (0.4 Gy) were 
calculated per 100 metaphases. Figure 3.5 shows that in all three cell lines, little (<0.2 
breaks/cell) or no chromatid breaks were formed in non-irradiated controls. When irradiated at 
0.4 Gy, all cell lines showed an increase in chromatid break frequency as expected. However, 
the chromatid break frequency in HL60 cells (1.1 breaks per metaphase) was significantly 
higher than in MX1 (0.8 breaks per metaphase) and MX2 cells with MX2 cells showing the 
lowest number of chromatid breaks (0.6 breaks per metaphase) with p=0.004 and 0.003 for 
MX1 and MX2 cells respectively. The p-value is defined here as the probability of obtaining 
10 μM 
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the results assuming the null hypothesis is correct. Here the significance level is taken as 5% 
(0.05) so any p-value obtained below 0.05 is statistically significant. 
 
 
 
Figure 3.5: Chromatid break frequency per metaphase in control and irradiated (0.4 Gy γ-rays) 
HL60, MX1 and MX2 cells. Bars refer to standard deviations from the mean calculated for 100 
cells per duplicate experiment.  
 
 
As cells have been incubated with colcemid, it could be postulated that the chromatid breaks 
result from colcemid incubation rather than irradiation. It has previously been determined that 
colcemid treatment increases the frequency of chromosome abnormalities; however, these 
experiments included 5 and 17 hour incubation periods 295. Here, colcemid was added only for 
1.5 hours and therefore the effect on chromatid break frequency in itself is quite low or absent 
as seen in the non-irradiated controls of Figure 3.5. Although it might seem simpler to forego 
colcemid treatment, it is necessary to acquire sufficient numbers of metaphases to be able to 
measure chromatid break numbers in at least 100 cells, as not all metaphases spread well. 
Also the addition of colcemid has proven to aid condensation and spreading, although the 
mechanism behind this is still unclear. The more condensed the chromosomes (up to a point), 
the easier chromatid breaks can be distinguished. 
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Figure 3.6: Topo IIα expression as measured by western blotting (Figure 3.1B) correlates 
positively with chromatid break number per cell (Figure 3.5). 
 
 
Figure 3.6 was plotted to determine if chromatid break frequency (Figure 3.5) and topo IIα 
expression (Figure 3.1B) correlated. A significant positive correlation (r2 = 0.93) shows that as 
topo IIα expression increases, so does chromatid break frequency. As topo IIα expression 
and activity are correlated (Figure 3.3B) this suggests that topo IIα activity is indeed involved 
in the formation of chromatid breaks. Whether or not this connection is direct is unclear from 
this data and remains to be determined. 
 
3.6 Is reduced chromatid break frequency a result of less 
DSB repair? 
Procedure 
DNA DSB repair was measured in HL60, MX1 and MX2 cells as described under section 
2.7.2 by Dr Peter Bryant. Cells were passaged at 2 x 105 per ml in RPMI medium and 
incubated for 2 days. 6 x 105 cells were transferred to 1.5 ml eppendorf tubes and cooled on 
ice for 30 minutes prior to irradiation. Tubes were irradiated on ice with 40 Gy of 137Cs 
gamma-rays. The dose-rate was approximately 3.5 Gy/minute. Unirradiated controls and time 
zero samples were held on ice while the other samples were transferred to a water-bath 
running at 37oC from 15 minutes up to 3 hours. After 3 hours incubation on ice or at 37oC, all 
samples were treated as described in section 2.7.2. Samples were run in a 200 ml 0.8% 
agarose gel in 0.5 tris borate EDTA (TBE) buffer (Sigma) containing 0.5 μg/ml ethidium 
bromide. All DNA double strand break repair experiments were performed in duplicate, as 
well as duplicates within experiments. 
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Results and discussion 
In some cases altered DNA repair is thought to be the cause of increased DNA damage 94,95 .  
Although it was previously discussed that radiosensitivity in the form of chromatid break 
induction might not be due to altered DNA repair, it was nonetheless important to check that 
the higher chromatid break frequency found in HL60 cells was not due to decreased DSB 
repair. DSB repair was determined by pulsed field gel electrophoresis, where the direction of 
the pulse changes regularly. This allows the DNA fragments caused by DSBs to be separated 
according to size 296. As we were interested only in the number of DSBs caused under certain 
conditions, and not the size of the resulting DNA fragments, a simple, non-pulsed gel 
electrophoresis assay was performed by Dr P. Bryant.  This technique still allows the DSBs to 
be separated, but it does not distinguish between different sizes of DNA, as DNA molecules 
larger than 15-20 kb migrate at the same rate through the gel in a size-independent manner.  
 
 
To determine if HL60, MX1 and MX2 cells differ in DNA repair kinetics, irradiated cells were 
left to repair for up to 3 hours. Figure 3.7 shows that with time, the number of DSBs reduces, 
reaching a plateau at around 3 hours, implying that rejoining has been completed. The data 
shown in panel A does however suggest that DNA repair was not completely finished, though 
it would have been more conclusive had the fraction of DNA released (FDR) been measured 
at 4 hours. It appears that the kinetics of DSB repair is similar in HL60, MX1 and MX2 cells 
(Figure 3.7). Therefore altered DNA repair kinetics could not account for differences found in 
chromatid break frequency.  
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Figure 3.7: A: Analysis of gel electrophoresis showing a disappearance of the relative DNA 
fraction remaining with time in HL60, MX1 and MX2 cells. B: duplicate of experiment. 
Experiments carried out by Dr Peter Bryant. 
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When comparing the duplicate experiments shown in Figure 3.7, it is clear that the amount of 
DNA released at 3 hours is different between the two experiments, suggesting slower or less 
repair in cells from panel A. Although the reason for this is not apparent, it does not alter the 
conclusion that HL60, MX1 and MX2 cells do not differ in repair kinetics within each 
experiment.  
 
3.7 Conclusion 
Lower topo IIα expression and activity was seen in MX1 and MX2 cells when compared with 
parental HL60 cells. This correlated with decreased chromatid break frequency, which could 
not have been affected by altered DNA DSB repair. 
  
 
 
 
 
CHAPTER 4 
 
LOWERED TOPO IIα LEVELS AFFECT CHROMATID 
BREAK FREQUENCY 
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4.1 Introduction 
In this chapter the effect of silencing topo IIα on the frequency of radiation-induced chromatid 
breaks in the human-telomerase reverse transcriptase-transformed retinal pigment epithelial 
(hTERT-RPE1) cell line was examined.  
 
Research using silencing RNA (siRNA) has soared since its optimisation by Fire et al. in the 
nematode Caenorhabditis elegans 297. The authors showed that double-stranded RNA in the 
cell, produced through the introduction of a mix of sense and anti-sense RNAs specific to 
coding sequences, was more effective in interfering mRNA translation than single stranded 
anti-sense RNA. Experiments involving siRNA against topo IIα have confirmed many roles of 
topo IIα including condensation and chromosome arm localisation at the metaphase plate 169 
as well as in apoptosis 173.  
 
The siRNAs used here (purchased from Ambion) are chemically synthesised 21 nucleotide 
double-stranded RNA with 3’ dinucleotide overhangs that are short enough to be incorporated 
in the RNA-induced silencing complex (RISC). This introduction of siRNAs exploits part of the 
RNA interference pathway that a cell uses to protect itself from viruses where long (>200 bp) 
double-stranded RNA species are cut to double-stranded RNA of 21-25 bp intervals with 
dinucleotide 3’ overhangs by the RNase protein Dicer 298. The siRNAs provided by Ambion 
mimic these small double-stranded RNAs already processed by Dicer and so go on to form 
part of the ‘silencing complex’. One strand of the RNA is assembled into RISC whilst the other 
strand is cleaved by Argonaute (or Slicer) proteins thus allowing the target mRNA to bind the 
RISC-associated strand. RISC assembly involves Dicer bound to the protein R2D2 as a 
heterodimer guiding the siRNA to its target RNA. Dicer/R2D2 is then replaced by the 
endonuclease Argonaute slicer protein Ago2 and once the other single-stranded siRNA is 
dissociated from the siRNA/RNA complex 299, the RISC complex is activated and cleaves the 
mRNA 300, thus ultimately lowering protein expression.  
 
4.2 Aims 
The first aim was to determine the mitotic index response as well as the normal frequency of 
chromatid breaks in hTERT-RPE1 cells exposed to a low dose of radiation. The second aim 
was to investigate the effect of lowering topo IIα expression, by treatment with siRNA, on 
radiation-induced break frequency. The effect of siRNA treatment on mitotic index was also 
tested.  
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4.3 Measurement of radiation response of hTERT-RPE1 cells 
The effect of radiation dose on mitotic index and chromatid break frequency was tested.  
 
Procedure 
The mitotic index for 1 x 104 cells was determined as described in section 2.5.1. hTERT-
RPE1 cells were irradiated at 0.3, 0.4 and 0.5 Gy γ-rays. Results were normalised against the 
non-irradiated control with this latter value set at 100%. The number of cells in G2 was also 
established through the same protocol. The number of cells in G2 was determined as follows: 
(G2/M) – M with G2/M determined by flow cytometric analysis after staining with PI (Figure 4.1 
Panel A), and M also determined by flow cytometry with an Alexa-conjugated anti-
phosphohistone 3 antibody as well as PI (Figure 4.1 Panel B).  
 
 
 
Figure 4.1 A: Representative diagram of cycling cells stained with propidium iodide. G1, G2/M 
and S phase cells can be clearly distinguished according to their DNA content (2n, 4n or in 
between respectively). B: Representative diagram of cycling cells stained with both propidium 
iodide and an Alexa-conjugated phosphohistone 3 antibody. Mitotic cells can now be visualised 
separately from G2 cells. 
 
 
Chromatid break frequency was also determined in exponentially growing hTERT-RPE1 cells. 
These were prepared following the protocol found in section 2.6. Briefly, cells were irradiated 
with a dose of 0.3 Gy and with parallel un-irradiated controls, incubated for 30 minutes at 
37°C before the addition of colcemid at 0.1 μg/ml for 1.5 hours. Following fixation, metaphase 
spreads were prepared on slides, stained, washed, and dried in air. 100 metaphases were 
analysed for chromatid breaks. 
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Results and discussion 
The effect of radiation on mitotic index was established using flow cytometry. The use of PI 
and anti-phosphohistone 3 labeling has already been described under section 3.4. Figure 
4.2A shows that an increase in radiation dose decreases the number of cells in mitosis by 
50%, 65% and 75% (Panel A) and increases the number of cells in G2 by 8%, 17% and 32% 
(Panel B) at 0.3, 0.4 and 0.5 Gy respectively. This suggests that the decrease in mitotic index 
is due to cells being blocked at the G2 checkpoint (section 1.3.2). It is thought that this G2 
block is necessary to allow cells to repair their DNA after ‘injury’ by, in this case, low doses of 
ionising radiation. If DNA damage repair systems are overwhelmed, cells will not progress to 
mitosis where damaged genetic material could be passed on to daughter cells, but instead 
cell checkpoints either hold cells back until repaired or signal cells to apoptose. Figure 4.2 
shows that hTERT-RPE1 cells illustrate a normal reaction when treated with ionising radiation, 
with the mitotic index decreasing with radiation dose whilst the number of cells in G2 
increases. This result suggests that hTERT-RPE1 cells have a functional G2 checkpoint.  
 
 
 
Figure 4.2: Flow cytometric analysis of hTERT-RPE1 cells irradiated with γ-rays ranging from 
0.3 to 0.5 Gy. Each data point represents the mean of 1 x 104 cells. A: The mitotic index was 
measured through labelling of cells with PI and an Alexa-conjugated antibody against 
phosphohistone 3, a marker of mitosis. The mitotic index decreased with radiation dose. 
Results were normalised against non-irradiated controls. B: The number of cells in G2 was 
calculated by deducting the number of cells in mitosis (determined from panel A) from the G2/M 
value measured by labelling of cells with PI only. 
 
 
A B0.0 0.1 0.2 0.3 0.4 0.5 0.60
5
10
15
20
25
30
35
Radiation dose (Gy)
In
cr
ea
se
 in
 G
2 
ce
lls
 (%
)
Lowering topo IIα expression 
 
69
Interestingly, the increase in G2 cell number is non-linear over the range of 0 - 0.3 Gy (Figure 
4.2B). This suggests that there is a threshold of DNA damage that is tolerated within hTERT-
RPE1 cells and that if the DNA damage is increased beyond this threshold, the G2 checkpoint 
is activated. The mitotic index on the other hand, does show a linear trend. Figure 4.2A shows 
that the mitotic index decreases with radiation dose and its linear relationship is most likely 
due to a low number of cells in mitosis distorting the actual trend between 0 – 0.3 Gy. Also, 
the 75% decrease in mitotic index seen in 0.5 Gy-irradiated cells compared to non-irradiated 
controls does not correspond with a 75% increase in G2 population at 0.5 Gy, which only 
increased by 32%.  This is most likely due to the same number of cells in mitosis representing 
a lower percentage of cells in G2.  
 
As well as looking into the effect of IR on mitotic index and number of cells in G2, its effect on 
chromatid break frequency was also established. As the aim of this thesis was to look into the 
mechanism behind chromatid break formation, it was important to determine whether or not 
chromatid break induction in hTERT-RPE1 cells is linear with radiation dose as found for 
other types of cells 105,108,112. The dose-effect relationship for chromatid breaks is shown in 
Figure 4.3 and it is clear that this relationship is linear as its R2 value is 0.97. At 0.3, 0.4 and 
0.5 Gy γ-irradiation cells averaged 0.81, 1.43 and 1.77 chromatid breaks per metaphase 
respectively..  
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Figure 4.3: Frequency of chromatid breaks in Giemsa-stained hTERT-RPE1 metaphases 
treated with 137Cs γ-rays at doses ranging from 0 to 0.5 Gy, as determined through the G2 assay.  
Bars represent standard deviations from the mean for 100 metaphases.  
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4.4 Analysis of cells in the G2 assay 
I attempted to determine if when analysing metaphases for chromatid breaks as part of the G2 
assay a proportion of S-phase cells were included in the irradiated population. 
 
Procedure 
To do this, hTERT-RPE1 cells were synchronised in S-phase with a thymidine block following 
the protocol found under section 2.8. Samples were taken at 0, 1.5 and 2.5 hours after 
release from thymidine. After thymidine release samples were incubated in colcemid 0.1 
μg/ml until they were harvested. A non-synchronised control was also collected at the zero 
time-point. The mitotic index was determined as described under section 2.5.1 for 1 x 104 
cells per sample.  
 
Mitotic indices of samples taken at 0, 1.5, 2.5 and 6 hours after release from thymidine were 
also established manually following the procedure in section 2.5.2. After thymidine release 
again samples were incubated in colcemid 0.1 μg/ml until they were harvested. The number 
of cells in mitosis was determined for 1000 cells per sample and counted at x10 magnification. 
 
Results and discussion 
It was important to determine if mitotic cells collected 1.5 – 2.5 hours after irradiation did 
actually acquire their original damage in the G2 phase of the cell cycle, as hypothesised, 
rather than the early part of S-phase. Theoretically, if cells are in early S-phase when 
irradiated, metaphase spreads would show breaks in both chromatids whereas cells irradiated 
in late S-phase or G2 would show breaks in only one chromatid. As breaks in only one 
chromatid are usually seen after 1.5 hours of irradiation, it is generally assumed that cells 
must have originally been in G2 when irradiated. This was tested by synchronising cells in S-
phase with excess thymidine and collecting cells at 0, 1.5 and 2.5 hours after release from 
thymidine, at which stage cells could progress through the cell cycle and the proportion of 
cells in S, G2 and mitosis could be analysed. Excess thymidine blocks cells in S-phase as 
when it becomes phosphorylated to dTTP, it inhibits the reduction of CDP by ribonucleotide 
reductase to dCDP 301. An increase in dTTP thus leads to the decreased reduction of the 
dCDP pyrimidine substrate, which is essential for DNA replication, ultimately resulting in an 
accumulation of cells in S-phase 301. The use of PI and an anti-phosphohistone 3 antibody for 
this mitotic index assay has been previously discussed in section 3.4. 
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Figure 4.4A shows that the proportion of cells in S and G2/M is 35% and 18% respectively in 
non-synchronised cells at the zero time-point. After synchronisation with thymidine, 56% of 
cells are found in S-phase and the number of cells in G2 decreases to 6%. 1.5 and 2.5 hours 
after release increases this G2/M fraction to 11% and 17% respectively. The increase in the 
number of cells in G2/M from 6% to 17% from 0 to 2.5 hours after thymidine release suggests 
that only part of the S-phase population has cycled to G2/M. This implies that the cycling 
population must originally be late S-phase cells that have not been blocked by thymidine.  
 
 
 
Figure 4.4 A: Flow cytometric analysis of propidium iodide-treated hTERT-RPE1 cells 
synchronised in S-phase with 2 mM thymidine for 16 hours and released at 0, 1.5 and 2.5 hours 
as shown in panels 2-4. Panel 1 shows unsynchronised cells. B: Flow cytometry analysis of 
propidium iodide and anti-phosphohistone 3-treated hTERT-RPE1 cells synchronised in S-
phase with 2 mM thymidine for 16 hours and released at 0, 1.5 and 2.5 hours as shown in panel 
2-4. Panel 1 shows unsynchronised cells. Boxed areas include cells in mitosis. 
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The mitotic index was also determined. In non-synchronised cells, the mitotic index equalled 
3% (Figure 4.4B). This decreased to 0% in synchronised cells released for 0 and 1.5 hours 
and increased to 1% at 2.5 hours after release. These results suggest that it takes more than 
1.5 hours and less than 2.5 hours for S-phase cells to accumulate in mitosis and that the 
increase in the G2/M population in Figure 4.4A is mostly due to an increase of cells in G2. 
More accurately, I would suggest that the S-phase cells seen in mitosis 2.5 hours after 
thymidine release are due to a few cells in late S-phase, as the whole synchronised S-
population (56%) does not appear to have cycled that far.  
 
 
 
Figure 4.5: Giemsa-stained hTERT-RPE1 cells at x10 magnification. Red and white arrows 
point to mitotic and interphase cells respectively.  
 
 
The mitotic index was also established manually. Cells were synchronised and released as 
before and mitotic cells could be distinguished from interphase cells (Figure 4.5 white arrows) 
with Giemsa staining as chromosomes without a nuclear membrane (Figure 4.5 red arrows). 
Table 4.1 shows that at 0, 1.5 and 2.5 hours after release from thymidine, 0.1% of cells were 
in mitosis. Only between 2.5 and 6 hours did the mitotic index increase to 0.9%. These 
numbers are lower than those obtained with the anti-phosphohistone 3 antibody (Figure 4.4) 
suggesting that histone 3 might be phosphorylated in late G2 just before entry into mitosis and 
thus using the anti-phosphohistone 3 antibody might pick up cells in both late G2 and mitosis. 
Another way in which mitotic index numbers might be altered is through the preparation of the 
samples. Nonetheless, the data of both the manually-established and the flow cytometry-
calculated mitotic index experiments suggest that even up to 2.5 hours after S-phase, early S-
phase cells have not reached mitosis and thus DNA damage seen in metaphases in the G2 
assay must have originated in G2. 
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Time after release (hours) 0 1.5 2.5 6 
Mitotic Index (%) 0.1 0.1 0.1 0.9 
 
Table 4.1: Results of manual counting of mitotic index in S-phase synchronised hTERT-RPE1 
cells released from 2 mM thymidine for 0, 1.5, 2.5 or 6 hours. The mitotic index was determined 
for 1000 cells at x10 magnification after Giemsa staining. 
 
 
 
These synchronisation results might have been affected by the thymidine block if it caused a 
delay in the cycling of cells, preventing cells from immediately resuming the cell cycle after S-
phase synchronisation. I cannot infer from my data that no cell cycle delay is initiated by the 
thymidine block. It is clear however that at 1.5 hours after release from thymidine, cells are 
cycling as the S-phase peak has shifted compared to the zero time-point (Figure 4.4A). As 
examples of thymidine-induced cell cycle delay are not found in the literature I can confidently 
say that the results in this cell synchronisation section are not affected by the thymidine block 
itself. 
 
4.5 siRNA knock-down of topo IIα expression 
4.5.1 Determining siRNA concentration 
Procedure 
Addition of siRNA against topo IIα 
In all the following experiments topo IIα expression was lowered using siRNA. SiRNA against 
topo IIα was added as described under section 2.9. Two separate siRNAs were added, 
namely 5’-GCUCCUAACUUCUAGUAACtt-3’ and 5’-CCUUCAACUAUCUUCUUGAtt-3’ that 
target different topo IIα exons, namely 5 and 26 respectively. In both siRNA sequences, the 
final tt located at the 3’ end denotes the dinucleotide overhang that is incorporated into RISC. 
SiRNA concentrations ranged from 0 to 2 nM. Also as a control, 1 nM scrambled siRNA was 
added parallel to the other studies. For a clear image as to where the siRNAs bind the topo 
IIα mRNA sequence I refer you to Appendix A. 
 
Analysis of topo IIα expression 
Once siRNA was added for 12 hours, samples were collected in sample reducing buffer 
(section 2.2). Protein concentrations were determined (section 2.3) and western blot analysis 
was carried out (section 2.4). The data was normalised against β-actin and non-siRNA-
treated control values were set at to 100% topo IIα expression. 
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Chromosome condensation 
It has been reported that reduced topo IIα expression affects chromosome condensation 
124,168,302-304. Therefore experiments were performed to test this as reduced chromosome 
condensation might interfere with chromatid break analysis. When looking at chromosome 
condensation, exponentially growing hTERT-RPE1 cells, treated with siRNA against topo IIα, 
were prepared and stained following the protocol in section 2.6. Cells were incubated with 
colcemid 0.1 μg/ml for 1.5 hours. Metaphase spreads were prepared on slides, dried in air 
and pictures were taken at x100 magnification.  
 
Immunocytochemistry 
After 1 nM siRNA treatment against topo IIα, exponential hTERT-RPE1 cells were also 
prepared for immunocytochemistry as described under section 2.10. 
 
RNA analysis 
RNA was extracted from siRNA-treated and control hTERT-RPE1 cells and cDNA formed 
from it as described under section 2.11. PCR was then performed as explained in the same 
section with forward and reverse primers against a coding region topo IIα or β-actin. A 
negative control was also carried out where primers against β-actin were added to a tube with 
no cDNA. The topo IIα and β-actin PCR reactions were performed separately and in triplicate. 
Primer sequences were taken from the literature 152,284. The GC base content and melting 
temperatures were determined using the online oligonucleotide properties calculator Oligocalc 
305. 
 
Appendices A and B show the target DNA sequences to which the forward and reverse 
primers against topo IIα and β-actin bind.  
 
PCR samples were sent, as described under section 2.11.5, to the Sequencing Service in the 
School of Life Sciences at Dundee University to test that the PCR products did in fact code for 
topo IIα or β-actin.  
 
Results and Discussion 
Firstly, it was important to determine the concentration of siRNA that lowered topo IIα 
expression as measured by western blotting. Figure 4.6 shows that increasing siRNA 
concentration, decreases topo IIα protein expression (Panel A). 1 and 2 nM siRNA incubation 
resulted in approximately 65% and 75% knockdown respectively (Panel B). The addition of 1 
nM scrambled siRNA did not affect topo IIα protein expression (Panel A) suggesting that the 
process of adding siRNA does not alter protein expression. Protein loading was similar in 
comparative samples as shown by β-actin expression in Figure 4.6A. As discussed in chapter 
3, it is clear that the antibodies are specific to either topo IIα or β-actin. As in HL60, MX1 and 
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MX2 samples (chapter 3), data was normalised against β-actin and following quantification by 
densitometry, topo IIα values obtained for control hTERT-RPE1 were set at 100% and topo 
IIα values in siRNA-treated cells expressed as a percentage of this hTERT-RPE1 value. This 
extra normalisation step was imposed as experiments were not carried out on the same gel or 
membrane and values even within the hTERT-RPE1 cell line varied slightly after 
normalisation against β-actin. Reasons behind these different values have been suggested in 
section 3.3. 
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Figure 4.6 A: Western blot of anti-topo IIα siRNA-treated and control hTERT-RPE1 cells 
probed against topo IIα and β-actin. B: Data from western blots was analysed showing that 
increased siRNA treatment decreases topo IIα expression. Topo IIα results from Panel A were 
normalised against β-actin levels and these results were further normalised against 0 nM siRNA 
concentration with this latter value set at 100%. 
 
A 
B 
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Dual antibody-sandwich ELISA experiments also showed that 1 nM siRNA against topo IIα 
decreased protein expression by approximately 70% (P. Bryant, personal communication). 
Generally, a siRNA experiment is deemed successful when the target protein expression level 
has decreased by approximately 80%.  For this reason, 2 nM siRNA against topo IIα was 
chosen as the concentration to use for further chromatid break experiments. 
 
When trying to determine if 2 nM siRNA against topo IIα had any effect on chromatid break 
frequency, it became clear that this concentration of siRNA was affecting chromosome 
structure and was therefore too high. Chromatid breaks could not be determined at 2 nM 
siRNA as chromosomes appeared less condensed as well as more entangled (Figure 4.7). 
This confirms a role for topo IIα in chromosome condensation. The addition of 1 nM 
scrambled siRNA did not affect chromosomal structure. 
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Figure 4.7: Metaphase spreads of Giemsa-stained hTERT-RPE1 cells treated with 0, 0.25, 1 
and 2 nM siRNA against topo IIα. Two metaphases are shown for each experimental treatment. 
The lowest panels show hTERT-RPE1 cells treated with 1 nM scrambled siRNA. The bar in the 
top left panel represents 10 μm. Pictures were taken at x100 magnification. 
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Rather than using 2 nM siRNA, I decided that 1 nM siRNA against topo IIα would be a better 
concentration for chromatid break frequency studies as it provided not only a good topo IIα 
protein knockdown, but it also did not affect chromosome condensation or individualisation. 
Figure 4.7 shows that 1 nM, unlike 2 nM, siRNA against topo IIα had no effect on 
chromosomal structure, nor did 0.25 nM.  
 
It was determined microscopically via immunocytochemistry that knockdown of topo IIα with 1 
nM siRNA was homogenous as lowered topo IIα expression appeared universal across all 
cells (data not shown). Also the addition of 2 nM siRNA against topo IIα caused abnormal 
chromosome structure, as shown in Figure 4.7, in all metaphases, again suggesting a 
universal knockdown. 
 
Another method used to determine topo IIα knockdown was PCR. Table 4.2 shows not only 
the sequence of the primers used, but also their % GC content and melting temperatures. 
Generally, the GC content should be between 40% and 60%. This % GC content determines 
the melting temperatures of the forward and reverse primers which should differ by no more 
than 5°C. Although the forward β-actin primer has a GC content of 72%, its melting 
temperature is only 3°C higher than that of the reverse primer and therefore these two 
primers can be used together. As the forward and reverse primers had been selected from 
the literature 152,284 but had not been used in conjunction with each other previously, it was 
important to ensure that their melting points made them compatible. The melting points are 
used to determine the annealing temperature during the PCR cycles. Here, an annealing 
temperature of 52°C was used which gives clear bands when the PCR products are run on an 
agarose gel as seen in Figure 4.8. 
 
 
Target Forward or reverse 
Primer 
Sequence 
GC 
Content 
Melting 
temperature
Topo IIα Forward ‘5-GCGTGTTGAGCCTGAATG-3’ 56% 50°C 
Topo IIα Reverse ‘5-GCTAGTCCACCTAAGACC-3’ 56% 50°C 
β-actin Forward ‘5-ACCCCGTGCCTGCTGACC-3’ 72% 57°C 
β-actin Reverse ‘5-AGGAAGGAAGGCTGGAGAGT-3’ 55% 54°C 
 
Table 4.2: Sequence of forward and reverse primers targeted to either topo IIα or β-actin along 
with their % GC content and melting temperature as determined using Oligocalc 305 . 
 
 
As siRNA theoretically targets mRNA, PCR is a useful way to check that the lowered protein 
knockdown (Figure 4.6) is in fact due to altered mRNA levels, rather than posttranslational 
modifications. Figure 4.8 shows that 1 nM siRNA treatment against topo IIα of hTERT-RPE1 
 lowered topo IIα mRNA. This was found when treating cells with the second siRNA as well 
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(data not shown). As the extracted RNA was converted into cDNA in preparation for the PCR, 
and the cDNA was used as a template for PCR, the results only indirectly relate to mRNA 
levels. Although it appears that no topo IIα mRNA is present in siRNA-treated cells, I believe 
this is due to sensitivity issues with detection as cells lacking topo IIα cannot separate sister 
chromatids in mitosis 124,170 and are therefore not viable. 
 
 
Figure 4.8: PCR products of cDNA, converted from mRNA, extracted from control hTERT-
RPE1 cells or treated with 1 nM siRNA against topo IIα. Experiments were performed in 
triplicate with forward and reverse primers against either topo IIα or β-actin. The negative 
control does not contain cDNA.  DNA was labelled with ethidium bromide. 
 
 
It was important to run β-actin controls alongside topo IIα to ensure, just as in western blots, 
that the same amount of DNA was added to each PCR reaction so that the results from topo 
IIα in different samples could be compared. Figure 4.8 shows that β-actin mRNA levels were 
in fact the same in control and siRNA-treated cells. As well as running β-actin controls, a 
negative control was run, which did not contain any cDNA. As no band was present, it proves 
that bands produced in the cDNA–containing samples were not due to any contamination. It 
was found that the single bands were in fact topo IIα or β-actin mRNA as PCR products were 
sent for sequencing and the results corresponded very well with known topo IIα or β-actin 
sequences (Appendix C and D respectively). The product sequences showed 94.4 and 97.8% 
identity for forward and reverse primers against topo IIα respectively as determined by 
LALIGN and 95% and 98% identity for human topo IIα mRNA as determined by BLAST. 
Sequences showed 99.7 and 98.7% identity for forward and reverse primer against β-actin 
respectively as determined by LALIGN and 99% identity with human β-actin mRNA for both 
primers as determined by BLAST.  
 
Also, the migration of the PCR products correlated well with the predicted size of the bands, 
with topo IIα- and β-actin-amplified mRNA equalling 1573 bp (Appendix A) and 499 bp 
(Appendix B) respectively. It was also determined that primers did not amplify genomic DNA. 
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Not only was genomic DNA removed in the process of converting mRNA to cDNA; in case 
some still remained, it was also ensured that the forward and reverse primers targeted 
different exons (Appendix A and B). As the PCR products were the same size as that 
predicted from the coding mRNA sequence of each protein, I can confidently say that no 
introns and therefore no genomic DNA were amplified.  
 
4.5.2 Chromatid break analysis 
Procedure 
Exponentially growing hTERT-RPE1 cells were treated with siRNA (for sequences see 
section 4.5.1) as described under section 2.9. Here cells were incubated with 0, 0.25 or 1 nM 
siRNA against topo IIα. Alongside these experiments, cells were also treated with a second 
siRNA against topo IIα targeting a different exon (1 nM) or 1 nM scrambled siRNA. Once 
incubated with siRNA for 12 hours, cells were irradiated at 0.3 Gy γ-rays and metaphase 
spreads prepared as mentioned under section 2.6. Non-irradiated controls were run alongside 
irradiated samples. Cells were added to slides and air dried before staining with 10% Giemsa 
in Gurr’s buffer and chromatid break frequencies counted in 100 metaphase cells. 
 
Results and discussion 
The number of chromatid breaks formed in both control and irradiated (0.3 Gy) cells were 
calculated in 100 metaphases. The effect of colcemid incubation has already been discussed 
in section 3.5. Figure 4.9 shows that in all cells (control and siRNA-treated) little or no 
chromatid breaks were formed in non-irradiated controls. When irradiated at 0.3 Gy, all cells 
showed an increase in chromatid break frequency as expected. Panel A shows that 1 nM 
scrambled siRNA does not alter chromatid break frequency from control cells. Both the 
control and scrambled siRNA-treated cells exhibit approximately 1 chromatid break per 
metaphase after γ-irradiation at 0.3 Gy. This suggests that the process of adding 1 nM siRNA 
to cells does not cause or prevent chromatid break formation. 0.25 nM siRNA against topo IIα 
also did not affect chromatid break frequency (Panel B). This is very interesting as Figure 4.6 
clearly shows that 0.25 nM siRNA does lower topo IIα expression. This suggests either a 
threshold or a separate pool of topo IIα involved in the formation of chromatid breaks. Another 
reason might be the non-synchronised nature of the cells as siRNA incorporation into G2 cells 
might be ‘diluted’ by cells in other phases of the cell-cycle. 
Lowering topo IIα expression 
 
81
 
0G
y
0.3
Gy
0G
y/1
nM
 sc
r-s
iR
NA
0.3
Gy
/1n
M 
sc
r-s
iR
NA
0.0
0.2
0.4
0.6
0.8
1.0
1.2
C
hr
om
at
id
 b
re
ak
s/
ce
ll
0G
y
0.3
Gy
0G
y/0
.25
nM
 si
RN
A 
1
0.3
Gy
/0.
25
nM
 si
RN
A 
1 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
C
hr
om
at
id
 b
re
ak
s/
ce
ll
 
0G
y
0.3
Gy
0G
y/1
nM
 si
RN
A 
1
0.3
Gy
/ 1
nM
 si
RN
A 
1
0.0
0.2
0.4
0.6
0.8
1.0
1.2
C
hr
om
at
id
 b
re
ak
s/
ce
ll
0G
y
0.3
Gy
0G
y/1
nM
 si
RN
A 
2
0.3
Gy
/1n
M 
siR
NA
 2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
C
hr
om
at
id
 b
re
ak
s/
ce
ll
 
Figure 4.9: Chromatid break frequency per cell in control and irradiated (0.3 Gy γ-rays) siRNA-
treated hTERT-RPE1 cells. A: Cells treated with or without 1 nM scrambled siRNA. B: Cells 
treated with or without 0.25 nM siRNA1 against topo IIα. C: Cells treated with or without 1 nM 
siRNA1 against topo IIα. D: Cell treated with or without 1 nM siRNA2 against topo IIα. Bars 
indicate standard deviations from the mean calculated for 100 cells.  
 
 
Panels C and D however do show that the addition of 1 nM siRNA targeted against different 
exons of topo IIα decreased chromatid break frequency in irradiated cells (p≤0.0001). As 
discussed in Chapter 3 the p-value is defined as the probability of obtaining the results 
assuming the null hypothesis is correct. The significance level is taken as 5% (0.05) so any p-
value obtained below 0.05 is statistically significant. Irradiated cells initially showed 
approximately 1 chromatid break per metaphase, however the addition of 1 nM of siRNA 
against topo IIα decreased this value by approximately 60% (Panels C and D). This suggests 
that topo IIα must be involved in the formation of chromatid breaks. Although chromatid break 
frequency was counted only once for 100 cells, the data is reproducible as treatment with 
either siRNA against topo IIα had acquired the same results. Also, the number of chromatid 
breaks obtained in radiation (0.3 Gy) -only cells in Figure 4.9 compare well with the radiation 
dose effect results of Figure 4.3. In both cases, the number of chromatid breaks, which was 
BA 
C D
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low in non-irradiated control cells, increased to approximately 0.8 - 1 chromatid break per 
metaphase when irradiated at 0.3 Gy. 
 
4.6 Is reduced chromatid breakage due to the G2/M 
checkpoint? 
It was important to test the effect of anti-topo IIα siRNA treatment on the mitotic index as I 
wanted to ensure that the lowered chromatid break frequency seen in siRNA-treated cells 
was not due to cells with high chromatid break frequencies being blocked in G2. 
 
Procedure 
hTERT-RPE1 cells were treated, alongside controls, with 1 nM siRNA against exon 5 of topo 
IIα (for sequence see section 4.5) for 12 hours as described under section 2.9. Cells were 
then irradiated at 0.3 Gy γ-rays alongside controls and prepared for mitotic index studies as 
explained under section 2.5.1. The proportion of cells in mitotis was determined with anti-
phosphohistone 3 for 1 x 104 cells in duplicate experiments. Results were normalised against 
values obtained from the control sample. 
 
Results and discussion 
Figure 4.10 shows that the addition of 1 nM siRNA against topo IIα in non-irradiated cells 
decreases the proportion of cells in mitosis by 40%. This confirms a role for topo IIα in normal 
G2 checkpoint function 303 and verifies normal checkpoint activity in the hTERT-RPE1 cells. 
Irradiated, non-treated cells also showed a lowered mitotic index, again confirming normal 
checkpoint function. However, no significant lowering of mitotic index was seen in these 
irradiated cells when incubated with 1 nM siRNA against topo IIα (41%) as compared with 
untreated, irradiated controls (36%) (Figure 4.10).  
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Figure 4.10: Mitotic index of control (unirradiated) and irradiated (0.3 Gy) hTERT-RPE1 cells 
treated with or without 1 nM siRNA against topo IIα as measured by flow cytometry. Cells were 
labelled with PI and an Alexa-conjugated antibody against phosphohistone 3 (FL1-H), a marker 
of mitosis. 1 x 104 cells per duplicate experiment were analysed per sample. Bars represent 
standard deviation for duplicate experiments. Results were normalised against the non-
irradiated non-treated control.  
 
 
Interestingly, the relative decrease in mitotic index from 0 to 0.3 Gy was not reduced further 
by siRNA incubation. Control samples showed a reduction by 60% (ratio 1:0.4) whereas the 
mitotic index in siRNA-treated cells decreased by only 40% (ratio 1:0.59) when irradiated at 
0.3 Gy (Figure 4.10). This suggests that siRNA incubation in fact not only inhibits further 
reduction in mitotic index when irradiated, but actually increases the ratio. Also, previous data 
suggests that at low doses (such as here: 0.3 Gy) the minor cell-cycle block induced does not 
significantly affect chromatid break frequency 306. It can therefore be argued that anti-topo IIα 
siRNA incubation at 1 nM does not lower mitotic index frequency and therefore the lowered 
chromatid break frequency cannot be explained by cells with a high chromatid break 
frequency being blocked in G2.  
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4.7 Conclusion 
The main finding of this results chapter was that lowered topo IIα expression, through the 
introduction of siRNA, in hTERT-RPE1 cells correlated with decreased radiation-induced 
chromatid breaks. It was clearly shown that 1 nM siRNA against topo IIα was sufficient to 
reduce not only mRNA, but also topo IIα protein levels and that the process of adding siRNA 
did not affect topo IIα protein levels. Also, 1 nM siRNA did not affect chromosome 
condensation therefore allowing chromatid break analysis. It was also determined that 
ionising radiation induces a G2 checkpoint response in hTERT-RPE1 cells as well as a linear 
induction of chromatid breaks. These results suggest that this cell line not only has a 
functional G2 checkpoint, but also that it was suitable for chromatid break analysis. siRNA 
incubation in irradiated (0.3 Gy) cells however, had no significant effect on the mitotic index, 
suggesting that the lowered chromatid break frequency seen in these cells was not due to 
cells with high DNA damage being halted in G2. It was also suggested that metaphases 
analysed in the G2 assay were originally in G2 and not in S phase. 
  
 
 
 
             
CHAPTER 5 
 
INHIBITING TOPO IIα ACTIVITY WITH ICRF-193 
DECREASES CHROMATID BREAK FREQUENCY 
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5.1 Introduction  
This chapter is based around experiments where topo IIα activity is lowered using the 
catalytic inhibitor ICRF-193. As already mentioned briefly in the introduction (section 1.6.7), 
ICRF-193 is a compound that targets topo II without stabilising the cleavable complex. As 
ICRF-193 actually traps the enzyme in the closed clamp form by inhibiting ATPase activity, it 
does not cause DSBs and can therefore be referred to as a catalytic inhibitor 224. Also, ICRF-
193 preferentially targets topo IIα rather than β, as experiments where topo IIα− or β-
containing plasmids were grown in yeast that were then treated with the inhibitor suggest a 
different range of active ICRF-193 specific to either topoisomerase IIα or β, namely 0.32 - 3.2 
μM and 10 - 100 μM respectively 225.   
 
Studies with ICRF-193 have already inferred a role for topo II in transcription 163, chromosome 
condensation and kinetochore structure 189, G2 checkpoint activity 54,226,307-309, anaphase 
chromosome segregation 170, early stages of neuronal differentiation 179 and re-entry into G1 
from a quiescent cell state 310. Also, experiments with ICRF-193 have provided further 
evidence for the specific action of drugs such as etoposide on topo II as treatment with ICRF-
193 before incubation with etoposide lowered topo II-induced DNA damage 234. 
 
5.2 Aims 
The first aim of this chapter was to determine whether lowering topo IIα activity with ICRF-193 
affected chromatid break frequency. Secondly, the way in which ICRF-193 might affect 
chromatid break formation was tested. 
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5.3 Determining ICRF-193 concentration 
ICRF-193 was used as a catalytic topo IIα inhibitor to determine if this isoform was involved in 
the formation of chromatid breaks. Before this could be achieved it was important to 
determine whether the condensation of chromosomes was affected by this inhibitor.  
 
5.3.1 Effect on chromosome structure 
Procedure 
ICRF-193 was added at 0, 100 nM, 1 and 32 μM to exponentially growing hTERT-RPE1 cells 
immediately before irradiation (0.3 Gy) with γ-rays. These, along with non-irradiated controls 
were then incubated for 30 minutes before the addition of colcemid 0.1 μg/ml for a further 2 
hours. Cells were incubated with ICRF-193 for 2.5 hours in total. Metaphase spreads were 
made following the protocol in section 2.6. Metaphase spreads were prepared on slides, 
stained with Giemsa, washed and dried in air. 
 
Results and discussion 
hTERT-RPE1 cells were originally treated with ICRF-193 at 1 and 32 μM, concentrations that 
were chosen as they fell within ranges that targeted either topo IIα alone or topo IIα and β 
together respectively 225. It was previously determined that less ICRF-193 was required to 
affect topo IIα than β, and it can therefore be assumed that concentrations below 10 μM 
ICRF-193 would affect topo IIα only whereas concentrations higher than 10 μM must affect 
both isoforms 225. 
 
Cells treated with 1 μM ICRF-193 showed abnormal chromosome condensation and 
spreading (Figure 5.1). No metaphases were present in metaphase spreads of 32 μM ICRF-
193-treated cells. Chromosome condensation and chromatid break frequency could therefore 
not be analysed at this high concentration, most likely due to activation of the intact G2 
checkpoint. The effects of 1 μM ICRF-193 and 2 nM anti-topo IIα siRNA-treated cells (section 
4.5.1) on chromosome structure, suggest that topo IIα has a role in not only decatenation but 
also chromosome condensation. Analysis of chromatid break frequency in cells where topo 
IIα activity is inhibited with ≥1 μM ICRF-193 is therefore impossible. 
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Figure 5.1: Two examples of metaphase spreads of Giemsa-stained hTERT-RPE1 cells treated 
without (left) or with 1 μM ICRF-193 (right) showing the de-condensing effect of the drug. 
Pictures were taken at x100 magnification. 
 
 
When cells were treated with 100 nM ICRF-193, no de-condensing effect was seen on 
chromosomes (Figure 5.2). This suggested that if 100 nM ICRF-193 does inhibit topo IIα and 
affect chromatid break frequency, then there must be a topo IIα activity threshold, that if 
passed, affects chromosome condensation and spreading. Figure 5.2 also shows that unlike 
1 μM ICRF-193, the frequency of IR-induced chromatid breaks can be determined after 
incubation with 100 nM ICRF-193 as chromatids are clearly visible. 
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Figure 5.2: Metaphase spread of Giemsa-stained hTERT-RPE1 cells treated with 100 nM 
ICRF-193 for 2.5 hours (x 100 magnification). 
 
 
5.3.2 Effect of ICRF-193 on mitotic index 
Having established a concentration (100 nM) of ICRF-193 that does not reduce chromosome 
condensation in the hTERT-RPE1 cell line, the effect of 100 nM ICRF-193 on mitotic index 
was tested. 
 
Procedure 
1 x 106 exponentially growing hTERT-RPE1 cells were incubated with or without 100 nM 
ICRF-193, for a total of 2.5 hours, immediately before γ-irradiation at 0 or 0.3 Gy. Cells were 
then left to recover at 37°C for 30 minutes and incubated with 0.1 μg/ml colcemid for another 
2 hours. Cells were then trypsinised (section 2.1.2) and pelleted by centrifugation at 600 x g. 
Mitotic indices were determined by flow cytometry (section 2.5.1). The number of cells in 
mitosis was determined for 1 x 104 cells per sample within each of the duplicate experiments. 
Results were expressed as a percentage of control values. 
 
Results and discussion 
As in chapter 4, I wanted to ensure that any effect that ICRF-193 might have on chromatid 
break frequency was not due to cells with high chromatid break frequencies being blocked in 
G2. The use of PI and anti-phosphohistone 3 labelling has already been described under 
section 3.4. Figure 5.3 shows that in non-ICRF-193-treated control cells the mitotic index 
decreased after irradiation (0.3 Gy) compared to non-irradiated controls from 100% to 40%. 
This 60% decrease in mitotic index after irradiation confirms results found in Chapter 4 
(section 4.6). Irradiation of cells after treatment with 100 nM ICRF-193 for 2.5 hours caused 
an additional depression of mitotic index (Figure 5.3). The mitotic index was reduced by 71% 
(radiation plus 100 nM ICRF-193) rather than 60% (radiation alone) when compared to the 
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non-irradiated, non-ICRF-193-treated control (100%). However, Figure 5.3 also shows that 
although ICRF-193 does reduce the mitotic index, it does not do so significantly as the ratio 
between non-irradiated and irradiated in both control and 100 nM ICRF-193-treated samples 
was still 1:0.4. Therefore the relative amount of cells proceeding to mitosis after irradiation in 
control and ICRF-193-treated cells is the same. 
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Figure 5.3: Mitotic index of control and irradiated (0.3 Gy) hTERT-RPE1 cells treated with or 
without 100 nM ICRF-193 as measured by flow cytometric analysis cells labelled with an Alexa-
conjugated antibody against phosphohistone 3, a marker of mitosis, and PI. 1 x 104 cells per 
duplicate experiment were analysed per sample. Bars represent standard deviations for 
duplicate experiments. Results were normalised against control samples. 
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5.3.3 Is the lab-stock of ICRF-193 active? 
As the inhibitor ICRF-193 used in the experiments described here had been stored at -20°C 
for several years, it was important to ensure that it was still active. This was achieved by 
determining if it lowered the ability of topo IIα to decatenate minicircles of kinetoplast DNA 
(kDNA) of the trypanosome Chritidia fasciculata. 
 
Procedure 
The kDNA decatenation assay was performed as described under section 2.12. Samples 
included the following: 
 
• kDNA only 
or 
• kDNA and 5 μl purified topo IIα (TopoGEN Inc.) 
or 
• kDNA, 100 nM ICRF-193 and 5 μl purified topo IIα. 
 
Results and discussion 
To check that our batch of ICRF-193 did indeed inhibit topo IIα activity, 100 nM ICRF-193 was 
added to purified topo IIα in vitro. Figure 5.4 shows that kDNA alone stayed in the well and 
did not migrate (Lane 1). When purified topo IIα was added to kDNA, the minicircles migrated 
and the distances corresponded to the decatenated nicked and circular kDNA markers (Lanes 
4, 2 and 3 respectively). When 100 nM ICRF-193 was added (Lane 5), this effect by topo IIα 
decreased with more interlocked kDNA remaining in the well and less DNA migration showing 
that less decatenation was achieved by topo IIα. This verified that ICRF-193 was active and 
does decrease topo IIα activity. It is important to stress though that this experiment was 
performed in vitro and that 100 nM ICRF-193 concentration in vivo might not achieve an equal 
inhibitory effect. Figure 5.4 therefore only shows that ICRF-193 is active at 100 nM in vitro, 
although the addition of 1 μM ICRF-193 in vivo which affected chromosome condensation 
(Figure 5.1), also suggests that at this concentration ICRF-193 is active.  
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Figure 5.4: UV-trans-illuminated image of 1% TAE gel electrophoresis plus 1 μg/ml ethidium 
bromide. Lane 1: kDNA only. Lane 2: decatenated marker. Lane 3: linear marker. Lane 4: 
purified topo IIα and kDNA. Lane 5: purified topo IIα, kDNA and 100 nM ICRF-193.  
 
5.4 Effect of ICRF-193 on chromatid break frequency in 
irradiated cells 
Procedure 
Exponentially growing hTERT-RPE1 cells were incubated with 25 or 100 nM ICRF-193 in 
medium immediately before irradiation (0.3 Gy). These along with un-irradiated or non-treated 
controls were incubated at 37°C for 30 minutes after irradiation before the addition of 
colcemid 0.1 μg/ml for 2 hours. Thus, cells were exposed to ICRF-193 for a total of 2.5 hours. 
Metaphase spreads were prepared as described in section 2.6. 10 μl of the fixed samples 
were dropped on to slides and air dried before staining with 10% Giemsa in Gurr’s buffer and 
chromatid break frequencies counted for 100 metaphase cells. Combined results from graphs 
A and B were normalised in graph C by setting the value of 0.3 Gy in each experiment at 
100%.  
 
Results and discussion 
The number of chromatid breaks formed in both control and irradiated cells (0.3 Gy) were 
averaged for 100 metaphases. As discussed in section 4.4, it is unlikely that 2.5 hours after 
irradiation early S-phase cells have progressed to mitosis and it is generally assumed that the 
metaphases analysed for chromatid breaks were originally in G2 when irradiated. The effect of 
colcemid incubation was discussed in section 3.5. It is shown in Figure 5.5 that in all cells 
(control and ICRF-193-treated) few or no chromatid breaks were formed in non-irradiated 
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controls. This suggests that incubation with ICRF-193 does not of itself affect chromatid break 
frequency in non-irradiated cells. The data presented in Graphs 5.5A and B were acquired in 
separate experiments and this might explain why irradiated cells in both graph A and B 
showed a chromatid break frequency of 0.8 and 0.6 per metaphase respectively. The value 
for irradiated only cells in Figure 5.5A confirms results seen in Figure 4.3 where 0.3 Gy also 
resulted in 0.8 chromatid breaks per metaphase. The lower chromatid break frequency (0.6 
per metaphase) in irradiation-only cells found Figure 5.5B is most likely due to altered growth 
of cells with a high passage number. Nonetheless, as all samples within this experiment were 
carried out under the same circumstances and were seeded at the same concentration from 
the same batch of cells, the data is still held to be valid.  
 
Graph 5.5A shows that incubation of cells with 25 nM ICRF-193, a dose that, as explained 
previously, I assume only affected topo IIα, reduced chromatid break frequency after 
irradiation by 24% (p=0.01). This reduction was even more substantial in hTERT-RPE1 cells 
treated with 100 nM ICRF-193 (Figure 5.5B, p=0.003) where chromatid break frequency was 
lowered by 40% when compared to irradiation-only cells. As discussed in Chapter 3 the p-
value is here defined as the probability of obtaining the results assuming the null hypothesis is 
correct. Here the significance level is taken as 5% (0.05) so any p-value obtained below 0.05 
is statistically significant. To be able to compare the data between graphs 5.5A and B, the 
values of IR-induced chromatid break frequencies in ICRF-193-treated cells was normalised 
against the radiation-alone cells within each experiment with the latter value set at 100%. 
Graph 5.5C shows this normalised data and demonstrates that the effect on chromatid break 
frequency is ICRF-193 dose-dependent. The data presented here not only shows that 100 nM 
ICRF-193 is an active concentration in vivo but also provides more evidence for the role of 
topo IIα in the formation of chromatid breaks.  
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Figure 5.5: Frequencies of chromatid breaks in two separate experiments (A and B) using the 
G2 assay in control (unirradiated) and irradiated hTERT-RPE metaphases incubated with or 
without 25 nM (graph A) or 100 nM (graph B) ICRF-193. Bars indicate standard errors from the 
mean for 100 metaphases. Combined results from graphs A and B have been normalised in 
graph C by setting the value of 0.3 Gy in each experiment at 100%.  
 
 
It appears that ICRF-193 affects both chromatid break frequency (Figure 5.5) and kDNA 
decatenation (Figure 5.4) almost instantaneously, most likely due to the way in which ICRF-
193 inhibits topo IIα, namely by trapping the protein 224. Interestingly, treatment of hTERT-
RPE1 cells with 100 nM ICRF-193 before irradiation affected chromatid break frequency 
suggesting that it does inhibit topo IIα at this concentration, yet it does not affect chromosome 
condensation. However, 1 μM ICRF-193 clearly does alter chromosomal condensation, 
suggesting that there must be a minimal topo II activity threshold, which if crossed decreases 
chromosomal condensation. This was already implied by experiments in Chapter 4 where 
cells treated with 0.25 nM siRNA against topo IIα decreased topo IIα expression, but did not 
affect chromosome condensation, unlike higher siRNA concentrations.  
B
C 
A 
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5.5 Does topo II affect radiation-induced DNA damage? 
Having determined that ICRF-193 lowers chromatid break frequency, the next step was to 
determine wether it affected DSB induction too as DSBs are known to cause chromatid 
breaks 10,109. Firstly the dose-effect relationship for radiation-induced DSBs in hTERT-RPE1 
cells was established. Next, the effect of ICRF-193 on radiation-induced DSBs was tested. In 
these experiments DSB induction was determined firstly by low voltage gel electrophoresis 
and then by immunocytochemistry against γH2AX. 
 
Procedure 
DSB induction as measured by low-voltage gel electrophoresis  
DNA double-strand break induction by radiation (γ-rays) was determined by low voltage 
electrophoresis. hTERT-RPE1 cells were seeded the day before an experiment at 2 x 105 per 
T25 flask in 5 ml complete DMEM-F12 medium to ensure cells were growing exponentially 
when used for the experiment the following day. After approximately 24 hours 4 x 105 cells 
were then irradiated at 0, 10, 20, 30 and 40 Gy on ice, trypsinised (section 1.2.1) and pelleted 
by centrifugation at 600 x g. The remaining protocol is fully explained under section 2.7.1. 
Briefly, the cells, embedded in agarose plugs, were slotted into a 200 ml ethidium bromide-
containing agarose gel that was run in 0.4 TAE buffer. Experiments were carried out in 
duplicate. 
 
To test the effect of ICRF-193 on radiation-induced DSBs, hTERT-RPE1 cells were seeded at 
2 x 105 in a T25 flask and 5 ml complete DMEM-F12 medium. A day later, cells were treated 
with or without 100 nM ICRF-193 for 2 hours at 37°C and 5% CO2. Cells were then irradiated 
at 0.3 or 10 Gy γ-irradiation on ice and DSBs estimated as described under section 2.7.1. 
Briefly, the agarose gel contained 1 μg/ml ethidium bromide and was run in a 0.4 TAE buffer 
for 96 hours. Experiments were performed in duplicate. 
 
DSB induction as measured by γH2AX foci  
Exponentially growing hTERT-RPE1 cells were also prepared for immunocytochemistry 
against γH2AX foci as described under section 2.7.1. After cells were grown to 90% 
confluency or serum-starved overnight, they were treated with 100 nM ICRF-193 for 2 hours 
then irradiated at 0.3 Gy. In another experiment cells were serum-starved overnight and then 
treated with 0, 5, 10 or 32 μM etoposide for 1 hour. In all cases cells were then allowed to 
recover for 20 minutes at 37°C, 5% CO2 with etoposide-treated cells allowed to recover in 
fresh medium containing no drug. Control experiments, where cells were not irradiated nor 
treated with ICRF-193 or etoposide, were carried out simultaneously. Cells were further fixed, 
blocked and stained as described in section 2.7.1. Experiments were performed in triplicate.  
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Results and discussion 
The effect of low dose IR on DSB induction in hTERT-RPE1 cells was tested. It was important 
to not only check that the DSB assay could be applied to hTERT-RPE1 cells but also to make 
sure that DSB induction was linear as found in other cell lines 11. The theory behind the low-
voltage gel electrophoresis DSB assay was discussed under section 3.6. Figure 5.6A shows 
that the DNA fragments in irradiated hTERT-RPE1 cells were clearly visible as a secondary 
band below the wells. Also, an increase in radiation dose caused an increase in the fraction of 
DNA released from the well (Figure 5.6A); the amount of DNA released is attributed to the 
number of DSBs that are formed. Densitometry analysis of Figure 5.6A determined the 
fraction of DNA released from the well due to DSBs to be 0, 0.05, 0.14, 0.22 and 0.26 at 
radiation doses of 0, 10, 20, 30 and 40 Gy respectively (Figure 5.6B). The linear induction of 
DSBs, with R2=0.9872, confirms studies in the literature in other cell lines 11 and signifies that 
this assay is a valid method of measuring DSB induction in hTERT-RPE1 cells.  
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Figure 5.6 A: 4-day low voltage gel electrophoresis of DNA in hTERT-RPE1 cells irradiated 
from 0 to 40 Gy of γ-rays in duplicate experiments. DNA was labelled with ethidium bromide. B: 
Analysis of Figure 5.6A showing a linear response between fraction of DNA released with an 
increase in radiation dose (Gy), with R2 = 0.9872. Bars are standard deviations from duplicate 
experiments. 
 
 
As it has been shown that topo IIα is involved in the formation of chromatid breaks, and it has 
previously been shown that chromatid breaks arise from single DSBs 10. It was important to 
determine if topo IIα played a role in the formation of DSBs. Using electrophoresis no DSBs 
B 
A 
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were seen in 0.3 Gy irradiated hTERT-RPE1 cells, whether treated with ICRF-193 or not 
(Figure 5.7). However, cells irradiated with 10 Gy γ-rays showed DSB induction with the 
fraction of DNA released equal to 0.14. Addition of 100 nM ICRF-193 to 10 Gy-irradiated cells 
did not significantly lower DSB induction (p=0.72), suggesting that topo IIα is not involved in 
the formation of the initial DSB.  Whether this is due to the relative insensitivity of the assay is 
unclear. What is certain however is that 100 nM ICRF-193 does not cause significant 
numbers of DSBs. Although ICRF-193 was thought to only act as a catalytic inhibitor, it could 
at high doses cause DNA damage 226,311. However, Figure 5.7 suggests that the concentration 
at which ICRF-193 has been used throughout this thesis does not induce DNA damage and 
therefore does act as a true catalytic inhibitor.  
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Figure 5.7 A: Induction of DSBs in hTERT-RPE1 cells treated with or without 100 nM ICRF-193 
followed by γ-irradiation at 0.3 and 10 Gy. DNA was labelled with ethidium bromide. B: Analysis 
of figure 5.7A with FDR equal to the fraction of DNA released (from well) determined as 
described in section 2.7.1. Bars are standard deviations from the mean in duplicate 
experiments.  
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Another method to measure DSB induction is immunocytochemistry for γH2AX. As mentioned 
in the introduction, the histone H2AX is phosphorylated at serine 139 by ATM shortly after 
irradiation in response to DSBs 23. This makes γH2AX a useful marker for DSBs and therefore 
measuring γH2AX foci can provide a measure of the number of DSBs per cell. The γH2AX 
assay requires the synchronisation of cells in G0 which is usually obtained by growing the cell 
population until it reaches confluency. The reason for this is to avoid cells in S-phase as 
generally replication processes induce many replication fork-associated DSBs, which would 
interfere with the analysis of radiation-induced DSBs. As the white arrows in Figure 5.8A 
show, using this method of synchronisation, in both control and irradiated cells, also picked up 
many cells that were still cycling and S-phase cells could be easily recognised as cells with a 
high number of DSBs (equal to approximately 40). It is even clearer from Figure 5.8B that 
some of these cells are still cycling as both cells in anaphase (left panel) and metaphase 
(right panel) are clearly visible. In this situation, it can easily be imagined that including the 
number of DSBs in S-phase cells would distort the calculated number of radiation-induced 
DSBs. It could be argued that as S-phase cells are quite obvious to spot, as they have such a 
high number of DSBs, they could simply be left out of the analysis. In doing this however, 
non-S-phase cells possibly with a true high radiation-induced DSB frequency would not be 
included.  
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Figure 5.8: Two examples of hTERT-RPE1 cells grown to 90% confluency probed with anti-
mouse-FITC-conjugated secondary antibodies against the primary mouse anti-γH2AX antibody 
as well as DAPI. A: Control and 0.3 Gy-irradiated cells at x63 magnification. White arrows 
indicate S-phase cells. B: Control unirradiated cells at x100 magnification. The left and right 
panels show cells in anaphase (a) and metaphase (m) respectively.  
 
 
hTERT-RPE1 cells were therefore synchronised in G0 by serum-starvation. This method 
yielded almost no cells in S-phase or mitosis suggesting that most cells had remained in 
G0/G1 (Figure 5.9). The γH2AX immunocytochemistry method is much more sensitive than gel 
electrophoresis, as DSBs are visible in cells irradiated at 0.3 Gy (Figure 5.8 and bottom 
panels of Figure 5.9), a dose where DSBs could not be measured by low-voltage gel 
electrophoresis (Figure 5.7). Figure 5.9 shows that control (non-irradiated) cells (top panels) 
or irradiated cells (middle panels panels) probed only with the secondary FITC-conjugated 
antibody (top panels) have little or no γH2AX foci.   
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Figure 5.9: Immunocytochemistry of serum-starved hTERT-RPE1 cells probed with γH2AX 
(FITC) and stained with DAPI (nucleus) (x100 magnification). The top two panels show non-
irradiated cells. The middle and bottom panels show irradiated (0.3 Gy) cells respectively, with 
cells in the middle panels probed only with the secondary anti-mouse FITC-conjugated antibody, 
whereas cells in the bottom and top panels were probed with both primary (mouse anti-γH2AX) 
and secondary antibodies. 
 
 
Figure 5.10 shows the quantification of γH2AX foci per cell, calculated as the mean frequency 
of foci in 100 cells in each of the triplicate experiments performed. In both control and ICRF-
193-treated non-irradiated samples, almost no foci were found, suggesting that no DSBs were 
formed. This confirms the conclusion derived from gel electrophoresis (Figure 5.7) as 100 nM 
ICRF-193 also did not induce any γH2AX foci. When irradiated at 0.3 Gy, the number of DSBs 
increased to a mean of 11 γH2AX foci per cell in both radiation-only and ICRF-193-treated 
plus irradiated cells. Thus, no significant difference was found in cells treated with 0.3 Gy or 
ICRF-193 plus 0.3 Gy. This again confirms the finding in Figure 5.7 that ICRF-193 does not 
lower DSB formation in irradiated cells, suggesting that topo IIα is not involved in the 
induction of DSBs. The number of foci corresponds well to other findings as it was previously 
determined that approximately 40 DSBs are formed per Gy in each cell 9,11,12. Accordingly, a 
dose of 0.3 Gy should result in 12 γH2AX foci per cell. The value obtained here for 0.3 Gy, 
namely 11 DSBs per cell, is not far from the expected result suggesting that this assay fits the 
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data found in the literature well. Also, it appears that the 20 minute recovery period after 
irradiation is long enough to initiate the signalling cascade as exemplified by the accumulation 
of the γH2AX foci at the sites of DNA damage.  
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Figure 5.10: Number of γH2AX foci per cell in control and irradiated (0.3 Gy) hTERT-RPE1 cells 
treated without or with 100 nM ICRF-193. The number of foci for each sample was determined 
for 100 cells in triplicate by immunocytochemistry. Cells were probed with anti-mouse-FITC-
conjugated secondary antibodies against the primary mouse anti-γH2AX antibody as well as 
DAPI. Bars represent standard errors from the mean for triplicate experiments. 
 
 
In view of the fact that topo IIα expression may be relatively low in G0, the question arises as 
to whether the experiments behind figure 5.10 are valid for cells in other phases of the cell 
cycle. To test this, the drug etoposide was used to determine whether topo IIα is active in G0. 
Etoposide preferentially targets topo IIα rather than β, as experiments where topo IIα or β-
containing plasmids were grown in yeast that were then treated with the poison suggest a 
different range in which etoposide is specific to either topoisomerase IIα or β, namely 10 - 
100 μM and 100 - >100 μM respectively 225. Thus the concentration used here (32 μM) should 
target just topo IIα. This drug is a classic topo II ‘poison’ that acts in a similar way to mAMSA 
and stabilises the cleavable complex thus increasing the number of DSBs formed by topo II 
222. The results shown in Figure 5.11 suggests that γH2AX foci in G0 can be used to test the 
role of topo IIα in the formation of radiation-induced DSBs because etoposide (32 μM) 
increased the number of γH2AX foci per cell significantly, more so than after irradiation at 0.3 
Gy. Treatment with only 5 or 10 μM etoposide also increased the number of γH2AX foci per 
cell when compared to non-treated cells (data not shown). Therefore etoposide, used at 
doses that affect only topo IIα, increased the number of γH2AX foci per cell thus suggesting 
that topo IIα in G0 is active at a level that could be affected by etoposide.  
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Figure 5.11: Image of immunocytochemistry against γH2AX in control, irradiated (0.3 Gy) and 
etoposide-treated (32 μM) hTERT-RPE1 cells at x10 and x63 magnification. Cells were probed 
with anti-mouse-FITC-conjugated secondary antibodies against the primary mouse anti-γH2AX 
antibody as well as DAPI.  
 
 
One might suggest that 100 nM ICRF-193 could never affect DSB induction as the probability 
of the inhibitor-affected topo II sites and 0.3 Gy-irradiation-affected DNA sites overlapping 
might be quite small; therefore radiation and inhibitor are unlikely to interact in the cell at this 
radiation dose. This however does not explain the results seen at the high IR dose (10 Gy) in 
Figure 5.7 where the probability of the two factors interacting is quite high, yet DSB induction 
is still not affected. Also, as lowered chromatid break frequency after irradiation at 0.3 Gy, it is 
unlikely that ICRF-193 and irradiation sites do not overlap. 
 
The effect of ICRF-193 on chromatid break frequency could theoretically be explained by its 
property to create a physical block when bound to topo II so that the DNA associated with 
topo II is shielded from radiation-induced damage. However, if this was the case, one would 
also expect DSB numbers to be affected in the same way as chromatid breaks i.e. lowered, 
as DSBs are more frequent in cells than chromatid breaks. DSB frequency however was not 
lowered by ICRF-193 after radiation suggesting that the effect of ICRF-193 on chromatid 
breaks is not simply a physical block and must be due to it specifically altering topo IIα 
activity.  
 
If ICRF-193 does not affect DSB frequency in cells, what is the mechanism behind its effect 
on chromatid breaks? I am suggesting that ICRF-193 lowers the conversion of the original 
radiation-induced DSB to chromatid breaks, which provides further evidence for the signal 
model 112. Thus not only is topo IIα involved in the formation of chromatid breaks, but it may 
be key in converting the original radiation-induced DSBs to chromatid breaks. 
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5.6 Conclusion 
Treatment of hTERT-RPE1 cells with 25 or 100 nM ICRF-193, concentrations that do not 
significantly affect chromosome condensation or mitotic index, decreased the frequency of 
radiation-induced chromatid breaks. This is indicative of a role for topo IIα in the formation of 
radiation-induced chromatid breaks. Also, the data supports the signal model suggesting that 
topo IIα is involved in converting radiation-induced DSBs into chromatid breaks.  
  
 
 
 
 
CHAPTER 6 
 
INHIBITING TOPO IIα AFFECTS HYDROGEN PEROXIDE-
INDUCED CHROMOSOMAL DAMAGE 
Role of topo IIα in H2O2-induced chromosomal damage 
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6.1 Introduction 
Oxidative stress is involved in the initiation of many diseases and causes reactive oxygen 
species (ROS) that can target cellular DNA, proteins and lipids. The ROS hydrogen peroxide 
(H2O2) has been shown to be involved in apoptosis 6. H2O2 occurs naturally as a by-product of 
oxygen metabolism and is usually decomposed into water and oxygen by peroxidases 6. Due 
to its oxidising abilities, H2O2 has also been manufactured to be used domestically as a 
source for bleaching and therapeutically to sterilise or combat acne.  
 
In this chapter, H2O2, rather than ionising radiation, was used as a source of chromosomal 
and DNA damage. It is known that γ-rays can result in DNA damage indirectly through the 
production of .OH radicals 3, which is also an endogenous product of H2O2 6. It has previously 
been determined that H2O2  is radiomimetic 5 and can cause both single and double strand 
breaks. Treatment of cells with .OH scavengers, such as DMSO or mannitol, reduces DNA 5 
damage. 
 
Hydrogen peroxide treatment (from 10 μM to 0.5 mM) has also been associated with 
chromosomal damage after 10 minute 312 or 3 hour 313 treatments resulting in chromosome-
type aberrations (dicentrics, acentric fragments) and chromatid-type aberrations (breaks, 
exchanges and gaps) respectively which were absent if cells were treated with ROS 
scavengers 312,313.  
 
Interest in hydrogen peroxide in this chapter is based not only on its radiomimetic and DNA or 
chromosome damaging properties but also for its potential to affect topo IIα activity. .OH 
radicals can result in the ‘poisoning’ of topo II 126, which might provide an explanation of action 
of topo IIα in the signal model of chromatid break formation. Cells appear more sensitive to 
H2O2 in S-phase than in G1 due to not only the more open and thus susceptible state of the 
DNA chromatin structure 314, but also the higher level of expression of topo IIα 128.  
 
6.2 Aim 
The aim of this chapter was to determine if topo IIα is involved in H2O2-induced chromosomal 
and DNA damage.  
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6.3 Does H202 induce chromosomal damage? 
As a first approach the extent of chromosomal damage caused by hydrogen peroxide was 
tested.  
 
Procedure 
Exponentially growing hTERT-RPE1 cells were treated with 0, 10, 50 and 100 μM H202 for 20 
minutes on ice. They were then left to recover in fresh medium for 30 minutes at 37°C and 
further incubated with colcemid 0.1 μg/ml for 1 hour. Metaphase spreads were prepared as 
described in section 2.6. 10 μl of the samples were dropped on to slides and air dried before 
being stained with 10% Giemsa in Gurr’s buffer, washed in first Gurr’s buffer and then water 
and finally air dried again. Other metaphase spreads were stained with 12 μl 
DAPI/vectashield. 
 
Results and discussion 
The effect of colcemid incubation was discussed in section 3.5. Incubation of cells with 50 or 
100 μM H202 did not result in any cells visible in mitosis suggesting that the amount of DNA 
damage caused by H202 induced the G2 checkpoint. Figure 6.1 shows the effect of 10 μM 
H202 on hTERT-RPE1 cells. Unlike non-treated cells, after 10 μM H202 treatment 
chromosomes appeared fragmented and entangled, and chromosomal ‘dots’ (red arrows in 
Figure 6.1) were also seen. It has been shown that H202 can excise chromatin loops through 
its effect on topo IIα 126. I thought that these ‘dots’ might be equivalent to excised chromatin 
loops. In order to confirm that these ‘dots’ were composed of DNA, cells were stained with the 
DNA-binding fluorescent dye DAPI rather than Giemsa. Figure 6.2 shows that the ‘dots’ do 
indeed stain with DAPI and so can definitely be identified as DNA. 
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Figure 6.1: Photomicrographs of Giemsa-stained 10 μM H202-treated hTERT-RPE1 cells at 
x100 magnification. The red arrows point to chromosomal damage that appear as ‘dots’.  
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Figure 6.2: Photomicrograph of DAPI-stained 10 μM H202-treated hTERT-RPE1 cells at x100 
magnification. The red arrows point to some chromosomal damage that appear as ‘dots’.  
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6.4 Are chromosome ‘dots’ produced by H2O2 excised 
chromatin loops? 
To determine if chromosome ‘dots’ seen in H202-treated cells were excised chromatin loops, 
metaphases were analysed by atomic force microscopy (AFM) in order to greatly increase 
resolution. 
 
Procedure 
Exponentially growing hTERT-RPE1 cells were treated with 0 or 10 μM H202 for 20 minutes 
on ice. Cells were then left to recover in fresh medium for 30 minutes at 37°C and further 
incubated with colcemid 0.1 μg/ml for 1 hour. Metaphase spreads were prepared as 
described in section 2.6. 10 μl of the samples were added to slides and air dried before being 
stained with 1% or 10% Giemsa in Gurr’s buffer for 10 minutes at room temperature, washed 
first in Gurr’s buffer followed by water and finally air dried again.  
 
The prepared samples were imaged at room temperature using AFM. This was done in 
collaboration with Francis McCarthy working for Georg Haehner at the School of Chemistry, 
University of St Andrews. Figure 6.3 shows a schematic of the underlying principles of an 
AFM. The AFM was used in contact mode, where the force between the tip and the sample 
surface was kept constant during scanning. In AFM when a force is exerted on the cantilever, 
any change in sample surface ‘bends’ the cantilever so as to maintain a constant force. Laser 
light is reflected off the cantilever onto a photodiode detector, which with appropriate 
electronics produces voltage from incident light. A change in sample surface causes the 
cantilever to bend, resulting in reflection angle variation. A change of the position of the light 
on the photodiode ultimately changes the voltage output. The sample was scanned using a 
piezoelectric translation stage scanner, which is made with piezoelectric crystals that can 
expand and contract when voltage is applied allowing for very fine control of movement.  
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Figure 6.3: Diagram of AFM imaging. The dashed lines indicate a movement of the cantilever 
due to altered sample surface which in turn changes the reflection of the laser onto the 
photodiode. 
 
 
The load applied to the sample ranged from 5 – 10 nN but was constant within each scan. 
Data was analysed with Gwyddion 2.12 that was developed by David Nečas and Petr 
Klapetek and supported by the Czech Metrology Institute. Most images were flattened with 
the provided software to eliminate low-frequency background noise during scanning detection. 
3-dimensional (3D) images were acquired with the same software. 
 
The AFM was invented by Binnig et al. 315 and has become a very useful tool for the analysis 
of biological samples. It was used here as it did not require any complex treatment of the 
sample and therefore chromosomal structures would remain unaltered. It was ensured that 
forces applied to the cantilever were low as high forces in contact mode AFM can move or 
affect the surface structure. AFM has been used for chromosomal analysis before, such as 
looking at the surface of ring chromosomes after 10 Gy X-irradiation (Figure 6.4) 316.  Figure 
6.4 clearly shows that ring structures can be visualised with AFM. Chromatid gaps induced by 
a neon beam have also been observed by AFM 317. The AFM had also been used to look at 
plasmid DNA linearisation after γ-irradiation 318. 
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Figure 6.4: Giemsa-stained light microscopy (A) and AFM image (B) of a ring 
chromosome induced by X-irradiation (10 Gy). Reprinted from Murakami et al. 2004 
316 (with permission from Elsevier Inc. publisher). Bar = 1 μm.  
 
 
Results and discussion 
Figure 6.5A shows chromosomes from 10 μM H2O2-treated hTERT-RPE1 cells imaged by 
AFM. Consecutive images zoom in on a chromosomal ‘dot’. The AFM allowed the imaging of 
sample surfaces with increasing spatial resolution starting from 80 x 80 μm down to 3.5 x 3.5 
μm in multiple increments. The 3D images in 6.5B allowed for even more interesting 
chromosome structure analysis. Focussing in on a chromosome ‘dot’ using AFM might have 
allowed us to determine if this ‘dot’ was in fact a chromosomal loop that had been excised in 
these cells. However this was not possible here as the resolution below 3.5 μm x 3.5 μm was 
not good enough to determine the topography of the chromosome. We showed that the 
chromosomal ‘dots’ were approximately 0.4 μm in length. The third picture of Figure 6.5A 
shows horizontal scratches (red arrow) that were due to the tip having picked up some debris 
that was then dragged along during scanning.  
 
It is possible that the resolution was affected by the 10% Giemsa stain. Murakami et al. 317 
found that Giemsa staining reduced the resolution of AFM imaging such that analysis at the 
nanometer level was not possible. They did not however specify the percentage of Giemsa 
used nor the incubation time. Others 319 however have managed to compare Chinese hamster 
ovary and human chromosomal structure with AFM at the nanometer level after 10% Giemsa 
staining for 8 minutes. Therefore the effect of 10% Giemsa on chromosomal analysis by AFM 
is still unclear. Although perhaps chromosomal analysis by AFM might best be achieved in 
non-stained samples, this would be extremely challenging as without phase-contrast 
microscopy attached to the AFM, metaphases could not be located. Also scanning a whole 
non-stained slide to find a ‘well-spread’ metaphase was not a possibility as the maximum 
A B
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range that could be scanned using this AFM set-up was 80 μm x 80 μm. The remaining 
experiments were therefore carried out using only 1% Giemsa. 
 
 
 
 
 
Figure 6.5: AFM images (A) and 3D chromosomal images (B) of hTERT-RPE1 cells treated 
with 10 μM H202 and stained with 10% Giemsa. The boxed area defines the total area scanned 
in the next image. White arrows point to chromosomal ‘dots’. The red arrow points to a 
scratched area. 
 
 
Next, untreated control metaphases stained with 1% Giemsa were analysed by AFM. Figure 
6.6 shows that the AFM technique does not affect chromosomal structure as cells not treated 
with H2O2 show no chromosomal damage and this confirms that the chromosomal ‘dots’ seen 
in Figure 6.5 were caused by H2O2. Also chromosomes stained with 1% Giemsa could be 
A 
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analysed by the AFM with increased accuracy when compared to chromosomes stained with 
10% Giemsa as structures were clearly distinguishable at 2 μm x 2 μm or lower. The change 
of shade of the image at 45 μm x 45 μm was a result of increasing the force slightly to get a 
clearer picture. 
 
 
 
 
Figure 6.6: AFM images (A) and 3D chromosomal images (B) of control hTERT-RPE1 cells 
stained with 1% Giemsa. The boxed area defines the total area scanned in the next image. 
 
 
Finally 10 μM H202-treated cells stained with 1% Giemsa were analysed by AFM. Figure 6.7 
shows that chromosomes were damaged and that ‘dots’ were formed again. The last of the 
consecutive images shows a ‘dot’ at a high resolution. Interestingly, the ‘dot’ does look as 
though it might be a ring. The height profiles in Figure 6.7B indicate that the dot’s surface 
does indeed decrease in height which might refer to the ‘hole’ of a loop even though it is not 
in the middle of the ‘dot’. This might perhaps be due to the preparation of the sample. Given 
A 
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the experimental time available, the results presented here are not ideal, therefore it is not 
possible to say that Figure 6.7 confirms that H2O2-induced chromosomal ‘dots’ are excised 
chromatin loops. They do however indicate what might be achieved with AFM in the analysis 
of H2O2-induced DNA damage in future experiments. 
 
 
 
 
 
Figure 6.7: AFM images (A) and height profiles (B) of hTERT-RPE1 cells treated with 10 μM 
H202 and stained with 1% Giemsa. The boxed area defines the total area scanned in the next 
image. White arrows point to chromosomal ‘dots’. 
 
 
 
A 
B 
Role of topo IIα in H2O2-induced chromosomal damage 
 
115
6.5 Does H2O2 induce chromosomal and DNA damage via 
topo IIα? 
It is clear that hydrogen peroxide induces chromosomal damage. To try to confirm that the 
‘dots’ (putative loops) were a result of topo IIα, the effect of the catalytic topo IIα inhibitor 
ICRF-193 on chromosomal damage was tested. A role for topo IIα in hydrogen peroxide-
induced DNA damage was also investigated. 
 
6.5.1 Chromosomal damage 
Procedure 
hTERT-RPE1 cells were treated with 0 or 10 μM H202 for 20 minutes on ice after incubation 
with 100 nM ICRF-193. Cells were allowed to recover from H202 treatment in fresh medium 
still containing 0 or 100 nM ICRF-193 for 30 minutes at 37°C and further incubated with 
colcemid 0.1 μg/ml for 1 hour. Total ICRF-193 treatment was 2 hours. Metaphase spreads 
were prepared as described in section 2.6. 10 μl of the samples were added to slides and air 
dried before being stained with 10% Giemsa in Gurr’s buffer for 10 minutes at room 
temperature, washed first in Gurr’s buffer and then water and finally air dried again. 
 
Exponentially growing hTERT-RPE1 cells were also treated with H202 ranging from 1 nM to 1 
mM and incubated on ice for 20 minutes. Cells were then left to recover in fresh medium for 
30 minutes at 37°C and further incubated with colcemid 0.1 μg/ml for 1 hour. Metaphase 
spreads were prepared as described above. Other metaphase spreads were stained with 12 
μl DAPI/vectashield. 
 
Results and discussion 
It was found that metaphases of cells treated with 100 nM ICRF-193 still demonstrated 
normal chromosomal structure (section 5.3.1). As discussed in section 5.3, 100 nM ICRF-193 
targets only topo IIα. Figure 6.8 shows that although chromosomes still appeared damaged 
and entangled as seen in Figure 6.1, the frequency of not only hydrogen peroxide-induced 
‘dots’ but also chromosomal fragmentation was severely reduced by ICRF-193. Therefore, 
although only qualitative observations were made, the results presented here do suggest that 
topo IIα is not only involved in the formation of the DNA ‘dots’ but also in chromosomal 
fragmentation.  
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Figure 6.8: Photomicrograph of Giemsa-stained 10 μM H202-treated hTERT-RPE1 cells after 
100 nM ICRF-193 incubation at x100 magnification. The inset picture is an example of 
chromosomal damage after incubation with 10 μM H202 in hTERT-RPE1 cells (derived from 
bottom panel in Figure 6.1). The red arrow indicates a chromosomal ‘dot’. 
 
 
Originally I aimed to determine the range of H2O2 concentrations where chromatid breaks 
were formed so as to calculate the number of chromatid breaks per cell and how ICRF-193 
affected this. However the ideal range of H2O2 concentration to produce just chromatid breaks 
was never quite determined, as at the lower doses (1 and 10 nM H2O2) no damage occurred, 
yet at the higher dose (>0.1 μM) damage was too high to calculate chromatid break frequency 
as DNA became fragmented. However, the red arrows in figure 6.9 show that at 0.1 μM H2O2, 
many chromosomal ‘dots’ are already visible that were also evident in cells treated with 10 μM 
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H2O2 (Figures 6.1 and 6.2). Chromatid breaks, such as those formed after IR, were not 
typically seen after incubation with 0.1 μM H2O2. As in the previous figures, these 
chromosomal ‘dots’ were proven to be DNA when stained with DAPI (Figure 6.10). In the 
previous section the effect of 100 nM ICRF-193 on H2O2-induced chromosomal damage was 
tested. Here however, a lower frequency of these ‘dots after treatment with H2O2 at 0.1 μM 
would be hard to quantify and hence chromosomal structure was not looked at after cells 
were treated with both ICRF-193 and 0.1 μM H2O2.  
 
 
 
 
Figure 6.9: Photomicrograph of Giemsa-stained 0.1 μM H202-treated hTERT-RPE1 cells at 
x100 magnification. The red arrows point to chromosomal damage that appear as ‘dots’.  
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Figure 6.10: Photomicrograph of DAPI-stained 0.1 μM H202-treated hTERT-RPE1 cells at x100 
magnification. The red arrows point to chromosomal damage that appear as dots.  
 
 
It has previously been shown that topo IIα is involved in the excision of chromosomal loops 
after oxidative stress 126. It is therefore possible that the ‘dots’ are excised chromosomal loops. 
If topo IIα is able to excise chromosomal loops, it would confirm the possibility of topo IIα 
being involved in chromatid break formation too as ‘omega’ loops (Figure 1.7) can be thought 
of as chromosomal loops not yet excised. 
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6.5.2 DNA damage 
Procedure 
The single or double strand break origin of chromosomal damage at 0.1 μM H202 was also 
investigated. SSB induction in 0, 0.1, 1 and 10 nM H2O2-treated hTERT-RPE1 cells was 
measured by the alkaline comet assay described in section 2.13. Hydrogen peroxide was 
added for 20 minutes on ice. The tail moment in control cells was subtracted from the results 
of H202-treated cells. Experiments were carried out in duplicate.  
 
DSB break induction was measured by low voltage gel electrophoresis in exponentially 
growing hTERT-RPE1 cells treated with 0, 0.01, 0.1, 1, 10, 100 and 1000 μM H2O2 for 20 
minutes on ice. Cells were then trypsinised and DSBs measured as described in section 2.7.1. 
DSB induction in 0.1 μM H2O2-treated cells, synchronised in G0 by serum starvation, was also 
measured with immunocytochemistry against γH2AX after 20 minutes recovery as described 
in section 2.7.1. All DSB experiments were carried out in triplicate. 
 
hTERT-RPE1 cells were also treated with or without 0.1 μM H2O2 for 0, 5, 10, 20 and 40 
minutes on ice or 1 mM H2O2 for 20 minutes on ice which served as a positive control. In 
other experiments cells were treated with 1 mM or 10 μM H2O2 for 20 minutes. Certain 
samples treated with 1 mM H2O2 were allowed to recover in H2O2-free medium at 37°C for 0, 
15 or 30 minutes. In all experiments, cells had previously been incubated with or without 100 
nM ICRF-193 for 2 hours. Cells were then trypsinised (section 2.1.2) and DSBs measured by 
either low voltage gel electrophoresis or immunocytochemistry against γH2AX as described in 
section 2.7.1. 
 
Results and discussion 
Chromosomal damage is generally attributed to DSBs. This is also the case here where 
damage to chromosomes in metaphases are analysed only 2 hours after H2O2 treatment. As 
mentioned in section 4.4, it is unlikely that metaphases analysed at the time interval used 
here include S-phase cells. Therefore most of the damage seen in chromatids must be due to 
DSBs rather than SSBs, as SSBs could not have been transformed into DSBs after 
replication. It was important to establish which doses of H202 caused SSBs only or both SSBs 
and DSBs in hTERT-RPE1 cells, as I wanted to determine if the chromosomal damage seen 
at 0.1 μM H202 was caused by SSBs or DSBs.  
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Figure 6.11 A: Induction of single strand breaks as determined by the alkaline comet assay in 
hTERT-RPE1 cells treated with 0 (panel 1), 0.1 (panel 2), 1 (panel 3) and 10 nM (panel 4) H2O2. 
DNA was labelled with propidium iodide. Pictures were taken at x10 magnification. B: Analysis 
of Figure 6.11A. The background value determined in control (non-treated) cells was subtracted 
from all samples. Error bars represent standard errors of the mean for 50 cells in duplicate 
experiments.  
 
 
SSB induction was measured using the alkaline comet assay. Figure 6.11A shows that H2O2 
at 0.1 nM caused SSBs and that the number of SSBs increased with H2O2 dose. Tail 
moments as quantified by Comet Assay IV (Figure 6.11B) were 6.8, 19.3 and 28.2 at 0.1, 1 
and 10 nM H2O2 respectively. Therefore at 0.1 μM H2O2, the concentration that induced 
chromosomal damage in Figures 6.9 and 6.10, many SSBs were formed.  
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Figure 6.12 shows that the number of DSBs increased with H202 dose between 10, 100 and 
1000 μM with the fraction of DNA released (FDR) equal to 0.09, 0.14 and 0.34 respectively. 
This shows that higher concentrations of H2O2 are needed to induce DSBs than SSBs. DSB 
induction was visible only at concentrations ≥10 μM H202. This is interesting as previous 
studies have shown that DSBs are formed at concentrations ≥ 100 μM H202 320 and therefore 
no DSBs would be formed at 10 μM H202 unlike here. This is most likely due to the neutral 
elution assay being less sensitive than the low voltage gel electrophoresis assay. When 
comparing the FDR at 10 μM H2O2 with data collected from Figure 5.6, it can be determined 
that this concentration is equal to a dose of approximately 13 Gy γ-radiation in terms of DSB 
induction. To confirm that no DSBs were present at 0.1 μM H2O2, cells were also probed 
against γH2AX as this assay is more sensitive than the low voltage gel electrophoresis assay 
as discussed in section 5.5.  
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Figure 6.12 A: Induction of DSBs in hTERT-RPE1 cells treated with varying concentrations of 
H2O2. DNA was labelled with ethidium bromide. B: Analysis of figure 6.12A with FDR is equal to 
frequency of DNA released (from well) and was determined as described in section 2.7.1. Error 
bars represent standard deviations from the mean in triplicate experiments.   
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Figure 6.13 confirms that 0.1 μM H2O2 does not induce DSBs as H2O2-treated cells averaged 
0.69 γH2AX foci per cell, a value close to that found in control cells (0.64 foci per cell). The 
results shown in Figure 6.13 pose some interesting questions about the formation of H2O2-
induced chromosomal damage. How is chromosomal damage such as the formation of 
chromosomal ‘dots’ and fragmentation caused in the absence of DSBs? Also the damage 
caused at 10 μM H2O2, where chromosomes looked fragmented and ‘dots’ were formed, 
seems disproportionate with the damage at 0.1 μM H2O2, where only chromosomal ‘dots’ 
were visible. It is possible that topo IIα is involved as .OH radicals are known to ‘poison’ topo 
II which as mentioned earlier is an enzyme that under these conditions causes DSBs 126. At 
10 μM H2O2 one might consider that the effect of .OH radicals on topo IIα is much larger than 
at 0.1 μM resulting in more complex chromosomal damage. The role of topo IIα in the 
formation of DSBs will be the focus of the latter part of this chapter. 
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Figure 6.13: Number of γH2AX foci per cell in control and H2O2-treated (0.1 μM) hTERT-RPE1 
cells. The number of foci for each sample was determined for 100 cells in triplicate by 
immunocytochemistry. Cells were probed with anti-mouse-FITC-conjugated secondary 
antibodies against the primary mouse anti-γH2AX antibody as well as DAPI. Error bars 
represent standard errors from the mean for triplicate experiments. 
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If topo IIα is indeed involved in causing chromosomal damage after incubation with 0.1 μM 
H2O2 where no DSBs are formed, perhaps increased incubation time of H2O2 would result in 
the formation of DSBs due to topo IIα poisoning and ICRF-193 would inhibit this. Figure 6.14 
shows that even after 40 minutes incubation with 0.1 μM H2O2 still no DSBs were formed. 
This was not due to experimental error as incubation with 1 mM H2O2 for 20 minutes did result 
in DSBs. As no DSBs were formed at 0.1 μM H2O2, the role of topo IIα could not be 
established through ICRF-193 treatment. Figure 6.14 does however again confirm that 100 
nM ICRF-193 does not induce DSBs. Perhaps the time period of this experiment (40 minutes) 
was too short to see any DSBs formed at 0.1 μM H2O2 as observation of the spread 
chromosomes was carried out 1.5 hours after a 20 minute H2O2 treatment.  
 
 
 
 
Figure 6.14: DSB induction in hTERT-RPE1 cells incubated with or without 100 nM ICRF-193 
and then treated with 0.1 μM H2O2 for 0, 5, 10, 20 or 40 minutes. The positive control is DNA 
from cells treated with 1 mM H2O2 for 20 minutes. DNA was labelled with ethidium bromide. 
 
 
Next, the effect of ICRF-193 on 1 mM H2O2 treatment was tested. It was already established 
that 1 mM H2O2 causes DSBs (Figure 6.12) and if topo IIα is involved in causing 
chromosomal damage, which is usually caused by DSBs, perhaps inhibition of DSB formation 
by ICRF-193 might be visualised. Figure 6.15 shows that treatment of cells with 100 nM 
ICRF-193 before incubation with 1 mM H2O2 decreases DSB induction. The FDR at 1 mM 
H2O2 decreased significantly (p=0.04) from 0.28 to 0.22 after ICRF-193 incubation. As 
discussed in Chapter 3 the p-value is defined here as the probability of obtaining the results 
assuming the null hypothesis is correct. Here the significance level is taken as 5% (0.05) so 
any p-value obtained below 0.05 is statistically significant. These DSB induction results 
suggest that topo IIα is involved in the formation of H2O2-induced DSBs. 
 
Role of topo IIα in H2O2-induced chromosomal damage 
 
124
 
 
 
 
 
Control ICRF-193
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
FD
R
 
Figure 6.15 A: Induction of DSBs in hTERT-RPE1 cells treated with or without 1 mM H2O2 or 
100 nM ICRF-193. DNA was labelled with ethidium bromide. B: Analysis of figure 6.15A with 
FDR equal to frequency of DNA released (from well). The FDR was determined as described in 
section 2.7.1. Error bars represent standard errors of the mean from duplicate experiments. 
 
 
If H2O2 does cause DSBs, does the number of DSBs increase with time after treatment 
because topo IIα is poisoned by the .OH radicals? Figure 6.16 shows the fraction of DNA 
released in cells incubated with or without ICRF-193, then treated with 1 mM H2O2 for 20 
minutes, and then left to recover for different lengths of time in fresh medium. Figure 6.16 
shows that recovery after H2O2 treatment decreased the number of DSBs found suggesting 
that DSB repair occurred. It therefore suggests that topo IIα is not involved in H2O2-induced 
DSB formation after H2O2 treatment of 20 minutes as the number of DSBs did not increase 
with time. Perhaps topo IIα did induce further DSBs, but they took longer to form than to be 
rejoined. As in Figure 6.15, inhibiting topo IIα with ICRF-193 decreased the number of DSBs 
formed after 1 mM H2O2 treatment. What is interesting is that ICRF-193 still decreased DSB 
formation even after 30 minutes of recovery from H2O2 when compared to H2O2-alone treated 
samples.  
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Figure 6.16: DSB induction in hTERT-RPE1 cells incubated with or without 100 nM ICRF-193 
and then treated with 1 mM H2O2 for 20 minutes on ice and allowed to recover in H202-free 
medium for 0, 15 or 30 minutes. DNA was labelled with ethidium bromide. 
 
 
As ICRF-193 affected the number of DSBs after 1 mM H2O2 treatment, perhaps the same 
trend would be seen in cells treated with 10 μM H2O2, another dose that causes DSBs (Figure 
6.12). DSB induction was first measured by immunocytochemistry against γH2AX as this 
method is far more sensitive than low voltage gel electrophoresis. The reason the γH2AX 
method was not used to measure DSB induction in 1 mM H2O2-treated cells was because the 
number of foci per cell would have been too high to measure accurately. Figure 6.17 shows 
that the number of γH2AX foci increases after 10 μM H2O2-treatment from 0.5 foci per cell to 
19 foci per cell. Incubation with 100 nM ICRF-193 alone did not increase DSB frequency (0.5 
foci per cell) and also did not affect DSB frequency after 10 μM H2O2 treatment either (19 foci 
per cell). This lack of effect of ICRF-193 on 10 μM H2O2-treated cells was also found with low 
voltage gel electrophoresis (data not shown).  
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Figure 6.17: Number of γH2AX foci per cell in control and 100 nM ICRF-193-treated hTERT-
RPE1 cells then incubated with 0 or 10 μM H202. The number of foci for each sample was 
determined for 100 cells in triplicate by immunocytochemistry. Cells were probed with anti-
mouse-FITC-conjugated secondary antibodies against the primary mouse anti-γH2AX antibody 
as well as DAPI. Error bars represent standard errors from the mean for triplicate experiments. 
 
 
The next question to answer was why does ICRF-193 treatment affect DSB induction after 1 
mM H2O2 treatment, but not 10 μM H2O2? This inconsistency might be related to the amount 
of 
.
OH radicals produced by H2O2. Perhaps higher levels of ROS, such as those induced by 1 
mM H2O2, are required to trigger topo II-induced DNA damage, whereas lower ROS levels, 
induced by ≤10 μM H2O2, do not poison topo II to such levels that DSBs are caused. This 
might relate to the concept of ‘cellular barometers’ 242 mentioned in section 1.6 where DNA 
damage poisons topo II to amplify damage to the DNA which in turn might initiate apoptosis if 
the damage is beyond repair. DNA fragmentation 321 is a ‘symptom’ of apoptosis and as topo 
IIα is known to be involved in apoptosis 173, the decrease of DSBs after ICRF-193 treatment 
at 1 mM H2O2 is most likely due to the apoptotic pathway signalling further DSB induction by 
topo IIα. Although it might follow that as chromosomes look fragmented at 10 μM H2O2 cells 
are going through apoptosis, this I think is unlikely as DSB numbers should also have 
decreased with ICRF-193 incubation yet they did not. This does not exclude the possibility 
that topo IIα is involved in the formation of chromosomal ‘dots’ at concentrations where H2O2 
does not induced apoptosis (0.1 μM) as it is possible that mis-exchange by topo IIα, a 
mechanism also suggested for chromatid break formation, might not be detected with assays 
that measure DSB induction.  
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6.6 Conclusion 
Hydrogen peroxide, presumably through 
.
OH radicals, induces chromosomal fragmentation 
and ‘dots’ that can be visualised using AFM. For further imaging by AFM, staining and set-up 
conditions need to be optimised. The chromosomal ‘dots’ are still apparent at doses of H2O2 
where only SSBs were produced which suggests the involvement of a DNA-damaging protein 
such as topo IIα which magnifies the damage to the chromosomal level. Only H2O2 
concentrations higher than 10 μM caused DSBs that were reduced when topo IIα activity was 
inhibited. A role for topo IIα in H2O2-induced chromosomal damage at levels that do not 
induce apoptosis seems likely but remains uncertain. The role of 
.
OH radicals in altering topo 
IIα activity after γ-irradiation in such a way as to induce chromatid breaks is therefore still 
unclear.  
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7.1 Final discussion 
The aim of this study was to determine if topo IIα plays a role in low dose IR-induced 
chromatid breaks as suggested by the signal model 112. The results presented in chapters 3 - 
5 support the hypothesis that topo IIα is involved in forming chromatid breaks after γ-
irradiation. I also showed that this involvement of topo IIα was not due to perturbation of the 
cell cycle or induction of the G2/M checkpoint nor altered DSB repair. The results also 
suggested a role for topo IIα in altering chromatid break frequency by lowering the conversion 
of the initial DNA damage to chromatid breaks.  
 
The signal model of chromatid breakage 112 was originally proposed to account for both a 
linear induction of chromatid breaks and the finding that DSB repair was not directly linked to 
chromatid break rejoining.  The signal model proposes that chromatid breaks are essentially 
mis-exchanges within and between chromatids that have been interrupted by fixing the cells 
during experiments thus rendering the exchanges incomplete 112. Perhaps the role of topo IIα 
in chromatid break formation, as suggested by the results in this thesis, is in the mis-
exchange of damage at the base of the chromatin loop which, in the case of intra-
chromosomal exchanges, would lead to the appearance of intermediate ‘omega’ figures. If so, 
how might topo II accomplish this mechanistically? Figure 1.9 shows that topo IIα forms a 
dimer with each monomer bound to a strand of the gated DNA helix whilst the T-segment is 
passed through the break of the G-segment to allow for DNA decatenation. This G-segment 
break is usually religated, except after incubation with topo II poisons such as mAMSA 231 and 
etoposide 322. One possibility is therefore that topo IIα is involved in creating chromatid breaks 
through acting irregularly, leading to a mis-exchange of the genetic material between the two 
double helices ultimately forming a chromatid break. Thus topo IIα might cause a mis-
exchange if two topo II molecules are located near each other at the base of a chromatin loop, 
each bound to two separate areas of one helix and inducing one DSB in each area of the 
strand. It has been shown that topo IIα is bound at the base of chromatin loops 121 so the 
occurrence of two dimers near each other is possible. If bonds between the dimers and DNA 
helices were cut and somehow the dimers were consequently bound to the wrong part of the 
helix, exchange between the two areas could occur. However, under which endogenous 
conditions two dimers might lose their connections with DNA is unclear.  
 
Perhaps a more realistic theory of chromatid breakage involving topo IIα is mis-exchange of 
genetic material accomplished by DNA repair mechanisms after topo II-induced DNA damage. 
Such mis-repair of topo II-induced DNA damage has also previously been suggested to result 
in chromosomal translocations as discussed in section 1.7.2. It is known that topo II creates 
protein-associated DSBs, which form irreversible DSBs after collision with a replication fork 243. 
Perhaps topo II creates protein-associated DSBs after low dose ionising radiation which are 
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not religated. However, how these are converted in G2, where DNA replication is absent, into 
irreversible DSBs is not clear. Collision of transcription forks with topo II-associated DSBs 
might induce irreversible DSBs in a similar manner to that suggested by Radford 122 . Another 
possibility might be that endogenous poisons, such as 
.
OH radicals, affect topo IIα 126 
catalytically, resulting in DSBs. 
 
Although the data here suggest that topo IIα is involved in chromatid break formation as 
proposed by the signal model 112, the nature of the signal is still unclear. To determine how 
topo IIα is involved or recruited in radiation-induced chromatid break formation, the role 
of 
.
OH radicals was tested in chapter 6. It was shown that topo IIα is involved in H2O2-induced 
chromosomal damage and chromatin ‘dots’. Interestingly, chromatin ‘dots’, thought to be 
excised chromatin loops, occur even at H2O2 concencentrations where no DSBs were 
produced suggesting that, as with chromatid breaks, topo IIα might be key in forming other 
types of chromosomal damage.  
 
These results have highlighted some interesting issues. Why did treatment of cells with 0.1 
μM H2O2 produce only chromosomal ‘dots’ and no obvious chromatid breaks (chapter 6) 
whereas irradiation at 0.3 Gy produced only chromatid breaks (chapters 3 – 5) if topo IIα is 
involved in both? Most likely the amount of 
.
OH radicals present after low dose ionising 
radiation and H2O2 treatment alters the effect of topo IIα in such a way that it either creates 
chromatid breaks or in rarer cases completely excises the chromatin loop.  
 
If 
.
OH radicals are involved in altering topo IIα activity after γ-irradiation as suggested here, 
how could this explain the formation of chromatid breaks after DSB induction by restriction 
endonucleases 10? Restriction endonucleases would not induce 
.
OH radicals. However, it is 
feasible that cells might have a high endogenous background of topo IIα poisons that produce 
topo II-associated DSBs, the same effect as 
.
OH radicals, and that chromatid breaks might 
still be formed in this way. The endogenous poisons might alternatively be abasic sites. It is 
known that 
.
OH radicals frequently induce abasic sites 323 and they can be present 
endogenously at a high level 239. Therefore although restriction endonucleases do not 
themselves induce 
.
OH radicals, they might still form chromatid breaks due to a background 
level of abasic sites leading to irregular topo IIα decatenation.  
 
The signal model of chromatid breakage proposes that damage at the base of a chromatin 
loop would need to consist of at least two non-IR-induced DSBs as seen in Figure 1.7. I, 
however, view chromatid breakage as a result of an original IR-induced-DSB located 
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randomly along a chromatin loop or at its base followed by an interaction of the original DSB 
and a separate topo II-induced DSB at the base of the loop. The topo II-induced DSB would 
result from the presence of abasic sites, which poison topo IIα. This theory of two DSBs 
interacting might appear to contradict data suggesting a linear induction of chromatid breaks 
with radiation dose 106. However, if one assumes a very high background of abasic sites, any 
DSBs induced by low dose radiation would have the same chance of being located next to an 
abasic site and therefore the induction of chromatid breaks would still appear linear with dose.  
 
7.2 Future outlooks 
The work presented here has increased our understanding of IR-induced chromatid breakage 
in showing that IR-induced DSBs interact with topo IIα in causing chromatid breaks. It is 
therefore a possibility that the inter-individual variation in chromatid radiosensitivity of 
lymphocytes of normal healthy individuals and between normals and breast-cancer patients 
70,86 could be attributed to variations in topo IIα expression, as shown here. Future studies 
could therefore be aimed at measuring topo IIα levels, expression or cellular localisation in 
these individuals and relating these to IR-induced chromatid break frequency. If a significant 
inter-relationship were found, measurement of topo IIα expression for example could form the 
basis of a possible future test or marker of IR-induced chromosomal radiosensitivity and 
cancer susceptibility. 
 
Inter- and intra-individual differences in radiosensitivity could be attributed to changes in diet. 
When taking into account the data presented here it is likely that an increase of topo II 
poisons such as genestein and quercetein (found in normal diets) induces different levels of 
topo IIα activity which would results in changes in radiosensitivity. It is therefore possible, with 
further investigation, that topo IIα can be used as a marker of not only inter- and intra-
individual differences in radiosensitivity but also of sporadic and heritable breast cancer cases. 
 
Also in this thesis only the effect of lowered topo IIα activity and expression on chromatid 
break frequency was tested. To further confirm the involvement of topo IIα in chromatid break 
formation overexpression studies should be conducted. It would also be interesting to see if 
topo IIα expression or activity is affected after either IR or incubation with H2O2. The role 
of 
.
OH radicals and abasic sites in creating chromatid breaks as well as the nature of 
chromosomal ‘dots’ should also be further investigated. 
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Appendix A – Topo IIα mRNA sequence 
data 
 
Acquired from:  National Center for Biotechnology Information (NCBI)  
Reference number: >gi|19913405|ref|NM_001067.2| Homo sapiens topoisomerase (DNA) II 
alpha 170kDa (TOP2A), mRNA) 
 
Altered to show exon boundaries (determined from Lang et al. 1998 152) so exons alternate 
from bold to normal font. 
 
 
ATGGAAGTGTCACCATTGCAGCCTGTAAATGAAAATATGCAAGTCAACAAAATAAAGAAAAATGAAGAT
GCTAAGAAAAGACTGTCTGTTGAAAGAATCTATCAAAAGAAAACACAATTGGAACATATTTTGCTCCGC
CCAGACACCTACATTGGTTCTGTGGAATTAGTGACCCAGCAAATGTGGGTTTACGATGAAGATGTTGGC
ATTAACTATAGGGAAGTCACTTTTGTTCCTGGTTTGTACAAAATCTTTGATGAGATTCTAGTTAATGCT
GCGGACAACAAACAAAGGGACCCAAAAATGTCTTGTATTAGAGTCACAATTGATCCGGAAAACAATTTA
ATTAGTATATGGAATAATGGAAAAGGTATTCCTGTTGTTGAACACAAAGTTGAAAAGATGTATGTCCCA
GCTCTCATATTTGGACAGCTCCTAACTTCTAGTAACTATGATGATGATGAAAAGAAAGTGACAGGTGGT
CGAAATGGCTATGGAGCCAAATTGTGTAACATATTCAGTACCAAATTTACTGTGGAAACAGCCAGTAGA
GAATACAAGAAAATGTTCAAACAGACATGGATGGATAATATGGGAAGAGCTGGTGAGATGGAACTCAAG
CCCTTCAATGGAGAAGATTATACATGTATCACCTTTCAGCCTGATTTGTCTAAGTTTAAAATGCAAAGC
CTGGACAAAGATATTGTTGCACTAATGGTCAGAAGAGCATATGATATTGCTGGATCCACCAAAGATGTC
AAAGTCTTTCTTAATGGAAATAAACTGCCAGTAAAAGGATTTCGTAGTTATGTGGACATGTATTTGAAG
GACAAGTTGGATGAAACTGGTAACTCCTTGAAAGTAATACATGAACAAGTAAACCACAGGTGGGAAGTG
TGTTTAACTATGAGTGAAAAAGGCTTTCAGCAAATTAGCTTTGTCAACAGCATTGCTACATCCAAGGGT
GGCAGACATGTTGATTATGTAGCTGATCAGATTGTGACTAAACTTGTTGATGTTGTGAAGAAGAAGAAC
AAGGGTGGTGTTGCAGTAAAAGCACATCAGGTGAAAAATCACATGTGGATTTTTGTAAATGCCTTAATT
GAAAACCCAACCTTTGACTCTCAGACAAAAGAAAACATGACTTTACAACCCAAGAGCTTTGGATCAACA
TGCCAATTGAGTGAAAAATTTATCAAAGCTGCCATTGGCTGTGGTATTGTAGAAAGCATACTAAACTGG
GTGAAGTTTAAGGCCCAAGTCCAGTTAAACAAGAAGTGTTCAGCTGTAAAACATAATAGAATCAAGGGA
ATTCCCAAACTCGATGATGCCAATGATGCAGGGGGCCGAAACTCCACTGAGTGTACGCTTATCCTGACT
GAGGGAGATTCAGCCAAAACTTTGGCTGTTTCAGGCCTTGGTGTGGTTGGGAGAGACAAATATGGGGTT
TTCCCTCTTAGAGGAAAAATACTCAATGTTCGAGAAGCTTCTCATAAGCAGATCATGGAAAATGCTGAG
ATTAACAATATCATCAAGATTGTGGGTCTTCAGTACAAGAAAAACTATGAAGATGAAGATTCATTGAAG
ACGCTTCGTTATGGGAAGATAATGATTATGACAGATCAGGACCAAGATGGTTCCCACATCAAAGGCTTG
CTGATTAATTTTATCCATCACAACTGGCCCTCTCTTCTGCGACATCGTTTTCTGGAGGAATTTATCACT
CCCATTGTAAAGGTATCTAAAAACAAGCAAGAAATGGCATTTTACAGCCTTCCTGAATTTGAAGAGTGG
AAGAGTTCTACTCCAAATCATAAAAAATGGAAAGTCAAATATTACAAAGGTTTGGGCACCAGCACATCA
AAGGAAGCTAAAGAATACTTTGCAGATATGAAAAGACATCGTATCCAGTTCAAATATTCTGGTCCTGAA
GATGATGCTGCTATCAGCCTGGCCTTTAGCAAAAAACAGATAGATGATCGAAAGGAATGGTTAACTAAT
TTCATGGAGGATAGAAGACAACGAAAGTTACTTGGGCTTCCTGAGGATTACTTGTATGGACAAACTACC
ACATATCTGACATATAATGACTTCATCAACAAGGAACTTATCTTGTTCTCAAATTCTGATAACGAGAGA
TCTATCCCTTCTATGGTGGATGGTTTGAAACCAGGTCAGAGAAAGGTTTTGTTTACTTGCTTCAAACGG
AATGACAAGCGAGAAGTAAAGGTTGCCCAATTAGCTGGATCAGTGGCTGAAATGTCTTCTTATCATCAT
GGTGAGATGTCACTAATGATGACCATTATCAATTTGGCTCAGAATTTTGTGGGTAGCAATAATCTAAAC
CTCTTGCAGCCCATTGGTCAGTTTGGTACCAGGCTACATGGTGGCAAGGATTCTGCTAGTCCACGATAC
ATCTTTACAATGCTCAGCTCTTTGGCTCGATTGTTATTTCCACCAAAAGATGATCACACGTTGAAGTTT
TTATATGATGACAACCAGCGTGTTGAGCCTGAATGGTACATTCCTATTATTCCCATGGTGCTGATAAAT
GGTGCTGAAGGAATCGGTACTGGGTGGTCCTGCAAAATCCCCAACTTTGATGTGCGTGAAATTGTAAAT
AACATCAGGCGTTTGATGGATGGAGAAGAACCTTTGCCAATGCTTCCAAGTTACAAGAACTTCAAGGGT
ACTATTGAAGAACTGGCTCCAAATCAATATGTGATTAGTGGTGAAGTAGCTATTCTTAATTCTACAACC
ATTGAAATCTCAGAGCTTCCCGTCAGAACATGGACCCAGACATACAAAGAACAAGTTCTAGAACCCATG
TTGAATGGCACCGAGAAGACACCTCCTCTCATAACAGACTATAGGGAATACCATACAGATACCACTGTG
AAATTTGTTGTGAAGATGACTGAAGAAAAACTGGCAGAGGCAGAGAGAGTTGGACTACACAAAGTCTTC
AAACTCCAAACTAGTCTCACATGCAACTCTATGGTGCTTTTTGACCACGTAGGCTGTTTAAAGAAATAT
GACACGGTGTTGGATATTCTAAGAGACTTTTTTGAACTCAGACTTAAATATTATGGATTAAGAAAAGAA
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TGGCTCCTAGGAATGCTTGGTGCTGAATCTGCTAAACTGAATAATCAGGCTCGCTTTATCTTAGAGAAA
ATAGATGGCAAAATAATCATTGAAAATAAGCCTAAGAAAGAATTAATTAAAGTTCTGATTCAGAGGGGA
TATGATTCGGATCCTGTGAAGGCCTGGAAAGAAGCCCAGCAAAAGGTTCCAGATGAAGAAGAAAATGAA
GAGAGTGACAACGAAAAGGAAACTGAAAAGAGTGACTCCGTAACAGATTCTGGACCAACCTTCAACTAT
CTTCTTGATATGCCCCTTTGGTATTTAACCAAGGAAAAGAAAGATGAACTCTGCAGGCTAAGAAATGAA
AAAGAACAAGAGCTGGACACATTAAAAAGAAAGAGTCCATCAGATTTGTGGAAAGAAGACTTGGCTACA
TTTATTGAAGAATTGGAGGCTGTTGAAGCCAAGGAAAAACAAGATGAACAAGTCGGACTTCCTGGGAAA
GGGGGGAAGGCCAAGGGGAAAAAAACACAAATGGCTGAAGTTTTGCCTTCTCCGCGTGGTCAAAGAGTC
ATTCCACGAATAACCATAGAAATGAAAGCAGAGGCAGAAAAGAAAAATAAAAAGAAAATTAAGAATGAA
AATACTGAAGGAAGCCCTCAAGAAGATGGTGTGGAACTAGAAGGCCTAAAACAAAGATTAGAAAAGAAA
CAGAAAAGAGAACCAGGTACAAAGACAAAGAAACAAACTACATTGGCATTTAAGCCAATCAAAAAAGGA
AAGAAGAGAAATCCCTGGTCTGATTCAGAATCAGATAGGAGCAGTGACGAAAGTAATTTTGATGTCCCT
CCACGAGAAACAGAGCCACGGAGAGCAGCAACAAAAACAAAATTCACAATGGATTTGGATTCAGATGAA
GATTTCTCAGATTTTGATGAAAAAACTGATGATGAAGATTTTGTCCCATCAGATGCTAGTCCACCTAAG
ACCAAAACTTCCCCAAAACTTAGTAACAAAGAACTGAAACCACAGAAAAGTGTCGTGTCAGACCTTGAA
GCTGATGATGTTAAGGGCAGTGTACCACTGTCTTCAAGCCCTCCTGCTACACATTTCCCAGATGAAACT
GAAATTACAAACCCAGTTCCTAAAAAGAATGTGACAGTGAAGAAGACAGCAGCAAAAAGTCAGTCTTCC
ACCTCCACTACCGGTGCCAAAAAAAGGGCTGCCCCAAAAGGAACTAAAAGGGATCCAGCTTTGAATTCT
GGTGTCTCTCAAAAGCCTGATCCTGCCAAAACCAAGAATCGCCGCAAAAGGAAGCCATCCACTTCTGAT
GATTCTGACTCTAATTTTGAGAAAATTGTTTCGAAAGCAGTCACAAGCAAGAAATCCAAGGGGGAGAGT
GATGACTTCCATATGGACTTTGACTCAGCTGTGGCTCCTCGGGCAAAATCTGTACGGGCAAAGAAACCT
ATAAAGTACCTGGAAGAGTCAGATGAAGATGATCTGTTTTAA 
 
 
Difference in coding length between forward and reverse primer for topo IIα: 1573 nucleotides 
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Appendix B – β-actin mRNA sequence 
data 
 
Acquired from:  National Center for Biotechnology Information (NCBI)  
Reference number: > gi|5016088|ref|NM_001101.2| Homo sapiens actin, beta (ACTB), 
mRNA 
 
Altered to show exon boundaries (determined from NCBI/CCDS ID CCDS5341.1) so exons 
alternate from bold to normal font. 
 
 
ATGGATGATGATATCGCCGCGCTCGTCGTCGACAACGGCTCCGGCATGTGCAAGGCCGGCTTCGCGGGC
GACGATGCCCCCCGGGCCGTCTTCCCCTCCATCGTGGGGCGCCCCAGGCACCAGGGCGTGATGGTGGGC
ATGGGTCAGAAGGATTCCTATGTGGGCGACGAGGCCCAGAGCAAGAGAGGCATCCTCACCCTGAAGTAC
CCCATCGAGCACGGCATCGTCACCAACTGGGACGACATGGAGAAAATCTGGCACCACACCTTCTACAAT
GAGCTGCGTGTGGCTCCCGAGGAGCACCCCGTGCTGCTGACCGAGGCCCCCCTGAACCCCAAGGCCAAC
CGCGAGAAGATGACCCAGATCATGTTTGAGACCTTCAACACCCCAGCCATGTACGTTGCTATCCAGGCT
GTGCTATCCCTGTACGCCTCTGGCCGTACCACTGGCATCGTGATGGACTCCGGTGACGGGGTCACCCAC
ACTGTGCCCATCTACGAGGGGTATGCCCTCCCCCATGCCATCCTGCGTCTGGACCTGGCTGGCCGGGAC
CTGACTGACTACCTCATGAAGATCCTCACCGAGCGCGGCTACAGCTTCACCACCACGGCCGAGCGGGAA
ATCGTGCGTGACATTAAGGAGAAGCTGTGCTACGTCGCCCTGGACTTCGAGCAAGAGATGGCCACGGCT
GCTTCCAGCTCCTCCCTGGAGAAGAGCTACGAGCTGCCTGACGGCCAGGTCATCACCATTGGCAATGAG
CGGTTCCGCTGCCCTGAGGCACTCTTCCAGCCTTCCTTCCTGGGCATGGAGTCCTGTGGCATCCACGAA
ACTACCTTCAACTCCATCATGAAGTGTGACGTGGACATCCGCAAAGACCTGTACGCCAACACAGTGCTG
TCTGGCGGCACCACCATGTACCCTGGCATTGCCGACAGGATGCAGAAGGAGATCACTGCCCTGGCACCC
AGCACAATGAAGATCAAGATCATTGCTCCTCCTGAGCGCAAGTACTCCGTGTGGATCGGCGGCTCCATC
CTGGCCTCGCTGTCCACCTTCCAGCAGATGTGGATCAGCAAGCAGGAGTATGACGAGTCCGGCCCCTCC
ATCGTCCACCGCAAATGCTTCTAG 
 
Difference in coding length between forward and reverse primer for β-actin: 499 nucleotides 
 
Start  
codon 
Stop 
codon 
Forward  
Primer 
β-actin 
Reverse  
Primer 
β-actin 
Appendices 
 
 
155
Appendix C – Dundee sequencing results 
Topo IIα 
Forward primer PCR product 
 Dundee result 
ATTGTTCCGGTGTCTCAGATGCTGATAGTGGTGCTGAAGGAATCGGTACTGGGTGGTCCTGCAAAATCC
CCAACTTTGATGTGCGTGAAATTGTAAATAACATCAGGCGTTTGATGGATGGAGAAGAACCTTTGCCAA
TGCTTCCAAGTTACAAGAACTTCAAGGGTACTATTGAAGAACTGGCTCCAAATCAATATGTGATTAGTG
GTGAAGTAGCTATTCTTAATTCTACAACCATTGAAATCTCAGAGCTTCCCGTCAGAACATGGACCCAGA
CATACAAAGAACAAGTTCTAGAACCCATGTTGAATGGCACCGAGAAGACACCTCCTCTCATAACAGACT
ATAGGGAATACCATACAGATACCACTGTGAAATTTGTTGTGAAGATGACTGAAGAAAAACTGGCAGAGG
CAGAGAGAGTTGGACTACACAAAGTCTTCAAACTCCAAACTAGTCTCACATGCAACTCTATGGTGCTTT
TTGACCACGTAGGCTGTTTAAAGAAATATGACACGGTGTTGGATATTCTAAGAGACTTTTTTGAACTCA
GACTTAAATATTATGGATTAAGAAAAGAATGGCTCCTAGGAATGCTTGGTGCTGAATCTGCTAAACTGA
ATAATCAGGCTCGCTTTATCTTAGAGAAAATAGATGGCAAAATAATCATTGAAAATAAGCCTAAGAAAG
AATTAATTAAAGTTCTGATTCAGAGGGGATATGATTCGGATCCTGTGAAGGCCTGGAAAGAAGCCCAGC
AAAAGGCTCCAGATGAAGAAGAAAATGAAGAGAGTGACAACGAAAAGGAAACTGAAAAGAGTGACTCCG
TAACAGATTCTGGACCAACCTTCAACTATCTTCTTGATATGCCCCTTTGTATTTAACCAAGGAAAGAAA
GATGAACTCTGCAGGCTAAGAAATGAAAAGACAGAGCTGGACACATTAAAAGAAGAGTCCATCAGATTG
TGGAAGAGACTGCTACATTTATTGAGATGGAGCTGTGAGCAGAAAACAGATGACAGTCGACTCTGGGAA
GGGGAGCAGGGAAAAAAACACAATTGCTGAGTTTGCCTCTCCGCGGTGTCAAGAGTCATCCGATACTGA
TGAGCGAAGGCGGAAGGAATAAGAATAGATGAAATCTGAGAGCCTTAGAGAGTGTGTGGCACAGAGGCT
ACCAAGTGGAGGACCGAAAGGAC 
 
 LALIGN result: Dundee result vs expected for topo IIα 
ulimit -t 30; /usr/molbio/bin/lalign -f -14 -g -
4 ./wwwtmp/.4737.1.seq ./wwwtmp/.4737.2.seq 3 > ./wwwtmp/.4737.out LALIGN finds the 
best local alignments between two sequences version 2.1u09 December 2006 Please cite: 
X. Huang and W. Miller (1991) Adv. Appl. Math. 12:373-381 resetting to DNA matrix 
alignments < E( 0.05):score: 80 (50 max)  
 Comparison of: 
(A) ./wwwtmp/.4737.1.seq Result primer F2 1196 bp                           - 1196 nt 
(B) ./wwwtmp/.4737.2.seq Expected 1283 bp                                   - 1283 nt 
 using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05 
 
94.4% identity in 1123 nt overlap (18-1098:40-1162); score: 4754 E(10000):0 
 
        20         30        40        50        60        70       
Result GATGCTGATAG-TGGTGCTGAAGGAATCGGTACTGGGTGGTCCTGCAAAATCCCCAACTT 
       : ::::::::  :::::::::::::::::::::::::::::::::::::::::::::::: 
Expect GGTGCTGATAAATGGTGCTGAAGGAATCGGTACTGGGTGGTCCTGCAAAATCCCCAACTT 
      40        50        60        70        80        90          
 
         80        90       100       110       120       130       
Result TGATGTGCGTGAAATTGTAAATAACATCAGGCGTTTGATGGATGGAGAAGAACCTTTGCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect TGATGTGCGTGAAATTGTAAATAACATCAGGCGTTTGATGGATGGAGAAGAACCTTTGCC 
     100       110       120       130       140       150          
 
        140       150       160       170       180       190       
Result AATGCTTCCAAGTTACAAGAACTTCAAGGGTACTATTGAAGAACTGGCTCCAAATCAATA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
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Expect AATGCTTCCAAGTTACAAGAACTTCAAGGGTACTATTGAAGAACTGGCTCCAAATCAATA 
     160       170       180       190       200       210          
 
        200       210       220       230       240       250       
Result TGTGATTAGTGGTGAAGTAGCTATTCTTAATTCTACAACCATTGAAATCTCAGAGCTTCC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect TGTGATTAGTGGTGAAGTAGCTATTCTTAATTCTACAACCATTGAAATCTCAGAGCTTCC 
     220       230       240       250       260       270          
 
        260       270       280       290       300       310       
Result CGTCAGAACATGGACCCAGACATACAAAGAACAAGTTCTAGAACCCATGTTGAATGGCAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect CGTCAGAACATGGACCCAGACATACAAAGAACAAGTTCTAGAACCCATGTTGAATGGCAC 
     280       290       300       310       320       330          
 
        320       330       340       350       360       370       
Result CGAGAAGACACCTCCTCTCATAACAGACTATAGGGAATACCATACAGATACCACTGTGAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect CGAGAAGACACCTCCTCTCATAACAGACTATAGGGAATACCATACAGATACCACTGTGAA 
     340       350       360       370       380       390          
 
        380       390       400       410       420       430       
Result ATTTGTTGTGAAGATGACTGAAGAAAAACTGGCAGAGGCAGAGAGAGTTGGACTACACAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect ATTTGTTGTGAAGATGACTGAAGAAAAACTGGCAGAGGCAGAGAGAGTTGGACTACACAA 
     400       410       420       430       440       450          
 
        440       450       460       470       480       490       
Result AGTCTTCAAACTCCAAACTAGTCTCACATGCAACTCTATGGTGCTTTTTGACCACGTAGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect AGTCTTCAAACTCCAAACTAGTCTCACATGCAACTCTATGGTGCTTTTTGACCACGTAGG 
     460       470       480       490       500       510          
 
        500       510       520       530       540       550       
Result CTGTTTAAAGAAATATGACACGGTGTTGGATATTCTAAGAGACTTTTTTGAACTCAGACT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect CTGTTTAAAGAAATATGACACGGTGTTGGATATTCTAAGAGACTTTTTTGAACTCAGACT 
     520       530       540       550       560       570          
 
        560       570       580       590       600       610       
Result TAAATATTATGGATTAAGAAAAGAATGGCTCCTAGGAATGCTTGGTGCTGAATCTGCTAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect TAAATATTATGGATTAAGAAAAGAATGGCTCCTAGGAATGCTTGGTGCTGAATCTGCTAA 
     580       590       600       610       620       630          
 
        620       630       640       650       660       670       
Result ACTGAATAATCAGGCTCGCTTTATCTTAGAGAAAATAGATGGCAAAATAATCATTGAAAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect ACTGAATAATCAGGCTCGCTTTATCTTAGAGAAAATAGATGGCAAAATAATCATTGAAAA 
     640       650       660       670       680       690          
 
        680       690       700       710       720       730       
Result TAAGCCTAAGAAAGAATTAATTAAAGTTCTGATTCAGAGGGGATATGATTCGGATCCTGT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect TAAGCCTAAGAAAGAATTAATTAAAGTTCTGATTCAGAGGGGATATGATTCGGATCCTGT 
     700       710       720       730       740       750          
 
        740       750       760       770       780       790       
Result GAAGGCCTGGAAAGAAGCCCAGCAAAAGGCTCCAGATGAAGAAGAAAATGAAGAGAGTGA 
       ::::::::::::::::::::::::::::: :::::::::::::::::::::::::::::: 
Expect GAAGGCCTGGAAAGAAGCCCAGCAAAAGGTTCCAGATGAAGAAGAAAATGAAGAGAGTGA 
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     760       770       780       790       800       810          
 
        800       810       820       830       840       850       
Result CAACGAAAAGGAAACTGAAAAGAGTGACTCCGTAACAGATTCTGGACCAACCTTCAACTA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Expect CAACGAAAAGGAAACTGAAAAGAGTGACTCCGTAACAGATTCTGGACCAACCTTCAACTA 
     820       830       840       850       860       870          
 
        860       870        880       890        900       910     
Result TCTTCTTGATATGCCCCTTTG-TATTTAACCAAGGAAA-GAAAGATGAACTCTGCAGGCT 
       ::::::::::::::::::::: :::::::::::::::: ::::::::::::::::::::: 
Expect TCTTCTTGATATGCCCCTTTGGTATTTAACCAAGGAAAAGAAAGATGAACTCTGCAGGCT 
     880       890       900       910       920       930          
 
          920          930       940         950       960          
Result AAGAAATGAAAA-GAC--AGAGCTGGACACATTAAAAG--AAGAGTCCATCAGATT-GTG 
       :::::::::::: ::   :::::::::::::::::::   :::::::::::::::: ::: 
Expect AAGAAATGAAAAAGAACAAGAGCTGGACACATTAAAAAGAAAGAGTCCATCAGATTTGTG 
     940       950       960       970       980       990          
 
      970           980       990          1000             1010    
Result GAAG--AGACT--GCTACATTTATTGA-GA--TGGAG-CTGTG-------AGCAGAAAAC 
       :::   :::::  :::::::::::::: ::  ::::: ::::        :: : :::   
Expect GAAAGAAGACTTGGCTACATTTATTGAAGAATTGGAGGCTGTTGAAGCCAAGGAAAAACA 
    1000      1010      1020      1030      1040      1050          
 
          1020           1030      1040              1050      1060 
Result AGATGAC--AGTCG-ACT--CTGGGAAGGGGAGCA--------GGGAAAAAAACACAATT 
       ::::::   ::::: :::  ::::::: ::: : :        ::::::::::::::: : 
Expect AGATGAACAAGTCGGACTTCCTGGGAAAGGGGGGAAGGCCAAGGGGAAAAAAACACAAAT 
    1060      1070      1080      1090      1100      1110          
 
                1070       1080       1090         
Result G-CTGAG--TTTGCCT-CTCCGCGGTGTCAA-GAGTCATCCGA 
       : ::::   ::::::: :::::::  ::::: ::::::: : : 
Expect GGCTGAAGTTTTGCCTTCTCCGCGTGGTCAAAGAGTCATTCCA 
    1120      1130      1140      1150      1160   
 
 
 
 BLAST result: Dundee result 
 
Accession Description Max score
Total 
score
Query 
coverage
E 
value 
Max 
ident Links
Transcripts 
NM_001067.2 
Homo sapiens 
topoisomerase (DNA) 
II alpha 170kDa 
(TOP2A), mRNA 
1764 1764 89% 0.0 95% 
 
 
 
Appendices 
 
 
158
Reverse primer PCR product 
Dundee result 
CCGTTGCTTTTTCCTCTTAGTTTTTTCTCAAAATCTGAGAAATCTTCATCTGAATCCAAATCCATTGTG
AATTTTGATTTTGTTGCTGCTCTCCGTGGCTCTGTTTCTCGTGGAGGGACATCAAAATTACTTTCGTCA
CTGCTCCTATCTGATTCTGAATCAGACCAGGGATTTCTCTTCTTTCCTTTTTTGATTGGCTTAAATGCC
AATGTAGTTTGTTTCTTTGACTTTGTACCTGGTTCTCTTTTCTGTTTCTTTTCTAATCTTTGTTTTAGG
CCTTCTAGTTCCACACCATCTTCTTGAGGGCTTCCTTCAGTATTTTCATTCTTAATTTTCTTTTTATTT
TTCTTTTCTGCCTCTGCTTTCATTTCTATGGTTATTCGTGGAATGACTCTTTGACCACGCCAA 
 
 LALIGN result: Dundee result vs expected for topo IIα 
LALIGN finds the best local alignments between two sequences version 2.1u09 December 2006 Please cite: X. Huang and W. 
Miller (1991) Adv. Appl. Math. 12:373-381 resetting to DNA matrix alignments < E( 0.05):score: 68 (50 max)  
 Comparison of: 
(A) ./wwwtmp/.18363.1.seq Ideal Topo II alpha sequence 408 bp                - 408 nt 
(B) ./wwwtmp/.18363.2.seq Result with topo II alpha reverse primer 408 bp    - 408 nt 
 using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05 
         
97.8% identity in 400 nt overlap (1-399:4-400); score: 1863 E(10000): 
1.1e-147 
 
               10        20        30        40        50        60 
Ideal  GCGTGGTCAAAGAGTCATTCCACGAATAACCATAGAAATGAAAGCAGAGGCAGAAAAGAA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Result GCGTGGTCAAAGAGTCATTCCACGAATAACCATAGAAATGAAAGCAGAGGCAGAAAAGAA 
            10        20        30        40        50        60    
 
               70        80        90       100       110       120 
Ideal  AAATAAAAAGAAAATTAAGAATGAAAATACTGAAGGAAGCCCTCAAGAAGATGGTGTGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Result AAATAAAAAGAAAATTAAGAATGAAAATACTGAAGGAAGCCCTCAAGAAGATGGTGTGGA 
            70        80        90       100       110       120    
 
              130       140       150       160       170       180 
Ideal  ACTAGAAGGCCTAAAACAAAGATTAGAAAAGAAACAGAAAAGAGAACCAGGTACAAAGAC 
       ::: :::::::::::::::::::::::::::::::::::::::::::::::::::::: : 
Result ACT-GAAGGCCTAAAACAAAGATTAGAAAAGAAACAGAAAAGAGAACCAGGTACAAAGTC 
            130       140       150       160       170       180   
 
              190       200       210        220       230          
Ideal  AAAGAAACAAACTACATTGGCATTTAAGCCAAT-CAAAAAAGGAAAGAAGAGAAATCCCT 
       ::::::::::::::::::::::::::::::::: :::::::::::::::::::::::::: 
Result AAAGAAACAAACTACATTGGCATTTAAGCCAATTCAAAAAAGGAAAGAAGAGAAATCCCT 
            190       200       210       220       230       240   
 
     240       250       260       270       280       290          
Ideal  GGTCTGATTCAGAATCAGATAGGAGCAGTGACGAAAGTAATTTTGATGTCCCTCCACGAG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
Result GGTCTGATTCAGAATCAGATAGGAGCAGTGACGAAAGTAATTTTGATGTCCCTCCACGAG 
            250       260       270       280       290       300   
 
     300       310       320       330       340       350          
Ideal  AAACAGAGCCACGGAGAGCAGCAACAAAAACAAAATTCACAATGGATTTGGATTCAGATG 
       ::::::::::::::::::::::::::::: :::::::::::::::::::::::::::::: 
Result AAACAGAGCCACGGAGAGCAGCAACAAAATCAAAATTCACAATGGATTTGGATTCAGATG 
            310       320       330       340       350       360   
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     360       370       380       390          
Ideal  AAGATTTCTCAGATTTTGATGAAAAAACTGATGATGAAGA 
       ::::::::::::::::::: ::::::::: : :: ::: : 
Result AAGATTTCTCAGATTTTGA-GAAAAAACT-AAGAGGAAAA 
            370       380        390        400 
 
 
 BLAST result: Dundee result 
Accession Description Max score
Total 
score
Query 
coverage
E 
value 
Max 
ident Links
Transcripts 
NM_001067.2 
Homo sapiens 
topoisomerase (DNA) 
II alpha 170kDa 
(TOP2A), mRNA 
688 688 94% 0.0 98% 
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Appendix D – Dundee sequencing results 
β-actin 
Forward primer PCR product 
Dundee result 
CGAACAAGCAACCGCGAGAAGTGACCCAGATCATGTTTGAGACCTTCAACACCCCAGCCATGTACGTTG
CTATCCAGGCTGTGCTATCCCTGTACGCCTCTGGCCGTACCACTGGCATCGTGATGGACTCCGGTGACG
GGGTCACCCACACTGTGCCCATCTACGAGGGGTATGCCCTCCCCCATGCCATCCTGCGTCTGGACCTGG
CTGGCCGGGACCTGACTGACTACCTCATGAAGATCCTCACCGAGCGCGGCTACAGCTTCACCACCACGG
CCGAGCGGGAAATCGTGCGTGACATTAAGGAGAAGCTGTGCTACGTCGCCCTGGACTTCGAGCAAGAGA
TGGCCACGGCTGCTTCCAGCTCCTCCCTGGAGAAGAGCTACGAGCTGCCTGACGGCCAGGTCATCACCA
TTGGCAATGAGCGGTTCCGCTGCCCTGAGGCACTCTCCGCTT 
 
 
 LALIGN result: Dundee result vs expected for β-actin 
LALIGN finds the best local alignments between two sequences version 2.1u09 December 2006 Please cite: X. Huang and W. 
Miller (1991) Adv. Appl. Math. 12:373-381 resetting to DNA matrix alignments < E( 0.05):score: 69 (50 max)  
 Comparison of: 
(A) ./wwwtmp/.14327.1.seq results dundee forward beta-actin primer 456 bp    - 456 nt 
(B) ./wwwtmp/.14327.2.seq ideal result beta-actin 435 bp                     - 435 nt 
 using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05 
 
99.7% identity in 395 nt overlap (9-402:41-435); score: 1952 E(10000): 
5e-155 
 
       10        20         30        40        50        60        
result CAACCGCGAGAAG-TGACCCAGATCATGTTTGAGACCTTCAACACCCCAGCCATGTACGT 
       ::::::::::::: :::::::::::::::::::::::::::::::::::::::::::::: 
ideal  CAACCGCGAGAAGATGACCCAGATCATGTTTGAGACCTTCAACACCCCAGCCATGTACGT 
               50        60        70        80        90       100 
 
        70        80        90       100       110       120        
result TGCTATCCAGGCTGTGCTATCCCTGTACGCCTCTGGCCGTACCACTGGCATCGTGATGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  TGCTATCCAGGCTGTGCTATCCCTGTACGCCTCTGGCCGTACCACTGGCATCGTGATGGA 
              110       120       130       140       150       160 
 
       130       140       150       160       170       180        
result CTCCGGTGACGGGGTCACCCACACTGTGCCCATCTACGAGGGGTATGCCCTCCCCCATGC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  CTCCGGTGACGGGGTCACCCACACTGTGCCCATCTACGAGGGGTATGCCCTCCCCCATGC 
              170       180       190       200       210       220 
 
       190       200       210       220       230       240        
result CATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGACTGACTACCTCATGAAGATCCTCAC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  CATCCTGCGTCTGGACCTGGCTGGCCGGGACCTGACTGACTACCTCATGAAGATCCTCAC 
              230       240       250       260       270       280 
 
       250       260       270       280       290       300        
result CGAGCGCGGCTACAGCTTCACCACCACGGCCGAGCGGGAAATCGTGCGTGACATTAAGGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
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ideal  CGAGCGCGGCTACAGCTTCACCACCACGGCCGAGCGGGAAATCGTGCGTGACATTAAGGA 
              290       300       310       320       330       340 
 
       310       320       330       340       350       360        
result GAAGCTGTGCTACGTCGCCCTGGACTTCGAGCAAGAGATGGCCACGGCTGCTTCCAGCTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  GAAGCTGTGCTACGTCGCCCTGGACTTCGAGCAAGAGATGGCCACGGCTGCTTCCAGCTC 
              350       360       370       380       390       400 
 
       370       380       390       400   
result CTCCCTGGAGAAGAGCTACGAGCTGCCTGACGGCC 
       ::::::::::::::::::::::::::::::::::: 
ideal  CTCCCTGGAGAAGAGCTACGAGCTGCCTGACGGCC 
              410       420       430      
 
 
BLAST result: Dundee result 
Accession Description Max score
Total 
score 
Query 
coverage 
E 
value 
Max 
ident 
Link
s 
Transcripts 
NM_001101.2 Homo sapiens actin, beta (ACTB), mRNA 811 811 96% 0.0 99%  
 
Reverse primer PCR product 
Dundee result 
CCAGCCGGACGCTCTTGCCATGGTGATGACCTGGCCGTCAGGCAGCTCGTAGCTCTTCTCCAGGGAGGA
GCTGGAAGCAGCCGTGGCCATCTCTTGCTCGAAGTCCAGGGCGACGTAGCACAGCTTCTCCTTAATGTC
ACGCACGATTTCCCGCTCGGCCGTGGTGGTGAAGCTGTAGCCGCGCTCGGTGAGGATCTTCATGAGGTA
GTCAGTCAGGTCCCGGCCAGCCAGGTCCAGACGCAGGATGGCATGGGGGAGGGCATACCCCTCGTAGAT
GGGCACAGTGTGGGTGACCCCGTCACCGGAGTCCATCACGATGCCAGTGGTACGGCCAGAGGCGTACAG
GGATAGCACAGCCTGGATAGCAACGTACATGGCTGGGGTGTTGAAGGTCTCAAACATGATCTGGGTCAT
CTTCTCGCGGTTGGCCTTGGGGTTCAGGGGGGCCTCGGGCTTTTAGCGCCCACGGCTTCAACATCGCAC
TTACTTGATTATACCCTACCAGGGGTAAAATCCGCGG 
 
 
LALIGN result: Dundee result vs expected for β-actin 
 
LALIGN finds the best local alignments between two sequences version 2.1u09 December 2006 Please cite: X. Huang and W. 
Miller (1991) Adv. Appl. Math. 12:373-381 resetting to DNA matrix alignments < E( 0.05):score: 71 (50 max)  
 Comparison of: 
(A) ./wwwtmp/.6108.1.seq results dundee reverse beta-actin primer 520 bp    - 520 nt 
(B) ./wwwtmp/.6108.2.seq ideal result beta-actin 495 bp                     - 495 nt 
 using matrix file: DNA (5/-4), gap-open/ext: -14/-4 E(limit)   0.05 
 
98.7% identity in 456 nt overlap (67-519:10-465); score: 2184 
E(10000): 3e-174 
 
         70        80        90       100       110       120       
result GCCCGAGGCCCCCCTGAACCCCAAGGCCAACCGCGAGAAGATGACCCAGATCATGTTTGA 
       : :::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
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ideal  GACCGAGGCCCCCCTGAACCCCAAGGCCAACCGCGAGAAGATGACCCAGATCATGTTTGA 
      10        20        30        40        50        60          
 
        130       140       150       160       170       180       
result GACCTTCAACACCCCAGCCATGTACGTTGCTATCCAGGCTGTGCTATCCCTGTACGCCTC 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  GACCTTCAACACCCCAGCCATGTACGTTGCTATCCAGGCTGTGCTATCCCTGTACGCCTC 
      70        80        90       100       110       120          
 
        190       200       210       220       230       240       
result TGGCCGTACCACTGGCATCGTGATGGACTCCGGTGACGGGGTCACCCACACTGTGCCCAT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  TGGCCGTACCACTGGCATCGTGATGGACTCCGGTGACGGGGTCACCCACACTGTGCCCAT 
     130       140       150       160       170       180          
 
        250       260       270       280       290       300       
result CTACGAGGGGTATGCCCTCCCCCATGCCATCCTGCGTCTGGACCTGGCTGGCCGGGACCT 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  CTACGAGGGGTATGCCCTCCCCCATGCCATCCTGCGTCTGGACCTGGCTGGCCGGGACCT 
     190       200       210       220       230       240          
 
        310       320       330       340       350       360       
result GACTGACTACCTCATGAAGATCCTCACCGAGCGCGGCTACAGCTTCACCACCACGGCCGA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  GACTGACTACCTCATGAAGATCCTCACCGAGCGCGGCTACAGCTTCACCACCACGGCCGA 
     250       260       270       280       290       300          
 
        370       380       390       400       410       420       
result GCGGGAAATCGTGCGTGACATTAAGGAGAAGCTGTGCTACGTCGCCCTGGACTTCGAGCA 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  GCGGGAAATCGTGCGTGACATTAAGGAGAAGCTGTGCTACGTCGCCCTGGACTTCGAGCA 
     310       320       330       340       350       360          
 
        430       440       450       460       470       480       
result AGAGATGGCCACGGCTGCTTCCAGCTCCTCCCTGGAGAAGAGCTACGAGCTGCCTGACGG 
       :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: 
ideal  AGAGATGGCCACGGCTGCTTCCAGCTCCTCCCTGGAGAAGAGCTACGAGCTGCCTGACGG 
     370       380       390       400       410       420          
 
        490       500         510           
result CCAGGTCATCACCAT-GGCAA-GAGCG-TCCGGCTG 
       ::::::::::::::: ::::: ::::: : : :::: 
ideal  CCAGGTCATCACCATTGGCAATGAGCGGTTCCGCTG 
     430       440       450       460      
 
 
BLAST result: Dundee result 
Accession Description Max score
Total 
score 
Query 
coverage 
E 
value 
Max 
ident 
Link
s 
Transcripts 
NM_001101.2 Homo sapiens actin, beta (ACTB), mRNA 809 809 85% 0.0 99%  
 
